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ABSTRACT 
 
NOVEL TRAF6-PROTEIN INTERACTIONS AND THE MOLECULAR  





An-Jey Andrew Su 
August 2016 
 
Dissertation supervised by Philip E. Auron, Ph.D.  
TRAF6 is an E3 ubiquitin ligase that is unique among TRAF family proteins in 
both its structure and protein-protein interaction specificity. It is further distinguished by 
its ability to transduce a multiplicity of receptors in varied biological systems.  Although 
TRAF6 activity is induced by these receptors, the mechanisms by which TRAF6 is 
activated under these stimulating conditions remain largely unclear.  To address this, 
standard molecular biological techniques were used to gain insight into the interplay of 
three proteins with TRAF6: 1) Syntenin-1 (Syn); 2) SRY (sex determining region Y)-box 
4 (Sox4); and 3) IL-1 receptor associated kinase 1 (IRAK1).  These three proteins 
physically interact with TRAF6 and affect its signaling activity by modulating subcellular 
localization, conformation or activation of the NF-κB/Rel family of transcription factors 
under stimulating conditions in cell lines of various tissue types.  While many previous 
  v 
studies focused on cytoplasmic TRAF6 and its activation, there are a several reports on 
the nuclear localization of TRAF6 as well as TRAF3 and TRAF4 in response to either 
extracellular stimulation or disease.  Ectopic Syn or Sox4 was found to not only attenuate 
TRAF6 signaling, translocates it into the nucleus of hematopoietic and monocytic cells.  
Syn attenuates TRAF6 activity in an ubiquitin and Sox4 dependent manner.  This, and the 
observation that Syn is impaired in its ability to attenuate a non-ubiquitinated TRAF6 
mutein (TRAF6ΔK), led to a hypothesis that Syn associates with TRAF6 in the 
cytoplasm following activation by IRAK1.  Notably, knockdown of Sox4 was found to 
potentiate TRAF6 activation and abrogates Syn inhibition of TRAF6.  Contrary to prior 
reports, use of domain deletions in both TRAF6 and Syn demonstrate that the full-length 
molecules are not necessary for their interaction.  Instead, mutagenesis or deletion of a 
newly identified TRAF Interaction motif (TIM) in Syn affects TRAF6 signaling and 
localization.  Interestingly, Syn also localizes to the nucleus when overexpressed with 
either wild type (WT) or a constitutively active TRAF6 (RZcc).  This study demonstrates 
that Sox4 also attenuates TRAF6 signaling and identifies a unique Sox4 TIM that is 
necessary for binding TRAF6.  TRAF6 and Sox4 colocalize under stimulatory 
conditions, thus providing a novel mechanism for TRAF6 entry into the nucleus.  In sum, 
TIR and TNF receptor signaling through TRAF6 dependent NF-κB activity is modulated 
by novel interactions with the Sox4 transcription factor in cooperation with Syn  The pair 
act on TRAF6 nucleocytoplasmic partitioning, conformation and modification state, 
modulating TRAF6c-dependent ell morphogenesis and intracellular signaling. 
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1.1 Cell signaling, Signal Integration and Signal Transduction 
The ability for biological systems to respond in an appropriate manner to various 
stimuli is critical for the maintenance of normal organismal physiology.  Multicellular 
organisms must deal with both external and internal signal inputs that may be 
mechanical, electrical and/or chemical.  Such systems typically display receptors on the 
cell surface to receive these multimodal inputs and then initiate specific responses.    
Additionally, cells must do this with a limited number of gene products at their disposal 
for use in their signaling networks.  Complexity and emergent properties in biology have 
evolved to deal with variable inputs that stimulate multiple pathways using multiple 
outputs that are integrated network responses to the inputs.  This behavior is conducted 
with a backdrop of interactions between multiple cell types and multiple contexts and 
environments for each cell type or combination of cell types (Butcher, Berg et al. 2004).  
While characterization of specific signaling pathways and their associated end responses 
have received intensive research, less studied is the integration of multiple receptor signal 
inputs that are differentially recognized by the network to trigger a specific cellular 
response (Gutierrez, O'Keeffe et al. 2008).  The result is reflected in the literature as 
incongruent reports often reflecting either contradictory or divergent signaling functions 
for single molecules. 
Extracellular signals need to be interpreted, integrated and amplified.  This 
process elicits cellular responses such as proliferation, differentiation, secretion, 
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contraction, metabolism and membrane excitation.  Receptors act as catalysts and 
amplifiers for this process.  In a signaling cascade, intracellular adapter proteins are used 
to effect downstream signal convergence and the final determination of cellular response.  
Two general regulatory mechanisms become apparent when considering the control of 
cellular signal transduction: 1) protein-protein interactions and 2) spatio-temporal control 
of signaling machinery.  Specificity of multifunctional signaling machinery is achieved 
through protein–protein interactions involving specific structural domains or binding 
motifs and adapter/scaffold proteins.  Additionally, the subcellular spatial and temporal 
expression of each molecular component is clearly important in the context of signal 
transduction (Meier and Somers 2011). Spatiotemporal control provides a regulatory 
mechanism for controlling the players involved in protein-protein interactions.  An 
example of this bi-modal control of intracellular signaling can be seen with inducible 
transcription factors that mediate rapid, but transient changes in gene expression in 
response to cellular demand.   In this study, signal convergence for multimodal receptor 
activation of members of the Rel/NF-κB transcription factor family, through the signaling 
adapter TRAF6 (Tumor necrosis factor receptor associated factor 6) is examined.  
TRAF6 is a very busy molecule, mediating signaling for many receptor systems critical 
for normal cellular and organismal physiology.  As such, the regulation and activation of 
TRAF6 must be exquisitely regulated.  Specifically, I am interested in how TRAF6 
signaling is modulated by both protein-protein interactions and subcellular localization.    
1.2 Biophysiological systems share recurrent organization and components 
An allegory to the pitfalls modern molecular biologist must avoid is found in 
Saxe’s six blind men of Indostan and their elephant, who were “each in isolation 
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potentially correct, but all were ultimately wrong!”  Armed with a reductionist strategy, 
investigators studying their favorite protein(s) in the alphabet soup of intracellular signal 
transduction networks can lose perspective of the integrative nature of biological systems.  
The central nervous system (CNS) along with the immune and endocrine systems 
together form a regulatory network in higher animals and man termed the Neuroimmune 
Super System (NISS) (Berczi, Quintanar-Stephano et al. 2009).  The healthy brain and 
spinal cord are under continual immune surveillance to guard against potential mediators 
of infection and damage. Uncontrolled response in the brain can be particularly 
deleterious, as in the case of meningitis.  Loss of immunity is just as bad, often resulting 
in cerebral infections.  While it is established that cells from the immune system interact 
with the CNS within the meningeal compartment of the central nervous system (CNS) 
(Ousman and Kubes 2012, Ransohoff and Engelhardt 2012), it was believed that the CNS 
lacked a classic lymphatic drainage system.  Most recently, it has been discovered that T-
cells gain entry into the CNS via functional lymphatic vessels that line the dural sinuses 
of mice (Louveau, Smirnov et al. 2015).  The vessels express all of the molecular 
hallmarks of lymphatic endothelial cells, are able to carry both fluid and immune cells 
from the cerebrospinal fluid, and are connected to the deep cervical lymph nodes.   While 
this finding is very exciting, many previously held assumptions of NISS processes would 
now need reconsideration.  One such topic might be the comparative similarities between 
the synaptic structures found in the immune system and those between neurons (Dustin 
and Colman 2002).  Such similarities harken to the of conserved organizational principles 
across biological systems.    
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1.3 Conserved Organizational Principles and Components Among Various Biological   
Synapses 
A synapse is a stable adhesive junction between two cells across which 
information is relayed by direct secretion.  Synapses are used by both the nervous system 
and immune system to directly convey and transduce highly controlled secretory signals 
between cell populations.  Each of these synapse types is built around a microdomain 
structure composed of central active domains of exocytosis and endocytosis that are 
encircled by outer adhesion domains (Figure 1.1).  Surface molecules that are 
incorporated into and around the active domains may modulate the functional state of the 
synapse (Dustin and Colman 2002).  In 2002, Dustin and Coleman proposed four criteria 
for defining synaptic junctions: (1) cells remain individual; (2) the apposed membranes 
are held together by adhesion molecules; (3) the junction is stable either through adhesion 
clamp or cytoskeleton polarity; and (4) directed secretion in response to signals from 
microdomains.  Analysis of the origins of the IS pattern formation over the past 15 years 
has seen an emergent modularity to synapse design that has provided solutions to 
lymphocyte biology and phagocytic processes (Dustin and Colman 2002, Dustin 2009, 
Goodridge, Reyes et al. 2011).  As the components most critical for lymphocyte signaling 
became known, efforts were made to uncover the subcellular localization of those 
components, both under resting and stimulated conditions (Paul 2003).  Seminal studies 
by Monks et al. provided images that showed a variety of molecules accumulating at the 
Interface between T cells and antigen-presenting cells (APCs).  These molecules’ 
membrane surface, were  spatially  segregated  over  time into distinct structures termed 
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Figure 1.1 Comparative schematics of immunological and neural synapses A) CNS 
synapse B) Effector immunological synapses with T-Cell as presynaptic and target 
cell as postsynaptic C) Inductive immunological synapse with DC as presynaptic 
and T-Helper cell as postsynaptic D) Diagram of IS formation. Green, TCR-MHCp 
interactions and MHCp in exocytic vesicles; red, LFA-1:ICAM-1 interaction; blue, 
soluble contents of exocytic vesicles and diffusing contents after release; yellow, 
CD43 at boundaries; orange, microtubules; cross-hatch, material in synaptic cleft 
(From Dustin, M. L. and D. R. Colman [2002]. "Neural and immunological synaptic 
relations." Science 298[5594]: 785-789. Reprinted with permission from AAAS.) 
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supramolecular activation complexes (SMACs) (Monks, Freiberg et al. 1998, Wetzel, 
McKeithan et al. 2002).  The immunological synapse (IS) is formed on the plane of 
adhesion between T cell and APCs where the molecules involved in antigen recognition 
and adhesive molecules rearrange and cluster into a characteristic ring like pattern of 
adhesion molecules surrounding a central supramolecular activation cluster (cSMAC) 
(Dustin and Shaw 1999, Davis 2002).   
The area of cell membrane where the IS forms is populated by lipid 
microdomains, where various signaling molecules collect to transmit the antigen 
recognition signal into the cell.  This activates the T cell defense programs and the lipid 
microdomains are utilized in spatiotemporal control of the signaling components.  Lipid 
microdomains have also been demonstrated as an important mechanism for the 
RANK/TRAF6/NF-κB signaling axis found in osteoimmunological systems (Ha, Kwak 
et al. 2003).  Metazoan physiological systems are rife with this type of shared 
mechanistic organization.  Given the integrated nature of organismal systems that arise 
from undifferentiated totipotent cells, it is not surprising that biological systems share 
mechanistic modalities that include the overlap of critical keystone molecules that are 
able to bridge the many cell surface receptor signaling systems.  TRAF6 is one such 
keystone molecule.  TRAF6 is uniquely poised to bridge a diverse array of physiological 
processes, including adaptive and innate immunity, bone metabolism and the 
development of several tissues including lymph nodes, mammary glands, skin and the 
central nervous system (Wu and Arron 2003).   
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1.4 TRAF6 is unique among TRAF family proteins 
 TRAF6 is an intracellular signal transducer that functions as an E3 ubiquitin 
ligase.  TRAF6 belongs to a family of proteins that were initially identified by the 
capability to interact with and regulate signaling through different members of the TNFR 
superfamily (Takeuchi, Rothe et al. 1996, Locksley, Killeen et al. 2001).  The TNFR 
superfamily consists of at least 26 members, including: Fas antigen; CD27; CD30; CD40; 
TNFR1; and TNFR2, which mediate immune regulation and inflammatory responses.  In 
mammals, six different TRAF proteins (TRAF1-TRAF6) have been described with 
TRAF1 clearly distinct from the others with respect to the architecture of the N-Terminal 
domain (Figure 1.2).  Among the members of the TRAF protein family, only TRAF6 has 
been demonstrated to transduce both TNFR family signaling and that for the unrelated 
interleukin-1/18 receptor/Toll-like receptor (IL-1R/TLR) superfamily that possess a 
conserved cytoplasmic TIR (Toll I-1 Receptor (TIR) domain (Table 1).  Upon TLR1/2/4, 
but not TLR3/9, signaling, TRAF6 translocates to mitochondria where it binds to ECSIT 
to induce mitochondrial reactive oxygen species (mROS) and enhance bacterial killing 
(West, Brodsky et al. 2011).  TRAF6 also mediates signaling for some growth factor 
receptors including: transforming growth factor beta (TGFβ), nerve growth factor (NGF), 
and endothelial growth factor (EGF).  TRAF6 signaling activates many transcription 
factors including: NF-κB, Jun-Fos dimers (Activator protein-1 or AP-1), Interferon 
regulatory factors (IRFs) and CCAAT/enhancer binding protein beta (C/EBPβ).  Such 
activity stimulates the production of cytokines or the differentiation of cells into several 
distinct phenotypes (Wu and Arron 2003).  TRAF6 has been demonstrated, using 
knockout  mice  and  RNAi  technology,  to  be  critical  for  CD40 signaling and receptor 
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activator of nuclear factor κB (RANK) signaling (Lomaga, Yeh et al. 1999, Davies, Mak 
et al. 2005).  RANK is known to mediate both canonical (TAK1/IKKα, β, γ) and non-
canonical (NIK/IKKα) NF-κB pathways (Mizukami, Takaesu et al. 2002, Novack, Yin et 
al. 2003, Xiao, Balasubramanian et al. 2012) (Figure 1.3).  
 
 
Figure 1.2 Structural Organization of The Known TRAF Family Proteins.  Shown is 
the number of amino acids (right) of murine TRAF proteins* and human TRAF 
proteins.  Boxes represent the relative positions of described protein domains and 
modules as indicated.  TRAF6 features shown reflect positions as reported for 
human TRAF6. The “module” containing both the TRAF-N (Coiled-coil) and 
TRAF-C (MATH) domains has historically been referred collectively as the 
“TRAF” domain, even though it contains two distinct, structurally independent, 
domains. Similarly, the “RING-Zinc Finger” module contains multiple Zinc Finger 









Table 1 TRAF Family Member Functions And Primary Subcellular Localization.  
Functions and localization was derived from online databases (Gene Cards, UniProt, 
The Human Protein Atlas), this research study and the literature cited herein. 
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In the mammalian immune system, when CD40 ligand on T cells engage CD40 
on B cells, numerous signals within B cells initiate, including the activation of Mitogen-
activated protein kinase (MAPK) and both classical and non-canonical NF-κB (Karin 
2008, Hostager and Bishop 2013).  The herpes viral oncoprotein, Tio, depends on TRAF6 
and Inhibitor of κB kinase (IKKγ or NEMO), and enhances the expression of the 
noncanonical NF-κB proteins, p100 and RelB (de Jong, Albrecht et al. 2010).   Further, 
OX40  activated the ubiquitin  ligase TRAF6, which triggered induction of  the  kinase 
NIK in  CD4+ T cells  and  the noncanonical transcription  factor NF-κB pathway (Xiao, 
Balasubramanian et al. 2012).  Thus,  TRAF6  differentially  affects  both  the  canonical 
and non-canonical NF-κB activation pathways by recruiting both TAK1 and NIK, 
respectively.  However,  the  mechanistic details of this phenomenon remain 
incompletely understood or  may  be  confounded by  the cell lineage, type  or 
developmental  state.  As such, greater detail is an important direction for future research.  
The  current  understanding  partially derives  from  research  in  the field  of 
neurotrophic  signaling,  suggesting  that  the  underpinnings  are  dependent  upon both 
direct  and  indirect protein-protein  interactions;  namely, TRAF6  interacts  with specific  
domains  of  variably  expressed  scaffolding   proteins  and  isoforms  of  those  proteins 
(Geetha and Wooten 2002, Wooten, Geetha et al. 2005) and/or polyubiquitination by 
TRAF6 of those extramolecular proteins.  In Schwann  cells, TRAF6 and an adapter 
protein RIP2 bind  directly  to the  p75NTR receptor in  a ligand dependent  manner to 
activate  NF-κB.  In the neuronal cell line  PC12, IRAK1  and  atypical  PKC  (aPKC) 
complex with TRAF6  and  recruit  p62/SQSTM1  to promote  nerve growth  factor 
(NGF)  activation  of  NF-κB.   The  various  domains  of  the  protein p62, also known as  






Figure 1.3 RANKL Binding To RANK Activates Canonical And Non-Canonical 
Signaling To The Transcription Factor NF-κB.  Signaling from RANKL and other 
receptors converge on a two different IκB kinase complexes that phosphorylate the 
NF-κB inhibitory proteins I-κB. 
  
  12 
sequestosome 1 (SQSTM1) can bind to RIP, aPKCs, TRAF6 and polyubiquitin chains in 
order to regulate proteosomal degradation of ubiquitinated proteins (Seibenhener, Babu et 
al. 2004, Babu, Geetha et al. 2005, Moscat, Diaz-Meco et al. 2007). Moreover, SQTM1 
modulates RANK signaling to NF-κB and mutations in SQSTM1 are associated with 
both sporadic and hereditary Paget's disease of Bone (PDB) in different populations.  
PDB is a hereditary disorder characterized by excessive localized bone resorption by 
osteoclasts (Layfield and Hocking 2004).  Recent work in immunobiology has implicated 
the herpes viral oncoprotein Tio, which promotes growth and transformation of human T 
cells in a recombinant herpes virus Saimiri background and to potently induce canonical 
NF-κB signaling through membrane recruitment of TRAF6.  In addition to triggering 
canonical NF-κB signaling in NEMO/IKKγ-dependent activation of the p52 and RelB 
isoforms of NF-κB, Tio also induces NEMO/IKKγ-independent generation of active NF-
κB p52 from its inactive p100 precursor (de Jong, Albrecht et al. 2010, de Jong, Albrecht 
et al. 2013).  Taken together the Tio and p62 studies underscore TRAF6’s role as a 
keystone adaptor molecule utilizing protein-protein interactions with other adaptor 
molecules to regulate both the canonical and noncanonical NF-κB activation pathways.  
  













Figure 1.4 Exon–intron Structure of Human TRAF Genes.  The exon–intron 
structures of the human genes encoding TRAF2 to TRAF6 according to the NCBI 
entries NT_025667 (TRAF2), NT_010019 (TRAF3), NT_030828 (TRAF4), 
NT_021877 (TRAF5) and NT_024229 (TRAF6) were matched with the cDNA 
sequences encoding TRAF2 to TRAF6 [accession numbers U12597 (TRAF2), 
U19260 (TRAF3), X80200 (TRAF4), AB000509 (TRAF5) and U78798 (TRAF6) 
Only exons encoding parts of the cDNA translated into protein were considered in 
this illustration.  Thus, exons numbered in this scheme with as 1 do not necessarily 
correspond to exon 1 of the respective gene in the database.  Exons encoding parts of 
the TRAF domain were summarized and labeled TD. The number of nucleotides 
encoded by each exon is indicated in the box representing the respective exon.  Gray 
boxes indicate exons containing multiples of three nucleotides. Modified from 
(Glauner, Siegmund et al. 2002). 
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1.5 TRAF6 molecular domain structure and function 
TRAF6 is a 61-kDa protein consisting of several distinct modules with specific 
functions.  The architecture of the TRAF family proteins is largely homologous, with the 
seven mammalian TRAFs hallmarked by distinct amino and carboxyl structures (Figure 
1.2) that consists of two distinct modules: an amino Ring-Zinc (RZ) module and a 
carboxyl TRAF module.  TRAF7 The human TRAF6 gene is located at chromosome 
11p12.  The exon–intron structures of human TRAF genes are diagrammed in (Figure 
1.4).  Remarkably, analyses of the human TRAF2, 3, 4, 5 and 6 genes revealed that they 
all share a stretch of three to six consecutive exons with a multiple of three nucleotides 
encoding the zinc finger domains of these molecules (Figure 1.4).  Thus, any combination 
of these exons results potentially in an in-frame splice-form of the respective TRAF 
isotype (Glauner, Siegmund et al. 2002).  The implication of such similarities in splice 
forms could account for differential subcellular localization and/or functionality amongst 
the TRAF family isoforms and isotypes. (For a through review and characterization of 
evolutionary consequences upon TRAF family genomic structure and functional 
implications please see (Grech, Quinn et al. 2000)).   
 Proceeding from the amino termini in TRAF2 through 7, the RZ module contains 
a RING zinc finger (Really Interesting New Gene) domain, which is common to E3 
ligases, followed by four to seven non-RING zinc fingers.  The RZ module is followed 
by the TRAF module, which is separated into TRAF-N and TRAF-C domains.  The 
TRAF-N is a coiled-coil (cc) domain is comprised of a single alpha helix, which is 
required for TRAF coiled-coil oligomerization, as implied by correlation with the X-ray 
crystal structures of TRAF2 and TRAF3.  TRAF modules potentially oligomerize as both 
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homotypic and heterotypic dimers and trimers.  The structure of the TRAF module of 
TRAF2 reveals a trimer where the coiled-coil (TRAF-N) domain forms a single stalk-like 
structure and the Ig-like anti-parallel -stranded MATH (Meprin and TRAF homology 
domain)/TRAF-C domain forms three interacting globulin structures beyond the stalk 
that terminate the oligomer (Ye, Park et al. 1999, Glauner, Siegmund et al. 2002).  The 
trimeric form of the TRAF2 C-terminal TRAF module is shown in Figure 1.5A.  With the 
exception of TRAF7, the remaining six members of the TRAF family possess a carboxyl-
terminal MATH domain that folds into a beta-sandwich structure that contains a groove 
that specifically interacts with receptors or intracellular proteins bearing a TRAF 
interaction motif (TIM).  For a thorough review of TRAF7 please see (Zotti, Vito et al. 
2012).  Importantly, TRAF1 through 5 all have similar TIM specificities, whereas 
TRAF6 binds distinct TIM sequences.  This is reflected in the distinct amino acid 
composition of the MATH domain groove that binds the TIM (Figure 1.5C).  Peptides 
with the sequence P-X-E-X-X-(acidic or aromatic residue) bind TRAF6 while, a 
PXQX(T/S) motif specifies binding to the other TRAFs, such as TRAF2 and TRAF3.  
Synthetic transduction TIM peptides (Figure 1.5D) have been shown to inhibit TRAF 
activity (Poblenz, Jacoby et al. 2007).  Interestingly, the reported crystal structures of the 
TRAF6 MATH domain (residues 346-504) only contained a monomeric TRAF6 MATH 
domain (Figure 1.5B) and not a coiled-coil multimerization domain (Ye, Arron et al. 
2002).  The TRAF6 MATH domain is structurally similar to both the TRAF2 and TRAF3 
MATH domains, which both crystallized as trimers (McWhirter, Pullen et al. 1999, Park, 
Burkitt et al. 1999), possibly because the crystallized fragments of TRAF2 and TRAF3 
included both coiled-coil and MATH domains.  Furthermore, it is known that the TRAF6 
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MATH contains a polyproline loop that is unique to the TRAF6 MATH and facilitates 
Src binding (Wong, Besser et al. 1999) and PI3K activity (Wang, Wara-Aswapati et al. 
2006) (Figure 1.6).  This would support the functionality of the coiled-coil domain in 
oligomerization of TRAF molecules.  Moreover, the divergent peptide-binding groove in 
the MATH domain of TRAF6, as compared to other TRAFs (Figure 1.5C), confers 
unique biological functions to TRAF6; it does not interact with peptide motifs that are 
recognized by TRAF1, -2, -3 or -5 (TIMs).  Comparing the peptide bound crystal 
structures of TRAF6 and TRAF2 reveals that bound TRAF6-binding peptides display a 
40o rotation in chain vector from that of the TRAF2-binding peptides.  As a result, side-
chains of TRAF6-binding peptides interact with surface pockets on TRAF6 that are 
vastly different from those on TRAF2 (Ye, Arron et al. 2002), as well as other TRAFs.  
TRAF Domain proteins are intracellular proteins that can act as adapters, binding 
either the cytoplasmic tails of receptors, upstream regulators, or downstream effectors 
(Table 2).  Both CD40 and RANK can recruit TRAF1, 2, 3, 5 and 6 to their cytoplasmic 
tails.  TRAF6 binds to more distinct TIM sites (T6IM) than the other TRAFs.  There are 
two distinct types of TIM: PXEXX(Ar/Ac) motif with the last residue either aromatic or 
acidic for TRAF6 (Figure 1.5D), and a conserved PXQX(T/S) motif with the last residue 
either a threonine or serine for TRAFs 1, 2, 3 and 5 (Wu and Arron 2003, Yoshida, 
Takaesu et al. 2008).  Similar to TRAF6, TRAF4 also bears a non-conserved substitution 
in the MATH binding site, helping to explain differences in receptor specificity (Ye, Park 
et al. 1999, Grech, Quinn et al. 2000, Rousseau, Rio et al. 2011).  By aligning various 
crystallized TRAF-receptor complexes it is possible to derive the TIM sequence.  The 
core of four conserved residues of the TIM are labeled P-2 to P3, centered about the zero 
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position (P0) that is invariably a Glu (Wu and Arron 2003).  Although, proteins bearing a 
TIM peptide are highly variable in their primary sequences, the conserved motif serves to 
converge this diverse set upon the MATH domain of TRAF proteins. Regardless, TRAF6 
specificity is the most distinct, resulting in greater selectivity for specific TIM interaction.  
In summary, there are three ways that TRAF proteins can be recruited to and actuated by 
ligand-engaged receptors: (1) Members of the TNF receptor superfamily that do not 
contain intracellular death domains, such as NFR2 and CD40, recruit TRAFs directly by 
TIM sequences in their intracellular tails; (2) Those that contain an intracellular death 
domain, such as TNFR1, utilize the adapter protein TRADD via a death domain-death 
domain (DD) interaction that results in TRADD assembling a complex of TRAF2 and 
RIP for survival signaling that competes with a DD interaction with FADD that activates 
caspase 8 for the induction of apoptosis; (3) Members of the TIR superfamily, containing 
a protein interaction module known as the TIR domain, recruit Myeloid differentiation 
primary response gene 88 (MyD88), a TIR domain and DD containing protein, and 
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Figure 1.5 TRAF Structural Models and Sequence Analysis for MATH Domain-
Protein Interactions.  A) Structural model of TRAF2 coiled-coil (CC) 
domain/MATH domain trimerization, shown by the symmetrical interaction of 
trimerized MATH/TRAF-C domains (cyan, blue and green) and yellow for the three 
coiled-coil domains (from (Ye, Park et al. 1999).  B) Accessible solvent surface 
contour representation of a single TRAF6 and TRAF2 MATH domain in an 
orientation similar to that shown in A. The superimposed worm representations of 
receptor peptide backbones are shown in magenta, emphasizing distinct orientations 
and specific MATH domain contacts (arrows). C) Conservation of exposed contact 
residues within the MATH domain of TRAF family proteins representing key 
features of the TIM grooves that interact with TIM peptides (from (Ye, Park et al. 
1999).  D) The three conserved key amino acids of proteins bearing TRAF6 TIM 
peptides identified from the structural analysis of peptide interactions with distinct 












Figure 1.6 The Unique TRAF6 Interaction Motif (T6IM) Allows Receptor 
Interaction Specificity for Signaling to C-Src and Subsequent PI3K Activation.  
Differences in the MATH domain and TRAF6 Interaction Motif (T6IM) between 
that of TRAF6 and other TRAFs, such as TRAF2 and TRAF5, provide unique 
receptor interaction specificities for signaling to c-Src and subsequent PI3K 
activation. Key: Red arrows indicate tyrosine phosphorylation targets; Dotted 
double-ended arrows indicate protein-protein interactions; and solid single-ended 
arrow indicates a likely IRAK relocalization form IL-1 receptor at the plasma 
membrane to cytoplasmic TRAF6. The multiple, promiscuous, TIM targets for 
TRAF2 and TRAF5 on the cytoplasmic region of RANK, and the unique 
membrane-proximal binding of TRAF6 to a TIM of distinct specificity, reflects the 





















Table 2 Examples of Receptors and Intracellular binding Partners that bind to 
TRAF Domain Proteins.  TRAF Domain proteins are intracellular proteins that can 
act as adapters, binding either the cytoplasmic tails of receptors, upstream 
regulators, or downstream effectors.   
  
TRAF Domain Proteins Binding Partners 
TRAF 1,2,3,5 CD40 
TRAF 1,2 TRADD 
TRAF6 IRAK1, Sox4 
TRAF2 TNFR1 
TRAF6 IL-1, CD40, RANK, TLR4 
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1.6 IRAK1 Initiates TRAF6 Ubiquitination Of Downstream Targets   
TLR4 is the principal signal-transducing receptor for lipopolysaccharide (LPS), a 
component of the outer membrane of Gram-negative bacteria, (Poltorak, He et al. 1998, 
Chow, Young et al. 1999).  Activated TLR/IL1R (TIR) recruit the adapter protein 
Myeloid differentiation primary response gene 88 (MyD88) to their cytoplasmic TIR 
domains, initiating assembly of the Myddosome, a multi-protein complex composed of 
MyD88, and the serine/threonine kinases: IL-1R-associated kinases (IRAK), IRAK4, 
IRAK1 and IRAK2.  This complex initiates the MyD88-dependent signaling pathway 
that has been implicated in LPS-induced tyrosine phosphorylation (Zeisel, Druet et al. 
2005).  IRAK2 activates IRAK1 through IRAK4-dependent phosphorylation.  IRAK1 
phosphorylation by IRAK4 results in a conformational change, dissociating IRAK1 from 
the TLR4 complex.  IRAK1 then either binds to then activates TRAF6 in the cytoplasm, 
(Akira and Takeda 2004) or TRAF6 dynamically interacts with receptor-bound IRAK1, 
resulting in rapid release and transfer to TRAF6 (Jiang, Johnson et al. 2003, Muroi and 
Tanamoto 2008).  Structurally, IRAK1 consists of an amino terminal domain (NTD) that 
contains a death domain (DD) that interacts with the DD of MyD88, and a proline-serine-
threonine rich region (ProST Domain) followed by a central kinase domain that has been 
shown to be dispensable for NF-κB activation (Li, Commane et al. 2001) (Figure 1.7).  
This might be due to the redundant functions of IRAK2 (Rhyasen and Starczynowski 
2015).  The carboxyl terminal domain (CTD) of IRAK1 contains three potential TRAF6-
binding sites (Glu544, Glu587, Glu706).  Mutating these Glu to Ala was found to 
significantly reduce NF-κB activation (Ye, Arron et al. 2002).  
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Figure 1.7 Structural Domain Architecture and Associated Functions of IRAK1.  
Amino Acid numbering is indicated for human IRAK1 and is annotated according 
to ELM Analysis (http://elm.eu.org/).  The ProST Domain is a proline-serine-
threonine rich region that is heavily phosphorylated upon IRAK1 activation 
(Kollewe, Mackensen et al. 2004). 
 
The NTD (death domain and ProST Region) plus the first half of the CTD were 
demonstrated to be sufficient for IL-1-induced activation of NF-κB (Li, Commane et al. 
2001).  The ephemeral nature of the IRAK1-TRAF6 interaction might account for the 
dearth of reports in the literature of TRAF6 being recruited by TIR to the membrane, as is 
the case with TRAF6 and RANK (Wong, Besser et al. 1999) or TRAF2/3 by CD40 
(Hostager, Catlett et al. 2000).  In particular, there is an absence of micrographic 
evidence for this interaction, although biochemical evidence has been reported to support 
a TRAF6-TIR interaction (Cao, Xiong et al. 1996, Qian, Commane et al. 2001, Jiang, 
Mak et al. 2004, Kollewe, Mackensen et al. 2004). 
 Covalent attachment of ubiquitin to proteins is a reversible, post-translational 
modification (similar to phosphorylation or acetylation) that distinguishes select proteins 
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for regulation and signal propagation.  Ubiquitylated proteins interact with other proteins 
bearing ubiquitin-binding modules (Rahighi and Dikic 2012).  To act an E3 ubiquitin 
ligase, TRAF6 forms a complex with the E2 ubiquitin conjugating enzyme Ubc13 and 
Ubc-like protein Uev1A.  This enables TRAF6 auto-ubiquitination, trans-ubiquitination, 
activation and downstream ubiquitination of targets such as TAK1 through a non-
degradative Lys63-linked polyubiquitination (Wang, Deng et al. 2001, Seibenhener, Babu 
et al. 2004, Rong, Cheng et al. 2007, Balkhi, Fitzgerald et al. 2008).  TRAF6 can also 
mediate Lys48-linked polyubiquitination, which induces proteosomal degradation of 
proteins such as RIP1 and IRAK1 (Newton, Matsumoto et al. 2008).  Since IRAK1 
activates TRAF6, this is a feed-forward mechanism for attenuation of TRAF6 signaling.  
Here, TRAF6 binds to Lys48-linked polyubiquitinated proteins like IRAK1 and they 
translocate together into the proteasome where IRAK1 undergoes proteosomal 
degradation while TRAF6 is recycled through de-ubiquitination, rather than by 
degradation.  The enzyme, Cylindromatosis (CYLD) is responsible for deubiquitinating 
Lys63-linked-TRAF6, -TRAF2 and - NEMO/IKKγ (Jensen and Whitehead 2003, 
Kovalenko, Chable-Bessia et al. 2003, Trompouki, Hatzivassiliou et al. 2003, Yoshida, 
Jono et al. 2005, Wooten, Geetha et al. 2008).  In addition to de-ubiquitinating enzymes 
(DUBs), proteins such as A20 act as ubiquitin-editing enzymes; substituting Lys63 linked 
poly-ubiquitin with Lys48 linked poly-ubiquitin on its target proteins (Sun 2008, 
Coornaert, Carpentier et al. 2009).   
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1.7 Shared signaling systems utilized in Osteoimmunology 
In bone remodeling, osteoclasts resorb old and damaged bone, which is then 
replaced by new bone deposited by osteoblasts.  Imbalances in either resorption or 
deposition of bone leads to a pathological decrease or increase in bone mass, the former 
often being caused by inflammatory diseases of the immune system.  For example, the 
autoimmune disease rheumatoid arthritis is an abnormal or prolonged activation of the 
immune system that causes bone loss by excessive osteoclast activity (Guo, Yamashita et 
al. 2008).  The first reports that cells of the immune system could influence the functions 
of bone cells were made over 40 years ago.  Then, in the 1980’s, antigen stimulated 
immune cells were shown to produce soluble factors that stimulate osteoclast bone 
resorption, and interleukin 1 (IL-1) was identified as one of these factors (Stashenko, 
Dewhirst et al. 1987, Blair, Zheng et al. 2007).  Accumulating evidence suggests that 
bone destruction associated with rheumatoid arthritis is caused by the enhanced activity 
of osteoclasts, resulting from the activation of the Th17 subset of helper T cells (Miossec 
2003).  Such work promoted the now decade old research field of osteoimmunology, 
which investigates the interplay between the skeletal and immune systems at the 
molecular level (Arron and Choi 2000, Lorenzo, Horowitz et al. 2008).  Numerous 
studies have shown that the two systems share a number of regulatory molecules 
including cytokines, receptors, signaling molecules and transcription factors. This is 
particularly true when comparing B cell with osteoclast biology (Takayanagi 2007).  
Together, Tumor necrosis factor alpha (TNFα) synergizes with Receptor Activator of 
Nuclear Factor Kappa B Ligand (RANKL) for enhanced osteoclast activation and activity 
(Jimi, Aoki et al. 2004). TNFα is considered one of the key inflammatory mediators 
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during bacterial infections.  Blood leukocytes, such as monocytes/macrophages, secrete 
TNFα as a host defense against bacterial infections (Chen, Pan et al. 2009, Funakoshi-
Tago, Kamada et al. 2009).  Trimeric RANKL (a member of the TNF family) in stromal 
cells is the essential osteoclastogenic ligand.  Each RANKL trimer recognizes either a 
single trimeric RANK (a member of the TNF receptor family) or the trimeric 
osteoprotegerin (OPG) decoy receptor, which inhibits osteoclastogenesis (Boyle, Simonet 
et al. 2003, Warren, Nelson et al. 2014).  Trimerization of RANK is a good example of a 
strategy for increasing and concentrating the signaling of an extracellular ligand in order 
to activate the downstream, intracellular signaling cascades. It is common for a single 
ligand to engage multiple rather than an individual receptor (Korpelainen, Karkkainen et 
al. 1999).  Multimeric receptor complexes may be homotypic or heterogeneous in subunit 
composition.  Oligomerization of active receptors allows the formation of receptor 
complexes composed of distinct, but similar subunits, which can have different signaling 
potentials (Pawson and Nash 2000).  Signaling by RANK in response to its ligand, 
RANKL, stimulates osteoclast formation and bone resorption.  Cells may also utilize 
receptor modularity of the extracellular (ligand-binding) and intracellular (signaling) 
regions.  This  allows a wide variety  of signals  to use  limited regulatory componentry 
(Katritch, Cherezov et al. 2012).   Additionally, cells  may also express different 
receptors for  the same ligand.  This  ligand may  have different effects  depending  on the 
effector domain of the receptor.  For  example, TLR4 and  MD-2 form  a heterodimer that  
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recognizes LPS (lipopolysaccharide) from Gram-negative bacteria (Kim, Park et al. 
2007).  Intracellularly, the receptors: TLR4, IL-1R and TNF-R signal to NF-κB through a 
common IKK-dependent pathway that allows us to view them as variations on a common 
theme (Figure 1.8). 
 
 
Figure 1.8 TIR and TNFR Signaling Pathways Converge During the Activation of 
IKKs.  Phosphorylation activates IKK, resulting in IkBα phosphorylation, 
ubiquitination and degradation.  Signal transduction through TNFR recruits RIPK, 
when poly-ubiquitinated, binds TAB adaptor proteins, inducing TAK1 activation.  
Activated IKKβ phosphorylates IkBα, which is modified with Lys48-linked chains.  
This form of IkBα is subsequently transported to the proteasome, where it is 
degraded, enabling NF-kB nuclear translocation.  
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1.8 TLR4, IL-1R and TNF-R signaling to NF-κB: variations on a common theme 
In mammals, the TIR family members are important mediators of inflammation, 
innate and adaptive immune responses.  The specificity of distinct TLRs is achieved 
through alternate and combinatorial adaptor usage (Yin, Lin et al. 2009).  MyD88 can 
recruit IRAK molecules to the plasma membrane.  Notably though, TRAF6 has not been 
visually demonstrated to be stably recruited by TIR to the membrane.  Thus, after TIR 
activation, IRAK is bound to the receptor and either interacts with TRAF6 after release or 
TRAF6 interacts in a “kiss and run” fashion with receptor bound IRAK.  Toll-like 
receptors (TLRs), as well as the receptors for tumor necrosis factor (TNF-R) and 
interleukin-1 (IL-1R), are important for initiating osteoimmunity function by the non-
canonical NF-B pathway via developmental signals activating NIK and IKK kinases. 
This activation causes proteolytic degradation of the inhibitory IκBδ domain of NF-
Bp100, generating active NF-B-p50, resulting in nuclear translocation of RelA:p50, 
RelB:p50 and RelB:p52 dimers, facilitating target gene expression. The canonical 
pathway is activated through pathogen and inflammatory signals activating NIK and 
IKK kinases. This activation results in the degradation of IκBα/IκBβ/IκBε, allowing for 
the nuclear translocation of RelA:p50, RelA:RelA and cRel:p50 dimers, which then 
activate a different set of genes from the noncanonical pathway. (Modified from (Shih, 
Tsui et al. 2011)).  Nevertheless, the principles of signaling are similar, involving the 
recruitment of specific adaptor proteins and the activation of kinase cascades in which 
protein-protein interactions are controlled by poly-ubiquitination (Verstrepen, Bekaert et 
al. 2008). MyD88 and IRAK1 play crucial roles as adaptor molecules in signal 
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transduction of the TLR/IL-1R superfamily, and it is known that expression of these 
proteins leads to the activation of NF-κB in a TRAF6 dependent manner.    
1.9 TRAF6 transduces both Canonical and Non-canonical Signaling to NF-κB 
The transcription factor NF-κB is a member of the widely expressed family of 
Rel-related transcription factors that are required for the induction of many genes.  In 
particular, these genes have been associated with the osteoimmunological and 
neurobiological systems (Kuner, Schubenel et al. 1998, Arron and Choi 2000, Lorenzo, 
Horowitz et al. 2008).  Furthermore, NF-κB has been demonstrated to critically regulate 
cancer, adaptive and innate immune response, apoptosis, inflammation, and cellular 
differentiation (Li and Stark 2002).  In mammals, the family has five members:  p50, p52, 
RelA (p65), c-Rel and RelB.  NF-κB consists of a 50-kDa protein (p50) and a 65-kDa 
protein (p65), as well as larger p100 and p105 heterodimers with smaller Rel family 
isoforms of NF-κB.  Family members can homo and hetero dimerize through a shared 
300 amino acid N-terminal DNA binding/dimerization domain, called the Rel homology 
domain, of which there are two different classes that possess a distinct intra-domain and 
DNA binding specificity (Chen, Ghosh et al. 1998, Wang, Huang et al. 2012).  Such 
modularity provides a platform for differential binding to gene expression enhancers, 
promoters and the control over gene expression.  The extensive range of stimuli that 
activates Rel family members underscores their importance in the integration of stimuli 
for transcriptional responses.  The complete details by which such diverse stimuli 
converge to activate this family of transcription factors have not yet been totally resolved 
and remains a highly researched topic of scientific investigation (Mercurio and Manning 
1999, Oeckinghaus, Hayden et al. 2011, Sun 2011).   
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NF-κB is activated through two signaling cascades: the classical (canonical) and 
non-canonical pathways.  Regarding immunological systems, the canonical pathway has 
historically been associated with inflammatory responses, while the non-canonical 
pathway is described to mediate immune cell differentiation and maturation and 
secondary lymphoid organogenesis.  Such differential effects arise from differences in the 
activation signals, regulatory mechanisms and involvement of specific NF-κB subunits.  
The non-canonical pathway predominantly targets activation of the p100/RelB complex 
via p100 processing to p52 to release the covalent IκBδ inhibitor, while the canonical 
pathway activates RelA/p50 and other NF-κB dimer complexes inhibited by non-covalent 
association with IκB and IκB inhibitors (n.b., p50 may be derived from constitutive 
p105 processing to release the covalent IκB inhibitor).  Despite the distinctions between 
the two pathways, recent studies have revealed numerous crosstalk mechanisms between 
pathways.  This crosstalk involves control of NF-κB monomer expression, interdependent 
proteolytic processing events of precursors, and the recent identification of IκBδ activity 
that is induced by one pathway and subsequently degraded by another (Oeckinghaus, 
Hayden et al. 2011, Shih, Tsui et al. 2011).  Regardless of this revised model, a brief 
review of the signaling mechanisms both distinct and common to each pathway remains 
relevant for research (including this study) that involves activation by receptors of both 
pathways, where TRAF6 overexpression can act as a surrogate or dominant positive for 
NF-κB activity (Wang, Wara-Aswapati et al. 2006, Wang, Galson et al. 2010). The 
ability of p62 (Sequestosome 1/SQSTM1) to complex with TRAF6 and other signaling 
adapter proteins may explain how TRAF6 activates both canonical and non-canonical 
NF-κB signaling pathways (de Jong, Albrecht et al. 2010, Zotti, Scudiero et al. 2014).  
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Recently, OX40 (CD134) has been implicated in TRAF6 mediated non-canonical NF-κB 
activity.  OX40 is a member of the TNFR superfamily that is expressed on primary CD4+ 
T cells when they are activated by CD28+ TCR ligation.  In activated primary CD4+ T 
cells, OX40 co-stimulates the cells to sustain NF-κB activity in an antigen-independent 
manner (Hildebrand, Yi et al. 2011).  Here, TRAF6 and cIAP2 were found to 
cooperatively activate the non-canonical NF-κB pathway. OX40 directly recruited 
TRAF6 and TRAF2/TRAF3/cIAP2/NIK complexes in which TRAF6 acted as the E3 
ligase to mediate Lys63-linked polyubiquitination of cIAP2 (Fan, Xiao et al. 2015).  
Taken together, TRAF6 can be considered another example of cells using adaptor 
molecules to integrate the multi-variant receptor activation signals by converging on 
limited, keystone effector molecules. 
1.10 Mechanisms of NF-κB Regulation by phosphorylation of I-κB 
Activation and nuclear translocation of NF-κB requires signal dependent 
phosphorylation, ubiquitination and proteosomal degradation of I-κB (Beg, Finco et al. 
1993, Heck, Bender et al. 1997).  The classical pathway for NF-κB activation requires 
IKK and IKKβ, as well as NEMO/IKK, whereas non-canonical signaling involves an 
IKK complex composed of two IKKα subunits and are NEMO independent (Figure 1.3). 
The canonical pathway is induced by pro-inflammatory signals such as cytokines, 
pathogen-associated molecular patterns (PAMPs), and some danger-associated molecular 
patterns (DAMPs).  Receptor activation ultimately triggers IKK activity, where IκBα is 
phosphorylated in an IKKβ and NEMO/IKKγ dependent manner.  This results in the 
nuclear translocation of mostly p65-containing heterodimers.  The non-canonical 
pathway is induced by certain TNF family cytokines, such as CD40L, BAFF and 
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lymphotoxin-β (LT-β) (Oeckinghaus, Hayden et al. 2011).  Here, a stimulus such as 
CD40L activates CD40 and NF-κB inducing kinase (NIK).  Activation of NIK is 
classically regulated by TRAF3, TRAF2 and additional ubiquitin ligases.  Receptor for 
lymphotoxin-β (LT-βR) and leads to homodimerization and IKKα phosphorylation of 
p100 associated with RelB, thereby resulting in the partial processing of p100 and the 
generation of transcriptionally active p52-RelB heterodimers.  There is speculation and 
some evidence for an unidentified TRAF6 dependent pathway X (see above), stimulated 
by CD40 that activates the IKK holoenzyme composed of all three subunits. In most 
cases, the activity of this complex depends on IKKβ (Karin 2008).   One strategy for 
treating CD40-driven inflammatory disorders is to block the downstream effectors of 
CD40. Blocking TRAF6 in MHC II (+) cells diminishes inflammation, but is complicated 
by CD40-TRAF6 blockade induced immunosuppression.   
1.11 Dual targeting of proteins is a means for controlling cell signaling and transcription 
Corralling genetic material and transcriptional machinery to the nucleus 
segregates it from the translational and metabolic machinery in the cytoplasm.  This 
provides a regulatory opportunity for cell signaling and gene regulation using nucleo-
cytoplasmic shuttling.  Among the numerous examples of nucleo-cytoplasmic shuttling 
proteins are the transcription factor 4 (Sox4) and its binding partner, the adapter protein, 
Syntenin (Syn) (Zimmermann, Tomatis et al. 2001, Beekman, Vervoort et al. 2012).  
Syntenin affects cancer cell motility and invasion through distinct biochemical and 
signaling pathways, including focal adhesion kinase and p38 mitogen-activated protein 
kinase (MAPK), resulting in activation of the NF-κB pathway (Boukerche, Aissaoui et al. 
2010).  Activation of NF-κB is a classical example of eukaryotic cell signaling regulation 
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by subcellular sequestration via protein-protein interactions.  Cells assemble proteins in 
the cytosol, but use selective bi-directional transport between the cytoplasm and the 
nucleus to regulate gene expression, signal transduction and cell cycle.  Latent NF-κB 
resides in the cytoplasm in an inhibited complex, bound by one of the IκB family 
members, as previously discussed.  IκB masks the nuclear localization signal (NLS) of 
both the NF-κB р65 and p50 subunits from interacting with the karyopherin-α/importin-
β1 complex, whereas IκB masks only one NLS, resulting in dynamic nucleocytoplasmic 
shuttling (Malek, Chen et al. 2001).  NLSs are short peptide motifs that mediate the 
nuclear import of proteins by binding to karyopherins/importins.  There are at least two 
nuclear import pathways: 1) the classical nuclear localization sequences (cNLSs) which 
involve the receptors importin-α/karyopherin-α and importin-β/karyopherin-β1; and 2) 
the karyopherin-β2 pathway, involving the proline-tyrosine (PY)-NLSs and the receptor 
transportin-1/karyopherin-β2 (Marfori, Mynott et al. 2011).  β-karyopherins are a family 
of soluble transport receptors that transport macromolecules through the nuclear pore 
complex (NPC) by an energy-dependent process.  Unmasking of the NLS on NF-κB p65 
and subsequent nuclear import as the cargo of the ternary karyopherin-α/importin-
β1/cargo complex requires proteosomal degradation of I-κB.  Untethered to the 
cytoplasm, NF-κB enters the nucleus, where it binds to B binding sites affecting the 
transcriptional profile of target genes (Baeuerle and Baltimore 1988, Baeuerle and 
Baltimore 1989, Ghosh and Baltimore 1990). 
The phenomenon of dual targeting or dual distribution of proteins is abundant in 
eukaryotic cells.  Echoforms is the term that for, identical or nearly identical proteins that 
are dually/differentially localized/targeted within a cell. This contrasts with isoforms, 
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which are related, but distinct, proteins that may be similarly localized. The targeting of 
echoforms can be determined prior to synthesis of the protein by generating multiple, 
different mRNAs derived from a single gene, or dual targeting of a single translation 
product (Figure 1.9).  Regardless, the differential subcellular positioning of echoforms 
strategically increases the complexity of eukaryotic signaling effectors from a finite pool 
of gene products.  Kisslov et al reported that dual targeted proteins are more 
evolutionarily conserved than proteins that are exclusively targeted.  They argue that 
maintenance of dual targeting is evolutionarily driven by a dual or discrete functionality 
of a single protein in different cellular compartments, without regard to the dual targeting 
mechanism (Kisslov, Naamati et al. 2014).  
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Figure 1.9 Mechanisms for Dual Targeting of a Single Translation 
Product.  (A) Two signals compete for different organelles on the same 
polypeptide.  (B) Ambiguous targeting signal is recognized by two organelles.  (C) 
Changes in the targeting signal accessibility caused by protein (i) folding (ii) binding 
to cellular factors (iii) modification or (iv) cleavage by a protease that exposes a 
targeting signal.  (D) Reverse translocation, polypeptides move back to the cytosol 
during translocation into an organelle.  (E) Trapping of proteins in an organelle by 
folding.  (F) Export of proteins out of an organelle.  (G) Release of proteins from 
organelles due to membrane permeabilization or breakage.  (H) Vesicular release of 
proteins from organelles.  (I) Release of proteins from organelles through tethering 
of membranes.  Used with permission from the author (Kalderon and Pines 2014). 
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1.12 Sox4 Molecular Domain Structure and Function 
All Sox-family proteins share a conserved SRY‐ box or HMG‐ box (high 
mobility group‐ box) AT-rich DNA binding domain.  Sox transcription factors were 
initially identified with the discovery of the sex determining factor, sex determining 
region on Y Chromosome (SRY) (Gubbay, Collignon et al. 1990).  SRY and Sox proteins 
are highly conserved in the HMG domain and belong to the same subgroup within the 
superfamily of HMG-box proteins.  In this superfamily, Sox proteins are characterized by 
having a single HMG domain that binds DNA in a sequence specific manner. Sox 
proteins bind to the minor groove of DNA via the consensus sequence 5’‐ A/T A/T CAA 
A/T G‐ 3’ (Laudet, Stehelin et al. 1993, Harley, Lovell-Badge et al. 1994).  When Sox 
proteins bind to the DNA minor groove, the DNA bends at an angle of 70-85° providing 
an additional structural component to the gene regulatory mechanism (Werner, Bianchi et 
al. 1995, Jauch, Ng et al. 2012).  The Sox family can be subdivided into groups A 
through H based upon a consensus within the HMG box sequence.  Sox4 is a member of 
the C subgroup of Sox proteins, which also includes Sox11 and Sox12 (Bowles, Schepers 
et al. 2000).  Group C members are distinguished from other Sox family subgroups by a 
conserved C-terminal transactivation domain (Figure 1.10).  The HMG box of Sox4 binds 
to and bends DNA with high affinity to the minor groove of DNA with the sequence 
AACAAT with the optimal 10bp sequence containing 5’ AG and 3’ G nucleotides 
directly adjacent to the core sequence (Vervoort, van Boxtel et al. 2013).  The SoxC 
proteins Sox4/11/12 are expressed widely in embryonic tissues, with the highest 
expression levels found in neural   









Figure 1.10 Comparison of Murine and Human Domain Structure of the SoxC 
Group Family of Proteins.  Sox4, Sox11 and Sox12 (formerly known as Sox 22) 
constitute the group C of Sry-related HMG box proteins. Members feature two 
functional domains: an Sry-related HMG box (Sox) DNA-binding domain and TAD 
comprised of the last 33 amino acids of the C terminus.  The TAD is 66% identical 
across all vertebrate SoxC proteins, 97% identical amongst Sox4 and Sox11 
orthologues and 79% identical amongst Sox12 orthologues.  SoxC protein domain 
architecture critically control cell fate and differentiation in major developmental 
processes, and that their up regulation may be a critical determinant of cancer 
progression.  Human molecular domain positions are derived from those reported 
by (Penzo-Mendez, Dy et al. 2007) and denoted in UniProt,  * Denotes Murine 
amino acid positions as described by (Dy, Penzo-Mendez et al. 2008). 
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and mesenchymal progenitor cells.  Sox4 was first identified as a transcription factor 
required for B- and T-lymphocyte differentiation.  The expression pattern of Sox4 during 
mouse embryogenesis has been analyzed by both whole mount and section in situ 
hybridization studies, which show that Sox4 is expressed in the mesenchyme of the 
branchial arches, trachea, esophagus and nervous system (Maschhoff, Anziano et al. 
2003).  Later in embryonic development, Sox4 is expressed in the embryonic growth 
plate where its expression is regulated via parathyroid hormone and parathyroid 
hormone-related protein receptor. Sox4 and Sox11 knockout mice develop multiple organ 
defects (Schilham et al., 1996; Sock et al., 2004), whereas Sox12 knockout mice are 
grossly normal (Hoser et al., 2008). However, various combinations of homo- and 
heterozygous SoxC mutations indicate that continued and cumulative activities of these 
three genes are required for widespread organ development; increasingly severe organ 
hypoplasia phenotypes were found with decreasing wild-type SoxC alleles (Bhattaram et 
al., 2010).  Partially SoxC-deficient embryos (Sox11-/-, Sox4+/- Sox11+/-, etc.) also display 
malformation of various organs. For example, Sox4-/-Sox11-/- embryos are minute at E9.5 
and show highly severe organ defects and extensive cell death. Nevertheless, these 
embryos appropriately express genes involved in cell lineages and embryo patterning, 
such as Pax1/7, Otx2 (orthodenticle homolog 2), Shh and Bmp4 (bone morphogenetic 
protein 4) (Bhattaram et al., 2010).  This suggests that SoxC proteins play important roles 
during early embryogenesis in sustaining neural and mesenchymal progenitor cells, rather 
than in cell lineage specification. In support of this, a reported target of SoxC 
is Tead2 (TEA domain family member 2), which is a transcriptional mediator of the 
Hippo signaling pathway that is crucial for organ size regulation (Bhattaram et al., 2010).  
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Additionally, Sox4-deficient mice exhibit arrest of B-cell development at the pro-B-cell 
stage.  Thus, Sox4 appears to be critical for normal development and maturation of 
endocardial cushions and for normal B-cell maturation. However, its function(s) in these 
processes is not yet clear (Maschhoff, Anziano et al. 2003).  Interestingly, Sox4 and 
Sox11 have been shown to have redundant functions in multiple systems, including an 
importance in the establishment of pan-neuronal protein expression and retinal ganglion 
cell development (Bergsland, Werme et al. 2006, Jiang, Ding et al. 2013). 
1.13 Sox4 localization depends on Syntenin 
Transcription factors like NF-κB and Sox proteins need to be translocated to the 
nucleus after translation in order to bind DNA and directly regulate gene expression.  
Control of the import and export of transcription factors is important for cell development 
and defense scenarios.   Improper nucleo-cytoplasmic shuttling of Sox transcription 
factors is associated with cancer and developmental disorders.  Mutations or problems 
that disrupt the proper timing, location or expression levels of Sox factors can lead to 
defects in organogenesis or other developmental disorders such as human sex reversal 
syndrome (HSR).  The etiology of HSR is defective nuclear import of SRY and Sox9 
(Preiss, Argentaro et al. 2001, Smith and Koopman 2004).  Sox4 has a bipartite nuclear 
localization signal (BP-NLS or -NLS) at positions 60-77 and 129-136, as identified by 
the Nuclear Protein Database (NPD, http://npd.hgu.mrc.ac.uk/user/index.php).  Half of 
Sox4’s BP-NLS is located within the N-terminus of the HMG box and just distal to it 
within the C-terminus, and allows Sox4 to be dually localized to both the nucleus and the 
cytoplasm (Figures 1.11).  Sox4 has been reported to accumulate with Syntenin in the 
nucleus (Farr, Easty et al. 1993, Beekman, Vervoort et al. 2012).  Syntenin interacts with 
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both the NTD and CTD of Sox4, but binds to 33 C-terminal residues of Sox4 to prevent 
poly-ubiquitin independent proteosomal degradation of Sox4 and co-relocalization with 




Figure 1.11 Sox4 Protein Domain Organization and Amino Acid Sequence.   A) 
Molecular Architecture of Human Sox4 Domains B) primary amino acid sequence 
annotated to show a Bi-Partite Nuclear Localization Signal (Underlined) (Kaur, 
Delluc-Clavieres et al. 2010), and a potential TRAF6 Interaction Motif (Red).  GRR 
and SRR represent glycine- and serine- rich regions respectively that are subject to 
posttranslational modification and either supports (GRR) or abrogates (SRR) 
apoptosis (Hur, Hur et al. 2004).     
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1.14 Syntenin is a dual PDZ domain containing scaffolding protein 
The SDCBP gene encodes the 298aa, 33kDa protein, Syntenin-1 (Syn).  Syn was 
initially identified as a binding partner of syndecan-1 (Grootjans, Zimmermann et al. 
1997).  Concurrently, Syn was also identified as a melanoma differentiation-associated 
gene 9 (mda9) in a melanoma cell line treated with IFN-γ (Lin, Jiang et al. 1998).   Syn is 
an adapter protein that couples transmembrane proteoglycans with cytoskeletal 
components and is involved in intracellular vesicle transport.  Structurally, Syn is 
composed of an N-terminal domain comprised of the first 113 amino acids followed by 
two adjacent PDZ domains (PDZ1 and PDZ2) and a short 24 amino acid CTD (Figure 
10).  The NTD can recruit the transcription factor Sox4 and eukaryotic translation 
initiation factor 4A (EIF4A) into signaling complexes and is important for 
homodimerization and heterodimerization with Syntenin 2 (Geijsen, Uings et al. 2001).  
Within the NTD of Syn are tyrosine residues that can be targeted by Src kinase for 
phosphorylation and act as docking sites for zeta-chain-associated protein 70 (ZAP70) 
and Src kinases (Beekman and Coffer 2008, Read and Gorman 2009).  Importantly, the 
NTD has been demonstrated to be involved in binding both free ubiquitin and 
ubiquitinated proteins. Specifically, the L4YPXL motif (amino acids 3 to 7 in Figure 10) 
was demonstrated to be a novel ubiquitin-binding motif for Syn binding ubiquitin as an 
obligate dimer.  The three LYPXL motifs in the NTD at positions 5, 47 and 51, are 
necessary for the interaction with ALIX/Aip1 during syndecan-lead cargo recruitment to 
exosomal compartments (Rajesh, Bago et al. 2011).  ALIX/Aip1 is a Lys 63-specific 
polyubiquitin binding adaptor protein that may regulate retroviral budding, endosome and 
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receptor trafficking and cytoskeleton-associated tyrosine kinases (Trioulier, Torch et al. 
2004, Dowlatshahi, Sandrin et al. 2012).   
The CTD of Syn has been shown to be necessary, but insufficient, for interaction 
with CD63, and along with the NTD stabilizes the full length protein (Cierpicki, 
Bushweller et al. 2005).  Both the NTD and CTD have been shown to regulate 
interactions between the PDZ domains of Syn and its binding partners, as mentioned 
above.  Additionally, phosphorylation of the NTD disrupts Syn interaction with the 
receptor protein tyrosine phosphatase (rPTP) CD148, demonstrating that post-
translational modifications of the NTD affect interactions between the dual PDZ domains 
and binding targets (Harrod and Justement 2002).  Recently it has been shown that the N- 
and CTD of Syn modulates targeting to the plasma membrane. Phosphorylation of Tyr56 
in the NTD decreases Syn localization of to the plasma membrane, while the basic 
residues K280/R281 at the CTD increased localization to the membrane (Wawrzyniak, 
Vermeiren et al. 2012).  It remains unclear however, the exact mechanism by which the 
N- and CTD of Syn contribute to Syn function. 
Postsynaptic density protein, Disc large, Zona occludens (PDZ) domains are 
protein-protein interaction modules that predominate in submembranous scaffolding 
proteins.  The PDZ domains of Syn serve as scaffolds for binding multiple peptide motifs 
with low to medium affinity (Beekman and Coffer 2008).  However, these PDZ domains 
bind to multiple peptide motifs (class I, class II and other sequences) with low to medium 
affinity, rather than by a unique sequence.  Such degenerate specificity is not unique to 
the Syn PDZ domains, but accounts for Syn localization, tissue expression and  




Figure 1.12 Molecular Domains and Interaction Motifs of Syntenin.  Human 
Syntenin is a 33Kda protein encoded by 298 amino acids.  Above the diagram of the 
linear sequence is a ribbon model of the tandem PDZ domains showing the 
unstructured linker (194-204) that may contain an imperfect T6IM.  Below the 
cartoon is the amino acid sequence for human Syn, annotated with specific domains 
and binding motifs for TRAF6 and Ubiquitin (Underlined). 
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scaffolding protein function.  Syntenin is widely expressed in all adult tissues (Grootjans, 
Zimmermann et al. 1997, Zimmermann, Tomatis et al. 2001).   
  Most protein ligands show preference for the PDZ2 domain of Syn, but peptides 
derived from IL-5Rα, merlin and neurexin interact with the PDZ1 domain with high 
affinity (Beekman and Coffer 2008).  Additionally, the Syntenin PDZ domains have been 
found to interact with membrane lipids using surface plasmon resonance experiments 
with liposomes modeled after the inner leaflet of the cell membrane.  Syn directly and 
strongly interacts with membrane phosphoinositol lipids and especially 
phophatidydylinsositol (4,5) bisphosphonate (PI(4,5)P2) (Zimmermann, Tomatis et al. 
2001, Zimmermann, Meerschaert et al. 2002, Zimmermann, Zhang et al. 2005).  Later 
studies showed that Syntenin-2 also interacts with PI(4,5)P2  and organizes nuclear 
PI(4,5)P2  pools, which are crucial for cell survival and proliferation (Mortier, Wuytens 
et al. 2005).  However, PDZ domain affinity for PI(4,5)P2 is insufficient for directing  
PDZ-containing proteins to subcellular  PI(4,5)P2  pools or to compartments rich in other  
phosphoinositides). This is  akin to what  is known  for  most PH domains, which also 
weakly  bind PI(4,5)P2  and cannot solely target their host proteins to phosphoinositide‐
rich domains (Lemmon 2003). Since PI(4,5)P2 is not present in certain cellular 
compartments, this could represent a way to direct Syn to interact with a subset of protein 
targets enriched within specific subcellular compartments.  While the dual PDZ domains 
of Syn are independent, and can independently integrate with C-terminal peptides, 
binding studies suggest that an intact full tandem PDZ works cooperatively (Grootjans, 
Zimmermann et al. 1997).  Crystal studies reveal extensive contact sites between the 
domains which are tethered by a short, unstructured five residue linker (Cierpicki, 
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Bushweller et al. 2005).  Such intramolecular interactions fix the PDZ domain 
orientation.  This orientation coupled with moderate affinities for the C-terminus of 
various peptides may be the structural underpinnings for the assembly of multimeric 
protein complexes (Figure 1.13).   
 Syn activation of the PI3K-Akt pathway in human melanoma cells has been 
linked to increased angiogenesis. Fibronectin activation of Focal Adhesion Kinase (FAK) 
and c-Src kinases is modulated by Syn and initiates the PI3K-Akt pathway. Activated Akt 
causes Hypoxia-inducible factor 1α (HIF-1α) translocation to the nucleus, which induces 
insulin growth factor-binding protein-2 (IGFBP-2) expression. After secretion, IGFBP-2 
interacts with αVβ3 integrin on endothelial cells, supporting pro-angiogenic factor 
Vascular Endothelial Growth Factor A (VEGF-A) expression (Das, Bhutia et al. 2012).   
Finally, Syn was shown to directly interact with TRAF6, resulting in IL-1R and TLR-4-
induced NF-κB activation (Chen, Du et al. 2008).  
  









Figure 1.13 Structural Basis for select Syntenin protein-protein Interactions.  
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Chapter 2 
 
HYPOTHESIS AND SPECIFIC AIMS 
 
Proper cellular response to both internal and external signals requires exact 
spatio-temporal positioning of intracellular components to facilitate their interaction and 
organize a coordinated response from a limited number of cellular effector molecules.  
Adaptor molecules are used to assemble protein complexes to converge diverse signaling 
pathways under variant conditions.  TRAF6 is a keystone adapter protein that transduces 
signaling from a wide array of upstream receptors.  TRAF6 is able to uniquely interact 
with proteins via its structural architecture and biological activities Specifically, its ability 
to auto-ubiquitinate, which sustains downstream E3 ligase activity and signaling as well 
as its unique MATH domain, which bears a TIM groove.  The TIM groove allows 
TRAF6 to uniquely interact with TRAF6 interaction motif (T6IM) peptides and T6IM 
bearing proteins.  Further, it has been shown that TRAF6 can also make intra and 
intermolecular interactions head to head (RZ-RZ) and head to tail (RZ-MATH) to 
autoinhibit downstream signaling (Yin, Lin et al. 2009, Wang, Galson et al. 2010). 
Overexpression of just the coiled-coil plus MATH domain sequence (ccMATH) has a 
dominant-negative effect on IL-1β/LPS signaling, as well as an antagonistic effect for 
TRAF6 recruitment by upstream activators (Darnay and Aggarwal 1999).  Similarly, 
ectopic expression of TRAF6WT or RZcc can act as a dominant positive and GFP fused 
TRAF6 constructs localize to the cytoplasm (Baud, Liu et al. 1999, Wang, Wara-
Aswapati et al. 2006, Wang, Galson et al. 2010).  Since ectopic dominant-positive 
expression is independent of upstream activators, I hypothesized the existence of 
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additional potential inhibitory intra- and inter-molecular interactions between the MATH 
domain and TIM bearing proteins and sought to continue investigating TRAF6 regulation 
and dynamics.  In a timely study by Chen et al., overexpression of Syn was found to 
inhibit TIR signaling to NF-κB, but not TNFα induced NF-κB activation in a dose 
dependent manner.  Furthermore, Syn associates with TRAF6 under physiological 
conditions, and dissociates from TRAF6 upon TIR stimulation (Chen, Du et al. 2008).  
Therefore, there may exist competition for TRAF6 between IRAK1 and Syn, as 
overexpression of IRAK1 disrupted the interaction of Syn with TRAF6 or Syn might 
otherwise sustain the auto inhibitory effect of closed RZ-MATH associated TRAF6.  
Initially I hypothesized that Syn associated with TRAF6 via a putative T6IM, but 
surprisingly, Syn was also able to inhibit the RZcc dominant positive activity for NF-κB.  
This observation coupled with the discovery that Syn overexpression caused the 
intranuclear relocalization of TRAF6 into the nucleus made me consider the possibility 
that Syn was acting as an adapter protein for another T6IM bearing protein that directly 
associated with TRAF6.  Another timely paper was published characterizing the 
stabilizing effect of Syn binding to the CTD of Sox4 (Beekman, Vervoort et al. 2012) and 
I quickly discovered a novel T6IM within Sox4, perhaps providing a mechanism for 
Syn’s effect upon TRAF6 activation and subcellular localization.  
2.1 Overall Goal 
The overall goal of this study is to identify novel TRAF6 Interaction Motif 
(T6IM)-bearing proteins that interact with TRAF6 and characterize their regulatory 
functions mechanisms upon downstream signaling. Such insights will help to explain the 
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phenomenon in which over-expressed ectopic TRAF6 in 293 cells acts as a dominant 
positive for NF-κB activity.  
 2.2 Hypothesis 
1. TRAF6 Interaction Motif (T6IM) controls TRAF6 signaling-bearing proteins such 
as IRAK1, disrupting TRAF6 RZ-MATH domain auto-regulation and competes 
with another inhibitory TIM-based TRAF6 binding protein. 
 
2. Syn uses the T6IM bearing transcription factor, Sox4 as an adapter molecule to 
coordinately both inhibit TRAF6-dependent NF-κB activity and to also 
translocate cytoplasmic TRAF6 into the nucleus. 
2.3 Specific Aims 
Aim 1.  Characterize IRAK1 modulation of TRAF6 auto-regulation and localization 
 
Aim 2.  Identify the molecular determinants of Syntenin-1/TRAF6 interaction  
 
Aim 3.  Understand the nature of Syntenin-mediated nuclear localization of TRAF6 
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Chapter 3 
 
MATERIALS AND METHODS 
 
3.1 Cell Culture 
 All cell lines were maintained at 37°C under 5% CO2 in sterile 100x20mm tissue 
culture dishes treated by Vacuum Gas Plasma (BD Biosciences).  Human 293 (CRL-
1573) and 293T (CRL-11268) cells were obtained from American Type Cell Collection 
(Manassas, VA) and were cultured in EMEM medium supplemented with 10% heat 
inactivated fetal bovine serum (Tissue Culture Biologicals Lot #103283), 2 mg/mL L-
Glutamine and 1% penicillin/streptomycin solution (Sigma).  293R cells are stably 
transfected 293 cells (American Type Culture Collection CTRL-1573) that ectopically 
express the IL-1R receptor (Wang et al., 2006).  293R cells were maintained and cultured 
in the same culture media as the 293 and 293T cells.  293R cells were cultured from 
cryopreserved aliquots of cells previously derived as described (Asea, Rehli et al. 2002, 
Yoshida, Kumar et al. 2004).   
THP-1 cells were cultured in RPMI media (10-040-CV, Cellgro) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS), 1% Penicillin/Streptomycin 
Solution (30-002-CI, Cellgro) and 500 µl of 2ME (21985-023, Invitrogen). Murine RAW 
264.7 (#TIB-71, American Type Culture Collection, Manassas, VA) were cultured in 
DMEM (10-013-CV, Cellgro) supplemented with 10% heat-inactivated fetal bovine 
serum (HyClone SH30070 Lot#AYC60564, AWC10533) and 1% 
Penicillin/Streptomycin Solution (Sigma) at 37°C under 5% CO2.  
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 Rat PC12 pheochromocytoma cells were provided by Dr. Yong-Jian Liu 
(University of Pittsburgh) and maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% horse serum and 5% fetal calf serum (Invitrogen, 
USA). For experiments, PC12 cells were seeded onto matrigel (Corning) treated 
multiwell Lab-Tek Chambered Coverglass (Nunc) for at least 24 hours prior to treatment.  
NGF (100 ng/mL) was then added.  Neurite outgrowth was measured using a modified 
protocol as previously described, at 24-hour timepoints up to 120h as indicated in the 
legend to each figure (Park, Lee et al. 2002, Hong, Noh et al. 2003) 
Murine 4B12 cells and calvaria-derived stromal (CDS) cells were a gift from Dr. 
Lynda F. Bonewald (University of Missouri at Kansas City, MO).  4B12 and CDS cells 
were cultured separately in α-MEM (SIGMA#M4526), containing L-glutamine 
(2.92mg/mL) (GIBCO#12561) supplemented with 10% Fetal Bovine Serum (Hyclone), 
penicillin/streptomycin at 100 U/mL; or α-MEM supplemented with 10% Fetal Bovine 
Serum, penicillin/streptomycin, L-glutamine (GIBCO#10378-016).  The 4B12 cells are 
maintained in α-MEM supplemented with 10% FBS and 30% calvarial-derived stromal 
cell conditioned media (CSCM).  To prepare CSCM, calvaria-derived stromal cells were 
cluttered until confluent in α-MEM supplemented with10% FBS. Media was changed, 
and cultured for an additional 4 days. Conditioned media was then collected and 
centrifuged to remove cell debris (10000 Å~ g, 30 min), and filter through a 0.45 /um 
pore-size filter.  CSCM was then added at  ~10mL media/55cm2 or 30mL/150cm2 dish. 
Murine ST2T cells were established by infecting the mouse stromal line ST2 with 
the retroviral vector expressing RANKL and provided by Dr. Deborah L. Galson 
(University of Pittsburgh) (Lean, Matsuo et al. 2000).  For co-culture, bone marrow cells 
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or RAW264.7 were seeded at 6x105 cells/cm2 with 6x104 /cm2 ST2-T cells and cultured 
in the presence of 108 M 1,25-dihydroxyvitamin D3 and 107 M dexamethasone.  
For osteoblast-free culture, 4B12 and RAW264.7 cells were cultured in the 
presence of 10 ng/mL recombinant human M-CSF (Genzyme) and 50 ng/mL 
recombinant mice RANKL (R&D Systems) to generate osteoclast-like cells.  Cells were 
plated overnight at a density of 2 × 104 cells/well in a 6-well plate in DMEM (Life 
Technologies, Inc. Rockville, MD) and heat inactivated 10% FBS (HyClone).  The next 
day the medium was changed to DMEM supplemented with 10% FBS and 50 ng/mL 
RANKL (R&D Systems).  After 24h, the medium was replaced by DMEM, pH 7.2 
[13.53 g DMEM (Sigma), 0.78 g sodium bicarbonate (Sigma), 10% FBS, and 50 ng/mL 
RANKL (R&D Systems).  For each sample, cells were fixed and stained for tartrate-
resistant acid phosphatase (TRAP) or lysed for RNA extraction. 
 3.2 Transfections 
Reporters or expression plasmids were transfected into cells with FuGENE HD 
transfection reagents (Roche Applied Science, Indianapolis, IN) or X-tremeGENE HP 
transfection reagent  (Roche Applied Science, Indianapolis, IN). At least one day before 
transfection, cells were seeded into tissue culture plates (Bioscience) or Lab-Tek 
Chambered Coverglass (Nunc) at a density = Relative Area * 2x104 according to the table 
below with normal culture media and allowed to settle overnight.  
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PLATE SIZE GROWTH AREA (cm2) Relative Area 
96 well 0.32 1x 
24 well 1.88 5x 
12 well 3.83 10x 
6 well 9.4 30x 
 
Table 3 Cell Density Seeding Formula for Various Tissue Culture Plates.  Relative 
Growth Area (cm2) for tissue culture plates used in determining seeding density of 
cells prior to transfection  
 
Prior to transfection, cells were allowed to reach 60-70% confluency.  A 3:1 
reagent (μl) : DNA (μg) ratio was used in all transfections.  This mixture was prepared as 
a 1:1 (volume : volume) of transfection reagent (TR):DNA. Plasmids were added into a 
microfuge tube with proper volume of serum-free Opti-MEM medium (Gibco).  Room 
temperature FuGENE HD or X-trememGENE HP was diluted in another microfuge tube 
with an equal volume of serum-free Opti-MEM medium as that used for plasmids, The 
TR solution was then added directly to the plasmid solution, mixed gently and incubated 
at room temperature for 15-20 min.  The plasmid-TR mixtures were then added (drop 
wise) into indicated wells containing the pre-seeded cells and incubated at 37oC under 
5% CO2 for at least 24 hours prior to subsequent treatment or analysis.   
3.3 Luciferase bulk-cell assay for NF-κB activity 
The NF-κB luciferase reporter, NF-κB/pGL2, contains a c-fos core promoter and 
four tandem repeats of NF-κB p65/p50 heterodimer binding sequences (Yoshida, Kumar 
et al. 2004).  The XT-Luc IL1B vector was generated previously as described in (Unlu, 
Kumar et al. 2007).  Briefly, BDC454 clone (Clark et al., 1986;Shirakawa et al., 1993) 
was partial digested with XbaI and TaqI to remove the appropriate length of human 
genomic IL1B DNA from −3757 downstream to +12. This 3.76 kbp sequence was 
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inserted into the SmaI site of the pGL3Basic vector.  The IL-1β XN Luciferase reporter 
was generated according to the Figure 3.1 in collaboration with Dr. Luke O’Neill (Trinity 
College, Dublin, Ireland).  In most cases 20ng of luciferase reporter was co-transfected 
with indicated expression plasmids into cells for at least 24 hours prior to assay,  with the 
transfection procedure described in the previous section.  Luciferase Assay System 
(Promega, #E-1501) was used to quantify NF-κB activity.  1x cell lysis buffer (Promega, 
Madison, WI) was freshly prepared and allowed to equilibrate to room temperature.  The 
transfected cells were then lysed with 50μL of 1X cell lysis buffer in each well and 
shaken for 20 min.  20 μl of supernatant from each well was used for luciferase activity 
analysis using a VERITAS luminometer (Turnaer BioSystems, Sunnyvale, CA) 
according to the manufacturer’s instructions.  
3.4 Reporters and Expression Plasmids 
The human wild-type TRAF6 and mutant coding sequences were engineered in 
both untagged pcDNA3.1 (fl) and dual-tagged pFLAG CMV 5a-YFP expression vectors 
in the EcoRI and EcoRV sites by PCR subcloning strategies.  The sequences coding for 
TRAF6 (1-273) is designated as RZ; TRAF6 (1-358) as RZcc; TRAF6 (346) were 
subcloned into pFLAG CMV 5a plasmid (Sigma-Aldrich) as previously described 
(Wang, Galson et al. 2010).  A mutant version of full-length TRAF6 containing lysine 
(K) to arginine (R) mutations at all lysine residues (referred to as TRAF6Δ K32-518R or 
TRAF6ΔK) and murine TRAF6 (mTRAF6) were provided as a gift by Dr. Yongwon 
Choi (University of Pennsylvania School of Medicine) (Walsh, Kim et al. 2008).   
The tagged human wild-type Syn and mutant Syn expression plasmids were a gift 
from Dr. Paul J. Coffer (Utrecht, Netherlands).  Murine Syntenin-1 in pCMV-Sport6 
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expression vector was purchased from Open BioSystems (Thermo Scientific Catalog 
#MMM1013-77128).  Human Sox4 and SDCBP (Syn) in pLX304 expression vectors 
were purchased from DNASU plasmid repository (Arizona State University, Tempe, 
AZ).  Tec kinase, BTK and variant expression vectors were provided by Dr. Lawrence P. 
Kane (University of Pittsburgh).  Both full-length murine Tec and BTK and their PH 
domains (first 152 aa Tec & first 174 aa for BTK) were inserted into vector pEGFP-N1 
(Clontech) between Xho1 and BamH1 in the multi-cloning site (MCS) of the vector. 
These engineered Tec kinase family reporters are CMV-driven and have Kan/Neo 
resistance.  The HcRed tagged human Sequestosome-1/P62 expression plasmid (P62-
HcRed) was previously created in our lab (Wang, Galson et al. 2010) using human p62-
pcDNA3.1 (courtesy of Dr. Deborah Galson, University of Pittsburgh) and a pFLAG 
CMV5a-HcRed1 expression plasmid.  Briefly, using PCR, the NLS was deleted from the 
HcRed1/Nuc vector (Clontech) and HcRed1 was then inserted into the Eco RV and Bam 
HI sites of pFLAG-CMV5a.  P62 was then cloned from p62-pcDNA3.1 by PCR and 
newly generated EcoRI and BglII sites were used to insert the sequence into the pFLAG-
CMV5a-HcRed1 plasmid.  The human MyD88 and HA-tagged human TLR4 plasmid 
was provided by Felix Randow and prepared as previously described (Randow and Seed 
2001, Asea, Rehli et al. 2002).  pEYFP-C1 vector was obtained from Clontech (Mountain 
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Expression 
PLASMIDS VECTOR species source label/tag clone ID 





V5-DEST human DNASU - 
 HsCD00
329922 









F-Syn pFLAG human Coffer FLAG   
ΔN Syn pMT2 human Coffer HA   
ΔPDZ1+2 Syn pMT2 human Coffer  HA   
ΔPDZ1 pcDNA3 human Coffer  HA   
ΔPDZ2 pMT2 human Coffer  HA   
mKATE Syn pcDNA3 human Coffer mKATE   
Myc Syn pcDNA3 human Coffer Myc   
XN pGL2 human O'Neill Luciferase   
XT pGL2 human Auron Luciferase   
IRAK1  pcDNA human Auron     
MyD88   pcDNA human Auron     
TRAF6ΔK pFLAG murine Choi  FLAG   
TRAF6C70A-
YFP pFLAG Human Auron 
 FLAG/Y
FP   
TRAF6-YFP pFLAG Auron Auron  EYFP   
EYFP  pEYFPC1   Clontech  EFYP  6005-1 
TRAF6-EYFP   pcDNA human Auron  EYFP   
TRAF6 pcDNA3.1 human Auron     
TRAF6 pFLAG human Auron  FLAG   
IRAKHcRed   pcDNA human Auron  HcRed   
Akt-GFP   human Kane  GFP   
BTK-GFP   human Galson  GFP   
Tec-GFP   human Galson  GFP   
PH-ATK-GFP   human Kane  GFP   
PH-BTK-GFP   human Galson  GFP   
PH-Tec-GFP   human Galson  GFP   
TLR4   pcDNA human Randow HA   
 
Table 4 Expression and Reporter Plasmids Used in this Study.  




Figure 3.2 Schematic Maps of the TRAF6 constructs Used in this Study.  All 
constructs were FLAG tagged or dually tagged with FLAG and YFP in subcellular 
localization studies.  Construct design and preparation was as previously described 
(Wang, Galson et al. 2010).  The C70A mutein was prepared by site-directed 
mutagenesis and subcloned into the TRAF6-YFP construct.  TRAF6ΔK and the 
corresponding murine wtTRAF6 plasmid were provided by Dr. Y.W. Choi 


















Figure 3.3 Schematic Maps of the Syn Constructs Used in this Study.  All human 
sequence constructs were HA tagged and verified by sequencing.   
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3.5 Statistical Analysis 
In all bulk cell luciferase assays, RLU values are reported as the mean of three 
experimental replicates along with the associated standard deviation  (s.d.) for this 
calculated mean to quantify the scatter or variability between experimental replicates.  
Each experiment was then repeated at least three times to verify the overall trend and 
pattern of the experimental results.   Graphs then are a single experiment containing three 
experimental replicates, representative of results from at least three biological replicates.  
The reported error for each mean provides an estimate of the s.d. of the overall 
population from a small sample size rather than the precision of the experimental mean to 
the actual population mean.  SEM can be misleading because by definition it produces a 
smaller value than the s.d.  SEM was not reported because SEM quantifies how precisely 
you know the true mean of the population, which is more appropriate in cases with large 
sample sizes.  Recently, concern over the wide misuse of P values has been addressed 
(Baker 2016).  In this study, the nature of the TRAF6 dominant positive signal is robust 
enough (orders of magnitude) that, it not only serves as an internal positive control but 
also obviates the need to calculate statistical significance in observed differences.   
3.6 Immunoprecipitation and Western Blotting 
Western blotting.  After indicated treatments, 293 or 293T cells were detached by 
pipetting and transferred to microcentrifuge tubes.  Cells were spun down with a bench-
top microcentrifuge at 5000 rpm for 3 min. aspirated culture medium and washed 
remaining cell pellets once with 1xPBS.  Pellets were re-suspended in 50μL of ice-cold 
lysis buffer per 106 cells.  Cell lysate was then incubated on ice for 30 minutes with 
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vortexing every 10 minutes, and then centrifuged at 14,000 rpm (10,000-15,500x g) at 
4°C for 10 minutes.  Supernatant was harvested and mixed with an equal volume of 
2xSDS-PAGE sample buffer supplemented with fresh 2-mercapto ethanol (Bio-Rad) and 
incubated at 98°C for 15-30 min.  Heat denatured samples were then loaded into a precast 
4-12% gradient SDS-polyacylamide gel (Lonza) and run with 1x Laemmli buffer (25mM 
Tris, 192mM Glycine, 0.1% SDS; pH 8.3) at 100V for about 2 hours. Resolved proteins 
were transferred from the SDS-polyacrylamide gel onto a PVDF membrane in 1X Tobin 
buffer (3.03g TRIS, 14.4g glycine, 150mL methanol per liter of solution, pH 8.3).  
Membranes were incubated in 5% non-fat milk with 1xTPBS (10 mM phosphate, 
140mM NaCl, 3 mM KCl, 0.05% Tween 20; pH 7.4) with slight shaking for 1 hour, and 
then incubated with indicated primary antibody for another 1-2 hours at RT with shaking 
or O.N. at 4°C.  Membranes were then washed in 1xTTBS with slight shaking for 3-5 
minutes to remove primary antibody.  The membrane was then incubated in a 1:10,000 
dilution of secondary antibody in 5% non-fat milk with 1xTTBS with slight shaking for 1 
hour.  The secondary antibody was removed and the membrane washed in 1xTTBS with 
slight shaking for 3-5 minutes.  Finally, the membrane was incubated with 
chemiluminescent substrate (Thermo Scientific, Waltham, MA) at RT for 5 minutes to 
prepare for signal visualization by X-ray film exposure.  
Immunoprecipitation.  Cell lysate supernatant was diluted using the same type of 
lysis buffer as described above into 200μL per 106 cells.  A specific antibody was added 
and the sample and then rocked at 4°C for 2-5 hours.  Then, 30μL of 50% protein A/G 
conjugated agarose slurry (Protein A/G PLUS-Agarose IP Reagent sc-2003) pre-absorbed 
by non-specific IgG (Normal rabbit IgG sc-2027, Santa Cruz Biotechnology) was added 
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to each sample tube and rocked at 4°C overnight.  The next day, agarose beads were 
centrifuged at 10,000rpm for 1 min.  Supernatant was then aspirated and beads rinsed 
with 500μL lysis buffer three times.  100μL 1xSDS-PAGE sample buffer was added to 
each sample tube containing the agarose beads. Re-suspended agarose beads by vortexing 
and then incubated at 98°C for 10 minutes.  SDS-PAGE and immuno-blotting procedures 
followed as described above for sample analysis. 
3.7 Reagents and Antibodies 
Depending on the experiment, RAW264.7 or 4B12 cells were stimulated with 
either 1μg/mL of E. coli 055:B5 Lipopolysaccharide (LPS) (Sigma) or 50ng/mL 
recombinant murine RANKL (R&D Systems) for indicated time periods.  RAW264.7 or 
293R cells were stimulated with 100ng/mL IL-1β (Millipore) for 6-8 hours prior to assay.   
In neurite growth assays, 293 and PC12 cells were stimulated with 50ng/mL 
recombinant human NGF (Millipore) for indicated time periods.  The primary antibodies 
for immunoprecipitation experiments include: Rabbit anti HA-probe (Y-11) (Santa Cruz 
Biotechnology, sc-805), Rabbit anti TRAF6 (H-274) (Santa Cruz Biotechnology, sc-
7221), Goat anti Sox4 PAb  (c-20) (Santa Cruz Biotechnology, sc-17326), Mouse anti 
HA-Tag (6E2) ( Cell Signaling Technology, 2367S), Mouse anti GFP mAb   (4B10)  Cell 
Signaling Technology, 2955S), and  mouse IgG1  anti FLAG M2 Monoclonal Ab F1804 
(Roche).  For western blotting, the secondary HRP conjugated antibodies were purchased 
from Santa Cruz Biotechnology, including: Donkey anti-Goat HRP (sc-2020), Goat anti-
Rabbit IgG-HRP (sc-2004), Donkey anti Goat HRP (sc-2020), Goat anti-mouse IgG-HRP 
(sc-2031).  In imaging studies, the Syntenin primary antibody was used to visualize 
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subcellular localization was purchased from Abnova (SDCBP MaxPab rabbit polyclonal 
antibody (D01)).  Cells interrogated for endogenous TRAF6 were probed with TRAF6 
(H-274) sc-7221 Rabbit (Santa Cruz Biotechnology),  Anti rabbit  Alexa 488-conjugated 
secondary antibody were from Molecular Probes (Eugene, OR).  
3.8 Immunoflourescent staining 
To visualize the subcellular localization of endogenous proteins, cells were 
seeded onto Lab-Tec glass chambered cover slides (Nunc) the day prior to treatment.  
Chambered slides were pretreated with either gelatin or matrigel (BD Biosciences).  After 
relevant stimulatory conditions (6h-5 days), the culture media was removed by aspiration 
and cells were fixed using a 3.7 % formaldehyde solution made by diluting a 37% 
formaldehyde stock with 1x PBS that has been freshly diluted from 10x PBS and warmed 
to 37°C pre-warmed to 37°C for 10 minutes.  37% Formaldehyde solution (Sigma-
Aldrich catalog no. F-1268 or F-1635).   In most cases, slides of fixed cells were treated 
with ProLong™ Gold antifade mounting solution (ThermoFisher Scientific) to suppress 
photobleaching and encourage signal preservation in case of long-term storage and 
analysis.  ProLong™ Gold with DAPI (ThermoFisher Scientific Cat# P36935) was used 
to visualize the nuclei in experiments where necessary. 
3.9 ELM Analysis 
Many protein-protein interactions occur between large globular domains but an 
estimated 15-40% are mediated by functional microdomains of 3-10 amino acids in size 
called Short Linear Motifs (SLiMs) (Neduva and Russell 2006). These often occur in 
intrinsically disordered regions and are involved in a number of functions such as 
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binding, cleavage, subcellular targeting and posttranslational modifications.  The ELM 
web server (http://elm.eu.org/) uses an algorithm that facilitates the exploration and 
identification of SLiM-mediated interactions within PPI networks. The website enables 
enquiries at the single protein level as well as within large-scale proteomic studies. 
Therefore, ELM analysis is useful in guiding experimental studies and facilitating the 
analysis of pathways within PPI networks. The web server is freely available 
at http://i.elm.eu.org (Dinkel, Van Roey et al. 2014). 
  























(KDa) (KDa) (KDa) 
YFP 27 29 x 29   
TRAF6 61 63 x 90 1-507 
TRAF6ΔR 47 49 x 76 125-522 
TRAF6C70 61 63 x 90 1-522 
RZcc 42 44 x 71 1-358 
Syn 33 35 36 63 1-298 
SynΔN 20 x 21 48 110-298 
SynΔP1 12 x 13 40 187-298 
SynΔP2 18 x 19 46 1-193 
SynΔP1+2 11 x 12 39 1-105 
Sox4 47 x x x 1-474 
 
 
Table 5 Calculated molecular sizes of un-tagged and dual-tagged TRAF6 and 
Syntenin proteins used in Co-IP and western blot analysis.  The formula used for 
the calculation: M.W. = Numbers of residues X 0.117 kDa. 
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3.10 Neuronal Differentiation and quantitative morphology 
A modified procedure adapted from Das et al. was used to assess differentiation 
and neurite outgrowth (Das, Freudenrich et al. 2004, Pool, Thiemann et al. 2008).   293 or 
PC12 cells were plated onto 12-well tissue culture plates coated with 40 μg/mL of rat tail 
collagen Type I (Sigma, St. Louis, MO) according to the manufacturer-recommended 
procedure. Cells were plated at a relatively low density (2x103 cells/cm2) in DMEM/F12 
medium containing 10%FBS, 2 mM HEPES, and 44 mM Na-bicarbonate. The next day 
after plating, the medium was replaced with serum free DMEM/F12 medium 
supplemented with 50 ng/mL NGF (human recombinant NGF, Sigma) and 0.25% bovine 
serum albumin (BSA; tissue culture grade from Sigma) with or without the 
pharmacologic inhibitors U0126, bisindolylmaleimide I (Bis I), or edelfosine (ET-18; all 
from Calbiochem, La Jolla, CA). Exposure to vehicle alone (culture medium) was used as 
the control. The cells were fed on Days 2, 4, and 6 by the addition of a concentrated stock 
of NGF for a final concentration of 50 ng/m.  Neurite growth was determined by 
manually tracing the length of the longest neurite per cell (using NIH Image software) for 
all cells in a field that had an identifiable neurite and for which the entire neurite arbor 
could be visualized. Data from the two fields in each well were pooled, and each well 
was designated as a ‘‘n’’ of one.  Experiments were repeated at least three times using 
cultures prepared on separate days. 
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3.11 RNA Expression analyses   
1x106 cells were plated into 6-well plates (353846, FALCON).  Following 
treatments, cells pellets were resuspended in 500µl of TRIzol reagent (15596-026, 
Invitrogen). After addition of 170µl of Chloroform (C606-1, Fisher) samples were 
vortexed, incubated at room temperature for 15min, and centrifuged at 13000 RPM in 
4°C for 15min.  The aqueous layer was removed, combined with an equal volume of 
Isopropanol (BP2632-4, Fisher), 1µl of Glycogen (9510, Ambion) and centrifuged at 
13000RPM in 4°C for 10 min.  Sample pellets were then washed with 500µl of 75% 
Ethanol (111ACS200, Pharmaco-AAPER) and centrifuged for 10min in room 
temperature at 14000 RPM.  Air-dried pellets were resuspended in 30µl of RNAse free 
water and subjected to DNAse treatments using Turbo DNA-free reagents (AM1907, 
Ambion) according to the manufacturer instructions in order to eliminate genomic DNA 
contamination. RNA was converted to cDNA using GoScript Reverse Transcription 
System (A5001, Promega). Relative expression levels were calculated using Ct 
method using B2M and 18srRNA as an endogenous controls.  In certain experiments 
RNA was directly subjected to an RT-PCR utilizing the Access RT-PCR system (A1250, 
Promega).   cDNA was analyzed using quantitative PCR (qPCR) carried out in a 
StepOnePlus Applied Biosystems Real Time Instrument (40 cycles).  Relative expression 
levels were calculated using Ct method. 
  









Gene Forward Reverse 
hTRAF6 GTTGCTGAAATCGAAGCACA CGGGTTTGCCAGTGTAGAAT 
hSox4 ACCGGGACCTGGATTTTAAC AAACCAGGTTGGAGATGCTG 
hSDCBP GATAAAGCGCACAAGGTGCT CATTTCTGGCTGCAGAGCTA 
mTRAF6 TCCACACAATGCAAGGAGAA CCATGACCTCTTCGTGGTTT 
mSox4 CTCGTCCTCTTCCTCCTCCT GCCGGGTTCGAAGTTAAAAT 





Table 6  mRNA analysis and qPCR primer sequences.  
  




4.1 IRAK1 modulation of TRAF6 auto-regulation and localization 
4.1.1 Rationale 
In 2010 our research group reported on the trans and cis intramolecular 
interactions between the TRAF6 RZ and MATH domains (Wang, Galson et al. 2010) and 
confirmed the homotypic RZ-RZ domain interaction demonstrated by others (Wooff, 
Pastushok et al. 2004).   The results of our study produced a model arguing that TRAF6 
activity depends on interconversion between a “closed” inactive and an “open” active 
structure.  Open TRAF6 can be “auto”-ubiquitinated, thus sustaining action upon other 
downstream proteins (Figure 4.1).  While it is known that MyD88, TRAF6 and IRAK1 
are all involved in TIR signaling to activate NF-κB, the full details of this process remain 
unresolved (Figure 4.2).  Although the overexpression of MyD88, IRAK1 or TRAF6 can 
each individually as a dominant positive for NF-κB activity in 293 cells, it is has been 
demonstrated that IRAK1 and not MyD88 induces oligomerization of TRAF6, which is 
sufficient for signaling to JNK and IKK (Baud, Liu et al. 1999).  Further, the X-ray 
crystal structures of TRAF2 and TRAF3, containing the coiled-coil and MATH 
(ccMATH) domains, reveal that both proteins can form trimers associated via the coiled-
coil domain (Park, Burkitt et al. 1999, Ni, Welsh et al. 2000).  Strikingly, the published 
structure of TRAF6 contained only a MATH domain monomer, without a coiled-coil 
domain (Ye, Cirilli et al. 2002).  It is unclear whether the omission in the crystallized 
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protein of the coiled-coil multimerization region during crystallization was intentional or 
necessary in order to produce a diffracting crystal. Glutaraldehyde crosslinking studies of 
purified TRAF proteins revealed both dimer and trimer forms for TRAF1, 2, and 3.  
However, TRAF6 appeared to generate a complex and less-clear pattern of 
multimerization (Pullen, Labadia et al. 1999).  The group that reported the TRAF6 
monomeric structure generated a trimeric model of TRAF6 by graphical superimposition 
of the TRAF6 MATH domain backbone onto the 3-fold symmetry observed in the 
TRAF2 structure (Ye, Cirilli et al. 2002, Ferrao, Li et al. 2012).   
 
 
Figure 4.1 A Model for TRAF6 Activation and Inhibition by Intra and Extra 
Molecular Interactions.  TRAF6 activity depends on interconversion between a 
“closed” inactive and an “open” active structure. 
  





Figure 4.2 Map of TRAF6 Mediated LPS and IL-1 Signaling.  TRAF6 plays central 
roles in response of LPS and IL-1 Signaling to nucleus. TIR sigaling involves 
recruitment of the adapter proteins myd88 and IRAK1 with recruit  TRAF6 and 
promotes activation of  transcription factors  such as NF-κB, via IKK or by 
activating PI3 kinase, which can then activate the transcription factors AP-1 or 
C/EBPβ.  These transcription factors acivate genes that lead to the production of  
pro-inflammatory cytokines.  
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One factor contributing to the challenges of crystallizing TRAF6 could be that the RZ-
MATH interaction is highly dynamic and the associated free energy is not favorable for 
crystal formation.  In an effort to gain insight into the TRAF6 intramolecular interactions 
and also to understand why ectopic expression of TRAF6 acts as a dominant positive for 
NF-κB, I hypothesized that IRAK1 activates TRAF6 by disrupting the intra/inter-
molecular RZ-MATH domain interaction, opening the “closed” TRAF6 structure.  To 
investigate this, plasmids for full length TRAF6, the RZ domain of TRAF6 and IRAK1 
were co-expressed in 293 cells.  Since wtTRAF6 and the RZ are known to associate , it 
seemed likely that co-expression of IRAK1 would disrupt this interaction and permit 
visualization of the results by performing both co-Immunopreciptation experiments well 
as microscopic examination of the subcellular distribution for ectopically expressed 
chimeric fluorescently-labeled molecules (e.g., TRAF6-YFP, RZ-YFP, MATH-YFP, 
ccMATH-YFP and IRAK1-HcRed).   
4.1.2 Subcellular Distribution of IRAK1 co-expressed with  “open” and “closed” TRAF6 
In agreement with previous reports, ectopic TRAF6-YFP was found to distribute 
to cytosolic speckles and several larger 1-2μm punctate in 293 cells while YFP was 
distributed diffusely throughout the cell (Figure 4.3A-B).  Interestingly, in RAW264.7 
cells, endogenous TRAF6 also displayed a pattern similar to that of ectopic TRAF6 in 
293 with some additional aggregation in what appears to be the nucleus (Figure 4.3C).   
  




Figure 4.3 IRAK1 Reduces the Number of Large TRAF6 Sequestosomes. A-B) 
confocal images show ectopic TRAF6 localized to sequestosome like cytoplasmic 
speckles or punctae.  40ng of either pFLAG-YFP or pFLAG-TRAF6-YFP was 
transfected into 293 cells seeded into a 24 well culture dish the prior day. C) 
Epiflourescent image of RAW264.7 cells stained for endogenous TRAF6.  In pre-
osteoclasts, TRAF6 appears to reside in cytoplasmic speckles, punctae or a nucleus-
like structure (yellow wedges).  In all conditions 3 independent biological replicates 
were conducted and several fields were taken at 200x.  A representative subfield is 
displayed and scale bar: 20μm.  
  
Our group previously demonstrated that the size of ectopic TRAF6 punctae correlates 
with TRAF6 induced NF-κB activity in a non-linear inverted U response (Wang, Galson 
et al. 2010).  One hypothesis on the nature of these large punctae is that they are 
autophagic sequestosomes, targeting TRAF6 for recycling by the ubiquitin binding 
protein p62/SQSTM1 and various DUBs.  To investigate this, p62-HcRed and TRAF6-
YFP were ectopically expressed in 293 cells and then examined by confocal microscopy 
as to their subcellular distribution.   In agreement with our previous findings (Wang, 
Galson et al. 2010),  TRAF6-YFP colocalizes with p62-HcRed when co-expressed in 293 
cells (Figure 4.4).  ELM analysis reveals a canonical TRAF6 interaction motif in p62 at 
AA positions 322-328, indicating the potential for p62 to interact with TRAF6 in a 
MATH-dependent manner (Figure 4.5).   


















Figure 4.4 SQSTM1/p62 and TRAF6 Colocalize in Cytoplasmic Sequestosomes.  
40ng of each expression plasmid was co-transfected into 293 cells.  After 24h, 
confocal images of ectopic p62-HcRed1 (red) and TRAF6-YFP (green) were taken.  
At right, display of both red and green channels produces a merged image where 
yellow color represents co-localization of the two fluorescent-tagged proteins.  
Displayed image individual channels from a subfield from a collection of fields 
acquired from multiple fields taken from three independent experiments.  Scale bar: 
20μm. 
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Figure 4.5 Eukaryotic Linear Motif (ELM Analysis) for Protein Interaction Sites of 
Human p62/SQSTM1 (UniProt q13501).  A) Interactive Summary and Graphic 
representation shows the canonical T6IM with favorable context toward the 
carboxy end of p62 B) Linear Sequence of T6IM within SQSTM1 and its positioning 
in at residues 320-328. 
 
This comports with Sanz et al. who demonstrated that p62 interacts specifically with the 
ccMATH (TD) of TRAF6 and not TRAF2 (Sanz, Diaz-Meco et al. 2000); although, they 
identify the region 228-254 as necessary for p62 binding TRAF6.  Additionally, in their 
study, TRAF6 and p62 only co-localized upon IL-1 stimulation in HepG2 cells.  They 
suggested that adding IL-1 was necessary to increase the endogenous concentrations of 
TRAF6 and IRAK1, but another possibility could be the need for an “open” TRAF6 
structure, where IL-1 recruits IRAK1 to activate TRAF6 and expose its TIM binding 
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groove to interact with p62/SQSTM1.  To address this, TRAF6-YFP, ccMATH-YFP or 
MATH-YFP was ectopically expressed in in 293 cells.  As expected, punctae were only 
visible with the addition of TRAF6-YFP, while ectopic ccMATH-YFP or MATH-YFP 
do not localize to punctae because they presumably inactivate TRAF6 ubiquination 
events and block NF-κB activity (Figure 4.6).  Co-expression of ectopic RZ or IRAK1 
with TRAF6-YFP was found to reduce the number of cells that display large TRAF6 
punctae or the number of punctae per cell respectively (Figure 4.6).  This modulation of 
sequestosome size or number can be correlated with the NF-κB activity, in luciferase 
reporter assays where transfecting mTRAF6 + IRAK1 into 293 cells synergize, super-
activating NF-κB, while transfecting RZ + mTRAF6 decreased NF-κB, activity by ~10% 
as compared to mTRAF6 alone (Figure 4.7).  Interestingly, the addition of both RZ and 
IRAK1 with TRAF6-YFP completely abolished the formation of sequestosomes (Figure 
4.6, left column).  On the other hand, neither RZ nor IRAK1 was able to induce TRAF6 
punctae when co-expressed with either ccMATH- or MATH-YFP (Figure 4.6).  While 
deletion of the RZ domain seemed to be sufficient to disrupt punctae formation, in some 
cases punctae were still formed when either ccMATH-YFP or MATH-YFP coexpressed 
with IRAK1-HcRed (Figure 4.8). Here, coexpression of ectopic IRAK1-HcRed along 
with either the ccMATH-YFP or MATH-YFP in 293 cells revealed colocalization of 
IRAK1-TRAF6 mutein pairs into cytosolic sequestosomes (Figure 4.8).  When IRAK1-
HcRed was coexpressed with only RZ-YFP, devoid of the MATH domain, there was no 
colocalization (Figure 4.8).  
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Figure 4.6 IRAK1 Opens TRAF6, Inducing Localization to Large Sequestosomes.  
24 hours prior to transfection, 293 cells were seeded into 24 well tissue culture plates 
and then transfected the next day with 40ng of each indicated plasmid with each 
condition receiving 120ng of total plasmid DNA.   Adding an appropriate amount of 
pFLAG-CMV5 empty vector equalized differences in total DNA.  Epiflourescent 
images demonstrate that ectopic TRAF6 localizes to cytosolic speckles or punctae.  
Co-expression of either the RZ domain or IRAK1 with wtTRAF6 reduces the 
number of large punctae, but addition of both RZ + IRAK1 completely abrogated 
sequestosome formation.  
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Since, sequestosomes correlate with excessively ubiquitinated TRAF6 and/or other 
interacting proteins which inhibit TRAF6 (Wang, Galson et al. 2010), a decrease in 
sequestosomes can be understood to result from co-expression of a TRAF6: RZ or 
IRAK1 activation pair.  The co-localization of the punctae with the protein p62/SQSTM1 
and the finding that IRAK1 plus the RZ domain together disrupt the punctae, suggests 
that the punctae are sequestosomes, p62-rich proteasome-like structures, which are 
induced by an open-active TRAF6.  Overexpression of inactive mutants displayed little 
or no sequestosome formation. Collectively, these results demonstrate that IRAK1 co-
localization with TRAF6 in the cytoplasm depends on the presence of the TRAF6 MATH 
domain and TRAF6 punctae are sequestosomes that can be induced by TRAF6 
activation. 
  











Figure 4.7 IRAK1 Synergizes with TRAF6 Dominant Positive while Coexpression of 
a RZ Mutein with TRAF6 inhibits NF-κB Activity.  25ng of each plasmid was 
cotransfected with 25ng of NF-κB, Luciferase reporter into 293 cells seeded into 96 
well tissue culture plates the previous day.  24 hours after transfection cells were 
harvested and assayed for luciferase signal.  A representative experiment is shown 
for the results of least three biological replicate experiments and quantification as 






























Figure 4.8 IRAK1 and MATH Domains Colocalize. Expression plasmids (40 
ng/each) coding for IRAK1-HcRed and TRAF6-YFP muteins were co-transfected 
into 293 cells according to procedures described in Materials and Methods.  Left 
panels display merged two color confocal mages which are representative subfields 
taken from three independent experiments.   Correlating highlighted insets are 
magnified at right and channels split into green (YFP), red (HcRed), and merged 
where yellow represents colocalization. 
 
  
  80 
4.1.3 TRAF6 RZ and MATH domain interact via the MATH TIM 
In order to correlate our microscopic observations with direct evidence for a 
physical interaction between IRAK1 and the MATH domain of TRAF6, 
immununoprecipitation experiments were designed according to the rationale diagramed 
in Figure 4.9.  Reasoning that TRAF6 may form homotypic interactions between its RZ- 
and either the RZ or MATH domain, I anticipated that an untagged-tagged RZ mutein 
(RZ) would exhibit increased binding to FLAG-tagged TRAF6-YFP (F-TRAF6-YFP) 
with two acceptor sites vs. a FLAG-ΔR-YFP mutein (F-ΔR-YFP) or C70A-YFP mutein 
which has been previously demonstrated to exhibit an impaired RZ-RZ interaction 




Figure 4.9 Model of IRAK1 Disruption of TRAF6 RING-MATH Interaction as 
Revealed by Immunoprecipitation.  
 
Predictably, ectopic IRAK1 was found to disrupt the wtTRAF6 interaction with a RZ 
mutein (Figure 4.10, Table 5).  In  the  left panel, two RZ western  signals are detected 
following IP  with  a  FLAG antibody  and  immunoblotting with an antibody (Santa Cruz  
  









Figure 4.10 IRAK1 Disrupts RZ-MATH interaction (Western blot of IP). A) Left 
panel indicates increased RZ western signal with the addition of IRAK B) Right 
panel is a separate control IP/IB that confirms identity of TRAF6 species in top 
band.  HC*: Heavy Chain IgG LC*: Light chain IgG.  In both western blots, whole 
cell lysates (WCL) extracted from 293 cells transfected with 1μg of each indicated 
plasmid were harvested 24h after transfection, incubated with FLAG antibody and 
prepared for western blot analysis.  PVDF membranes containing 50μg of WCL 
protein were then probed with TRAF6 (directed at the RZ) or FLAG antibody.  A 
representative blot of two independent experiments is shown.  
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sc-H274) that recognizes an epitope corresponding to amino acids 1-274 of TRAF6 or the 
RZ domain.  These two bands represent the RZ mutein (lower) and dual tagged F-ΔR, -
C70A or -TRAF6-YFP (upper).  There is an obvious increase in ectopic RZ mutein signal 
between lanes 1&4, which is greater than that seen between lanes 2&5 or 3&6.   In the 
right panel (a different membrane in which samples from the same WCL were 
immunoprecipitated with FLAG antibody, then immunoblotted with FLAG antibody 
before transfer to the PVDF membrane) no RZ western signal e.g. a lower band is 
detected and serves as a control.  The untagged RZ mutein cannot be precipitated with 
FLAG antibody and thus the dual tagged TRAF6 muteins are visualized as  higher bands 
that correspond to their molecular weights (Table 5).  Insomuch, adding IRAK1 increased 
the RZ mutein western blot signal, demonstrating that wtTRAF6 but not ΔR 
autoinhibition was overcome, increasing mutein RZ binding to both the RZ or MATH 
domains of FLAG tagged TRAF6 (Figure 4.10).  This result supports the hypothesis that 
IRAK1 activates TRAF6 by disrupting the RZ and MATH domain association via the 
MATH domain TIM recognition groove.  Moreover, there exists a putative T6IM in the 
RING domain of TRAF6, as revealed by ELM analysis and scrutiny of the primary 
sequence (Figure 4.11).  This previously unreported RING domain T6IM is modeled in 
Figure 4.12 and could be the basis for a direct TRAF6 RZ-MATH interaction.  Such an 
interaction would support a structurally “closed” inactive TRAF6 molecule.  
Interestingly, this T6IM is adjacent to the cysteine at position 70 (C70) that has been 
identified as the critical residue for recruiting the E2 ubiquitin conjugase, Ubc13 (Yin, 
Lamothe et al. 2009).  The integrity of the Zn2+ finger motif within the RING domain has 
been shown as necessary to function and mutation of C70 (TRAF6-C70S) abolishes 
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interaction of TRAF6 with Ubc13 (Wooff, Pastushok et al. 2004).  Relatedly, the 
TRAF6-C70A mutant inhibited TRAF6 autoubiquitination (Lamothe, Besse et al. 2007).  
In our Co-IP experiment, substituting a ΔR (125-522) deletion mutein for wtTRAF6 
produced an overall decrease in RZ mutein signal on Western blot (Figure 4.10), both 
with and without IRAK1 coexpression.  However, adding IRAK1 clearly increased the 
free RZ signal in a manner similar to that of wtTRAF6.  Using the C70A mutein in place 
of wtTRAF6 did not show any differences in IRAK1 modulation of RZ binding to the 
MATH domain of TRAF6.  Given that addition of a TIM peptide is insufficient to 
activate TRAF6 (Poblenz, Jacoby et al. 2007), along with the results in this section, it 
seems that IRAK1 activation of TRAF6 depends on factors beyond simple TIM groove 
occupation and RZ-MATH dissociation. 
 









Figure 4.11 ELM Analysis Shows TRAF6 Primary Amino Acid Sequence Contains 
a TRAF6 Interaction Motif Sequence in Its RING Domain.  A) Analysis for 
Q9Y4K3 (human TRAF6) shows global protein domain structure and various 
motifs within linear sequence   B) sequence for RING domain of human TRAF6 












Figure 4.12 Molecular Modeling of TRAF6 RING Structure Featuring aa63-69 
Putative TIM Sequence. A) Peptide backbone and B) van der Waals space fill 
structures indicating the putative TIM amino acids. C) Peptide backbone structure 
(Red) with TIM amino acid side chains presented as van der Waals space fill. RING 
finger cysteine side chains are presented as yellow tubes with coordinated Zn (Green 
spheres).  Space fill amino acid side chains are colored according to the Shapely 
standard: http://life.nthu.edu.tw/~fmhsu/rasframe/COLORS.HTM.  
 
  86 
4.2 Super-stimulatory effects of ligands demonstrate bimodal inhibition of TRAF6 
While some details have emerged, the molecular mechanism by which 
endogenous TRAF6 is activated by upstream factors has not yet been fully determined.  
In agreement with others, I found that ectopic expression of MyD88, IRAK1 or 
wtTRAF6 acts as a dominant positive for Upstream activators potentiate TRAF6 
dominant positive when co-expressed.  NF-κB activity resulting from co-transfection in 
293 cells with indicated expression vectors, and the luciferase reporter previously 
described (Wang, Wara-Aswapati et al. 2006).  In agreement with others, I found that 
ectopic expression of any of these three molecules acts as a dominant positive for NF-κB 




Figure 4.13 Ectopic Expression of TRAF6, IRAK1, or MyD88 is capable of 
Activating NF-κB.  293 cells were co-transfected with 25ng of indicated expression 
vectors and 25ng NF-κB-Luciferase reporter.  
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Predictably, titrating increasing amounts of TRAF6 (Figure 4.14A) or RZcc (Figure 
(4.14B) acted as a dominant positive with maximal stimulation occurring abruptly in both 
cases at high concentration of plasmid, while transfecting a control empty vector had no 
affect on NF-κB activity.  Overexpression allows TRAF6 to act as a surrogate for 
receptor-dependent upstream stimulation in various NF-κB signaling pathways.  To test 
the hypothesis that overexpression of TRAF6 was effectually titrating out an inhibitory 
molecule(s), I reasoned that NF-κB activity in either RAW264.7 or 293R cells induced 
by a minimal amount of ectopic TRAF6, could be increased by addition extracellular 
stimulatory ligands IL-1β (Figures 14.15) or LPS (Figure 14.16B) to levels greater than 
the saturation point achieved by ectopic TRAF6 alone.  Interestingly, “super-stimulation” 
by IL-1β in 293R averaged unimpressive 1.5x increases over saturated dominant positive 
activity induced by transfecting saturating amounts of TRAF6 (100ng) alone but 
costimulation with minimal dose of activating TRAF6 (20ng) or RZcc (10ng) produced a 
5-7x “super-stimulation” (Figure 4.15).  This supports the model that ectopic TRAF6 or 
RZcc acts as a dominant positive by overcoming the stoichiometry of putative inhibitory 
proteins interacting that attenuate TRAF6.  Unexpectedly, ectopic expression of TRAF6 
alone in the pre-osteoclast cell lines, 4B12 (Figure 4.16A) or RAW264.7 (Figure 4.16B) 
did not have a dominant effect for NF-κB activity.  Despite the unresponsiveness of both 
pre-osteoclast lines to ectopic TRAF6, NF-κB activity was still inducible by LPS 
stimulation or transfection of the NF-κB-p65 subunit itself (Figure 4.16B).  Furthermore, 













Figure 4.14 Ectopic expression of either A) TRAF6 or B) RZcc (1-358) acts as a 
dominant positive for NF-κB activity in a dose dependent manner in 293T epithelial 
cells co-transfected with a NF-κB–Luciferase reporter.  A representative experiment 
is shown for the results of at least three biological replicate experiments and 
quantification as indicated for three experimental replicates (average±s.d.).   EV: 





















































Figure 4.15  Co-stimulation of 293R cells expressing TRAF6 and RZcc with IL-1β 
and “super-stimulates” NF-κB Activity.  Stably transfected 293 cells expressing the 
IL-1 receptor (293R) were stimulated with IL-1β (10ng/mL) for 6-8 hours 24h after 
transfection of A) TRAF6 or B) RZcc as indicated and 25ng NF-κB luciferase 
rporter prior to preparation for luciferase assay.  A representative experiment is 
shown for the results of at least three biological replicate experiments and 
quantification as indicated for three experimental replicates (average±s.d.) and fold 
increase with co-stimulation.  EV: Empty expression vector control. 




Figure 4.16 TRAF6 Does Not Act as a Dominant Positive for NF-κB Activity in Pre-
osteoclast Cells A) 4B12 and B) RAW264.7. 4B12 or RAW264.7 cells were co-
transfected with 25ng NF-κB–Luciferase reporter and TRAF6 or p65 (25ng) as 
indicated and then in the case of RAW264.7 cells stimulated with LPS (100ng/mL) 
for 6-8 hours 24h after transfection prior to harvesting for luciferase analysis.  A 
representative experiment is shown for the results of at least three biological 
replicate experiments and quantification as indicated for three experimental 
replicates (average±s.d.).  EV: Empty expression vector control. 
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as monitored by transfecting either a XN- or XT- IL-1β Luciferase reporters (Figure 
4.17).  Of these two constructs, the XN IL-1β -Luc, which is driven by an IL-1β promoter 
that contains elements that run downstream to the site of the IL-1β promoter, has nearly 
three fold greater activity than that of the XT IL-1β promoter when induced by LPS in 
RAW264.7 cells (Figure 4.17).  Thus, a model emerges where over-expression of TRAF6 
has two modalities for increasing NF-κB activity: (1) It can shift the equilibrium of 
TRAF6 toward the open active conformation previously reported by our laboratory 
(Wang, Galson et al. 2010) and (2) titrate out the inhibitory effects of inhibitory 
molecules that depend upon TIM interaction.  To address the possibility that murine 
RAW264.7 cells were unresponsive to ectopic wtTRAF6 (human) due to species-specific 
differences between RAW264.7 and 293 (human) cell lines, both murine (Figure 14.18A) 
and human (Figure 14.18B) wtTRAF6 were separately transfected into RAW264.7 cells.  
Here, ectopic expression of neither species of TRAF6 sequence activated NF-κB.  Any 
“super-stimulatory” effect when co-stimulated with LPS was also absent (10ng/mL) 
(Figure 4.18A, 4.18B).  Additionally, in a manner similar to results when transfecting 293 
cells, NF-κB was activated in RAW264.7 cells transfected with IRAK1 (Figure 4.19A).  
This suggests a difference in IRAK1 signaling downstream to TRAF6 between the 
epithelial/neuronal (293) and macrophage-monocyte/pre-osteoclast (4B12 and 
RAW264.7) cell lines used in this study.  Interestingly, while ectopic expression of 
wtTRAF6 was not effective at inducing NF-κB in RAW264.7 and 4B12, transient 
transfection of RZcc was able to activate NF-κB in both cell lines (Figure 4.19B, 4.19D). 
As expected, stimulating RAW264.7 with either IL-1β (Figure 4.19B) or RANKL 
(Figure 4.19C) was found to actuate NF-κB.    









Figure 4.17 LPS induces IL-1β activity in pre-osteoclast RAW264.7 cells.  RAW 
264.7 were transfected with 25 ng/well of either XN- or XT- IL-1β Luciferase 
reporters or PGL3 luciferase empty vector (EV) and then stimulated for 6hrs with 
LPS (10ng/mL) 24h post transfection before harvested for bulk luciferase assay.  A 
representative experiment is shown for the results of least three biological replicate 
experiments and quantification as indicated for three experimental replicates 
(average±s.d.).  EV: Empty expression vector control.    
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However, co-stimulation with RZcc + IL-1β/RANKL had a greater effect than 
costimulation with TRAF6 + IL-1β/RANKL supporting previous reports that the MATH 
domain is inhibitory (Figure 14.19B, 14.19C) (Ye, Arron et al. 2002, Poblenz, Jacoby et 
al. 2007, Wang, Galson et al. 2010, Trudeau, Nassar et al. 2013).  Collectively, these 
results suggest that the MATH domain of TRAF6 possesses some inhibitory character, 
which may be attributed to either auto-regulation and/or an exogenous inhibitor that 
could depend on a T6IM interaction (Table 7).  Deleting the MATH domain abrogated 
TIM-based inhibitory protein interaction with TRAF6 and increased NF-κB activation 




  293 RAW264.7 4B12 
  pre-neuronal pre-osteoclast pre-osteoclast 
TRAF6 YES NO NO 
RZcc YES YES YES 
 
Table 7 Summary of TRAF6 dominant positive activity in various cell lines.  Full 
TRAF6 acts as a dominant  positive for NF-κB activity in 293 epithelial but not pre-
osteoclast cell lines 4b12cand Raw264.7. 
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Figure 4.18 LPS or ectopic p65 but not ectopic TRAF6 induces NF-κB activity in 
murine RAW264.7 cells regardless of any species differences in human and murine 
TRAF6 sequences transfected.  25ng of p65 or indicated amounts of TRAF6 were 
transfected with 25ng of NF-κB luciferase reporter and appropriate amounts of 
pFLAG empty vector so that total DNA transfected totaled 150ng/well.  Cells were 
stimulated with LPS the next day for 8 hours then assayed for luciferase activity.  A-
B) A representative experiment is shown for the results of least three biological 
replicate experiments and quantification as indicated for three experimental 






















Figure 4.19 RZcc acts as a dominant poistive in AW264.7 and 4B12 cells.  NF-κB is 
activated by ectopic IRAK1 or stimulation by IL-1β/RANKL in RAW264.7 cells; 
additinally, ectopic RZcc expression can activate NF-κB in 4B12 and RAW264.7 
cells.  A) RAW264.7 cells were co-transfected with 25ng of each indicated plasmid 
and 25ng of NF-κB–Luciferase reporter B) RZcc or wtTRAF6 was transfected as 
indicated along with and 25ng of NF-κB–Luciferase reporter and then co-stimulated 
with 100ng/mL IL-1β 24 hours post transfection for 8 hours prior to harvesting fro 
luciferase assay.  C) RAW 264.7 cells were transfected with 25ng of indicated 
plasmids and 25ng of NF-κB–Luciferase reporter 24h prior to stimulation with 
50ng/mL RANKL the following day for 6 hours before preparation for luciferase 
assay.  D) 4B12 cells were transfected with indicated amounts of RZcc and 25ng of 
NF-κB–Luciferase reporter before harvesting for luciferase assay the following day.  
A-D) A representative experiment is shown for the results of least three biological 
replicate experiments and quantification as indicated for three experimental 
replicates (average±s.d.).  EV: Empty expression vector control. 
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4.3 Molecular Dynamics of TRAF6-Syntenin Interaction 
4.3.1 Syntenin inhibition of NF-κB activators 
 Seminal work characterizing the ability for a human homologue of 
the Drosophila Toll protein to activate NF-κB utilized ectopic expression of a 
constitutively active CD4/human Toll receptor construct (Medzhitov, Preston-Hurlburt et 
al. 1997, Medzhitov, Preston-Hurlburt et al. 1998).  Later, overexpression of CD14, 
TLR4, and MD-2 was reported to confer LPS sensitivity to otherwise LPS-unresponsive 
293T cells, without disrupting the induction of LPS tolerance (Medvedev and Vogel 
2003).  In contrast to these studies, I found that ectopic expression of TLR4 alone acts as 
a dominant positive for NF-κB activity in 293T cells (Figure 4.20A).  As such this system 
allowed me to dispense with the need to initially transfect TLR4 into 293 cells so that 
LPS could be used to induce NF-κB activity.   Instead attenuation of TLR4 signaling by 
Syn was assessed by mere coexpression of Syn and TLR4 in 293 cells.  Coexpression of 
Syn was found to inhibit ectopic TLR4 induced NF-κB activity (Figure 4.20B).  Further, 
Syn was found to inhibit NF-κB activity in IL-1β stimulated 293R cells (Figure 4.21A) in 
a dose dependent manner (Figure 4.21B).  As with TLR4, ectopic Syn also inhibited the 
NF-κB activity in LPS, IL-1β or RANKL stimulated RAW264.7 cells (Figure 4.22).  
Beyond inhibition of NF-κB signaling initiated by the cell surface receptors, NF-κB 
activity induced in 293T cells transfected with the intracellular activator MyD88 was also 
inhibited by Syn in a dose-dependent manner (Figure 4.23A).  Interestingly, although 
ectopic TRAF6 fails to act as a dominant positive in RAW264.7 cells, transecting IRAK1 
instead was found to induce NF-κB activity.  Such NF-κB activity induced by dominant 
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positive amounts of IRAK1 In 293T cells was attenuated by coexpression of Syn (Figure 
14.23B).  Finally, in agreement with Chen et al., ectopic expression of Syn attenuated 
dominant positive TRAF6 activation of NF-κB in 293 cells (Figure 4.24A).  TRAF6 
dominant positive activity in 293T cells was not affected by the addition of EYFP to the 
carboxy terminus of the molecule.  Moreover, the fluorescent chimera could be inhibited 
by ectopic GFP-Syntenin (Figure 4.24B).   
 
Figure 4.20 Syntenin can block NF-κB activity induced by dominant positive ectopic 
expression of TLR4 in 293T cells.  A) 293T cells were transfected 25ng NF-κB 
luciferase reporter and indicated amounts of HA-TLR4 and then prepared for 
uciferase assay 24 hours post transfection.  B) 293T cells were transfected with 
150ng of TLR4 and 50ng of Syn or pHA empty vector (EV) 24 hours prior to 
luciferase assay.  A representative experiment is shown for the results of least three 
biological replicate experiments and quantification as indicated for three 
experimental replicates (average±s.d.).  






Figure 4.21 Syntenin inhibits IL-1β activation of NF-κB in 293R cells. A) 
Optimization for IL-1β  stimulation of 293R cells transfected with 25ng NF-κB 
luciferase reporter and stimualtd the next day for 8 hours prior to luciferase assay.  
B) 293R cells expressing the IL-1 receptor were co-transfected with indicated 
amounts of Syn and 25ng of with 25ng NF-κB luciferase reporter, then simulated 
with stimulated with IL-1β (10ng/mL) for 6-8 hours 24 h post-transfection.  Bars are 
quantification of (average±s.d.) for a representative experiment done in triplicate 
and qualitatively similar to at least three independent experimental replicates.   
  












Figure 4.22 Syn inhibits NF-κB activity induced by LPS, IL-1β or RANKL 
stimulated RAW264.7 cells but not NF-κB activity induce by dominant positive 
RZcc.  RAW264.7 cells were co-transfected with either 100ng pFLAG-RZcc, 25ng of 
mSyn or pFLAG empty vector and 25ng of NF-κB–Luciferase reporter and then co-
stimulated with 100ng/mL IL-1β. 50ng/mL RANKL or 100ng/mL LPS 24 hours post 
transfection for 8 hours prior to harvesting for luciferase assay.  A representative 
experiment is shown for the results of at least three qualitatively similar biological 
replicate experiments and quantification as indicated for three experimental 
replicates (average±s.d.).  
 
  




Figure 4.23 Syntenin attenuates NF-κB activity induced by ectopic expression of 
MyD88 and IRAK1 wchih signal upstream of TRAF6.  A) 293T cells were seeded 
into 96 well plates 24 hours prior to transfection with 50ng of expression plasmid of 
MyD88 along with 25ng NF-κB  Luciferase reporter and indicated amounts of 
murine Syntenin expression plasmid.  Cells were harvested and processed for 
Luciferase Reporter Assay 24 hours following transfection.  B) RAW264.7 were 
seeded in 96 well plates 24 hours prior to transfection.  50ng of each Indicated 
plasmid was transfected along with 25ng of NF-κB Luciferase reporter and 
pcDNA3.1 was used to equalize total transfected DNA to 200ng.  Bars are 
quantification of (average±s.d.) for a representative experiment done in triplicate 
and qualitatively similar to at least three independent experimental replicates.   
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Figure 4.24 Syntenin attenuates NF-κB activity induced by ectopic expression of 
TRAF6.  A) 293 cells were seeded into 96 well plates 24 hours prior to transfection 
with 50ng of expression plasmid of TRAF6 along with 25ng NF-κB  Luciferase 
reporter and indicated amounts of murine Syntenin expression plasmid.  Cells were 
harvested and processed for Luciferase Reporter Assay 24 hours following 
transfection.  B) 293T cells were seeded into 96 well plates 24 hours prior to 
transfection with 50ng of expression plasmid of TRAF6-EYFP along with 25ng NF-
κB Luciferase reporter and 50ng of GFP-human Syntenin expression plasmid.  Cells 
were harvested and processed for Luciferase Reporter Assay 24 hours following 
transfection.  and pEYFP was used to equalize total transfected DNA to 200ng.  
Bars are quantification of (average±s.d.) for a representative experiment done in 
triplicate and qualitatively similar to at least three independent experimental 
replicates.    
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4.3.2 Molecular Domains involved Syntenin-TRAF6 interactions 
I hypothesized that Syn associated with TRAF6 via a putative T6IM at amino 
acids (194-200) in the unstructured linker region between the tandem dual PDZ domains 
of Syn to inhibit TIR signaling (Figure 10).  The C-terminal TRAF6 MATH domain, 
which is often defined as a structure involved in the integration of upstream receptor-
proximal signals, has also been reported to be involved in downstream signal 
transduction.  Examples include RANK ligand signaling through its receptor in 
osteoclasts ((Wong, Besser et al. 1999)) and the super-activation of NF-κB p65 
homodimers by IL-1 (Yoshida, Kumar et al. 2004).  To test this, NF-κB Luciferase 
reporter assays were carried out on 293T cells co-expressing ectopic RZcc and Syn.  
Surprisingly, ectopic Syn was also able to inhibit NF-κB activity induced by dominant 
positive ectopic RZcc (Figure 4.25A), which lacks the MATH domain and does not 
possess a T6IM interaction site.  This phenomenon was independent of the species 
sequence of transfected Syn (Figure 4.25B).  Next, TRAF6 was coexpressed with a series 
of Syn deletion muteins systematically testing which functional domains of Syn were 
necessary for inhibiting TIR signaling.  Deletion of amino acids 194- 298 of Syn 
(ΔPDZ2) minimally abrogated Syn inhibition of dominant positive TRAF6-activated NF-
κB signaling (Figure 4.26).  In contrast, deleting both PDZ domains and the CTD 
(ΔPDZ1+2) of Syn did not inhibit the NF-κB signal, but in some cases increased the 
signal to suprathreshold levels beyond ectopic TRAF6 alone (Figure 4.26A).  Deletion  of 
1-109 (ΔN)  retained  WT-like activity,  whereas  deletion  of 1-192  (ΔPDZ1) was super-  
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Figure 4.25 Syntenin attenuates NF-κB activity induced by ectopic expression of 
RZcc.  A) 293T cells were seeded into 96 well plates 24 hours prior to transfection 
with 50ng of expression plasmid of RZcc along with 25ng NF-κB  Luciferase 
reporter and indicated amounts of murine Syntenin expression plasmid.  Cells were 
harvested and processed for Luciferase Reporter Assay 24 hours following 
transfection.  B) 293 cells were seeded into 96 well plates 24 hours prior to 
transfection with 50ng of expression plasmid of either TRAF6 or RZcc along with 
25ng NF-κB Luciferase reporter and 50ng of either murine or human Syntenin 
expression plasmids as indicated.  Cells were harvested and processed for Luciferase 
Reporter Assay 24 hours following transfection.  and pEYFP was used to equalize 
total transfected DNA to 200ng.  Bars are quantification of (average±s.d.) for a 
representative experiment done in triplicate and qualitatively similar to at least 
three independent experimental replicates. 
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Figure 4.26 The CTD Is The Dominant Factor In Syn Attenuation Of TRAF6 
Signaling.  CTD And NTD Of Syntenin Can Attenuate TRAF6 Induced NF-Κb 
Signal.  A) 293T cells were transfected with 25ng indicated plasmids and 25ng NF-
κB reporter 24 before preparation for luciferase assay.  Bars are quantification of 
(average±s.d.) for a representative experiment done in triplicate and qualitatively 
similar to at least three independent experimental replicates.  B) schematic of 
TRAF6 and Syn plasmids used.  Human plasmids were tagged with either a 9aa HA 
tag or an 8aa FLAG tag as indicated. 
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inhibitory, similar to the mSyn effect.  Collectively, these data suggest that the sequence 
between 193 and 298 is responsible for TRAF6 inhibition, with 1-192 possibly providing 
some intra-molecular regulation of ΔPDZ1.  To support the results from the activity 
assays for the Syn deletion muteins Co-IP experiments were preformed with HA-tagged 
versions of Syn in order to determine whether the putative T6IM of Syn was sufficient 
for TRAF6 binding.  Strikingly, only full length Syn was found to physically interact 
with TRAF6 (Figure 4.27).  This could suggest that only full-length Syn binds to TRAF6, 
but that the inhibitory activity is associated with some other signaling component. 
 4.3.3 Syntenin inhibits TRAF6 in an Ubiquitin-dependent manner 
The NTD of Syn was recently shown to contain 3 novel Ub binding motifs, which 
interact with the carboxy-terminal region of ubiquitin via a non-covalent interaction 
(Okumura, Yoshida et al. 2011, Rajesh, Bago et al. 2011).  To understand how the 
ubiquitination state of TRAF6 might affect interaction with Syn regulation of TRAF6, 
ectopic lysine-deficient TRAF6ΔK (Walsh, Kim et al. 2008) was transfected in 293 cells 
and NF-κB activity measured by the NF-κB Luciferase reporter assay (Figure 4.28A).  
Ectopic Syn was less effective at inhibiting dominant positive NF-κB activity by 
TRAF6ΔK, as compared to inhibition of wtTRAF6.  Further, over-expression of Syn 
deletion muteins with TRAF6ΔK revealed a nearly opposite effect as compared to 
wtTRAF6. While, the PDZ2 (+CTD) of Syn seemed to be sufficient for inhibition of 
wtTRAF6, the Syn CTD (deletion muteins that lacked the NTD and (ΔN and ΔPDZ1) 
were  unable  to  attenuate  TRAF6ΔK induced NF-κB activity.  Meanwhile,  ΔPDZ2 and  
 
 
























Figure 4.27 Only full length Syn was found to interact with TRAF6.  A) 293 cells 
were seeded into 6 well plates and transfected with 1μg FLAG-TRAF6 and 1μg 
indicated HA-tagged Syntenin construct. Western blots containing 50 μg protein of 
whole cell lysates (WCL) of 293 cells harvested 24h after transfection of indicated 
plasmids. Lysates supernatants were incubated with anti-FLAG agarose beads for 6 
hours at 4°C.  Absorbed proteins were eluted and denatured by 1x SDS-PAGE 
buffer and β-mercapto ethanol at 95°C and  then prepared for western blot.  
Proteins were resolved on a 4-12% gradient gel and transferred onto a PVDF 
membrane.  Membranes were blotted with LEFT) anti-FLAG antibody or RIGHT) 
anti-HA antibody.  A representative blot of two independent experiments is shown. 
Left panel indicates sucessful FLAG-TRAF6 precipitation, right panel indicates that 
only full length HA-Syn co-immunoprecipitated with FLAG-tagged TRAF6. 
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ΔPDZ1+2 were yet able to inhibit TRAF6ΔK induced NF-κB activity (Figure 4.28B).  
This result, taken together with previous reports, supports that the NTD of Syntenin 
interacts with ubiquitinated TRAF6 i.e. an active “open” TRAF6 (Wang, Galson et al. 
2010) rather than “closed” un-ubiquitinated TRAF6.  
4.3.4 Inhibition of Src Family Kinase increases Syn attenuation of TRAF6 induced NF-κB 
activity 
Syn has been reported to activate NF-κB by binding to c-Src, inducing 
downstream target genes leading to cell migration and invasion (Boukerche, Aissaoui et 
al. 2010).  Classically Src has been found to be neither necessary nor sufficient for NF-
kB activity, only increasing the activity of NF-B over that derived by IKK-dependent 
release of IB by activation of PI-3K and Akt/PKB (Madrid, Mayo et al. 2001, Storz, 
Doppler et al. 2004, Wang, Wara-Aswapati et al. 2006).  Presumably, TRAF6 can further 
activate NF-B via c-Src in this manner.  Additionally, TRAF6 and c-Src induce 
synergistic AP-1 activation via a PI3-kinase-AKT-JNK pathway (Funakoshi-Tago, Tago 
et al. 2003).  However, at least one report implicates c-Src directly activating NF-B 
during hypoxic conditions via mROS (Funakoshi-Tago, Tago et al. 2003, Lluis, Buricchi 
et al. 2007).  In some of our NF-B luciferase assays, Syn appeared to inhibit TRAF6 
with a nonlinear dose response (Figure 4.29A).  When Syn was overexpressed in 293 
cells, it appears to activate NF-κB in an inverted U dose response with a peak centered in 
low  concentrations (Figure 4.29A).  It  is possible  that  ectopic Syn inhibits TRAF6 only  
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Figure 4.28 Syntenin inhibits TRAF6 in an Ubiquitin-dependent manner.  A) Values 
represent NF-κB activity resulting from co-transfection in 293 cells with indicated 
amounts of mTRAF6 or mTRAF6ΔK, 50ng mSyn and 25ng NF-κB luciferase 
reporter.  A) A lysine deficient TRAF6 is inhibited less as compared to wtTRAF6 by 
Syntenin. B) Syn ΔN is less effective at inhbiting TRAF6ΔK vs wtTRAF6.  
Suggesting that the N terminus may bind to Ubiquinated, activated TRAF6.  293 
cells were transfected with 25ng mTRAF6 or mTRAF6ΔK, 50ng of indicated 
Syntenin mutein and 25ng NF-κB luciferase reporter.   Bars are quantification of 
(average±s.d.) for a representative experiment done in triplicate and 
qualitatively similar to at least three independent experimental replicates.    
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when the amount corresponds to activated “open” TRAF6 with proper stoichiometry, due 
to it’s own ability to activate NF-κB.  To investigate this further, I sought to remove the 
downstream activation of Src.  First, I determined the effect of PP2, a selective inhibitor 
of Src family kinase (SFK) members (Hanke, Gardner et al. 1996), on activation of the 
NF-B pathway (Figure 4.29B-D).  Indeed, ectopic Syn was found to activate NF-κB as a 
dominant positive in 293T cells and this activity was inhibited by addition of PP2 (Figure 
4.29B).  Notably, this Src-dependent activity did not have a comparable dose response.  
When PP2 was added to 293 cells transfected with a dominant positive amount of 
TRAF6, there was an order of magnitude less NF-κB activity, and Syntenin was found to 
inhibit TRAF6 induced NF-κB activity, regardless of the presence of the PP2 inhibitor 
(Figure 4.29C, 4.29D).  Interestingly, inhibition of Src Family Kinases by PP2 was found 
to exaggerate the ectopic Syntenin-dependent attenuation of TRAF6-activated NF-κB 
activity by six fold in a more linear manner, supporting the hypothesis that Syn inhibition 
of TRAF6 has a stoichiometric mechanism, possibly due to the mutual activation of Src 




























Figure 4.29 Pharmacological inhibition of Src Family Kinases increases the 
attenuation of TRAF6 induced NF-κB  activity by ectopic Syntenin.  A) Ectopic 
exprsssion of Syntenin activates NF-κB in a Src dependent but Syn inhibits distinct 
dose response.  A) 293 cells transfected with indicated amounts of HA-Syntenin and 
25ng NF-κB  luciferase report activates NF-κB  at low dosage B) 293T cells were 
plated 24 hours prior to trasnfected with indicated amounts of HA-Syn or EV: pHA 
empty vecotor and 25ng NF-κB uciferase reporter, 6 hours after transfection cells 
were treated with Src inhibitor PP2 (10μM) and allowed to rest O.N. before 
luciferase assay C)  PP2 inhibits TRAF6, attenuation of TRAF6 dominant positive is 
by Syntenin is not affected by PP2 treatment.  25 ng of Syn and or TRAF6 were 
transfected into 293T cells and treated with PP2 to a final concntration of 10μM as 
indicated 6 hours after transfection.  D) Normalized values indicating effect of PP2 
upon Syn attenuation of TRAF6 induced NF-κB acttivty in 293 cells transfetd with 
25ng TRAF6 and indicated amounts of mSyn.  Cells were treated with PP2 as 
indicated to a final concentraion of 10μM. Values are quantified as average±s.d. for 
a representative experiment done in triplicate and qualitatively similar to at least 
three independent experimental replicates. 
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4.3.5 Syntenin can relocalize TRAF6 to the nucleus 
Although TRAF6 is typically located in the cytosol in order to act as a signal 
transducer in the TIR signaling pathway, there have been reports of intranuclear TRAF6 
(Bai, Kitaura et al. 2005, Bai, Zha et al. 2008, Pham, Zhou et al. 2008).  Additionally, our 
group has reported that truncated inactive TRAF6 muteins (RZ-, ccMATH- and MATH 
domains), in contrast to WT, localize to both the nucleus and cytoplasm (Wang, Galson 
et al. 2010).  To visually contextualize the inhibitory effects of Syntenin upon TRAF6, 
the subcellular distribution of both molecules as ectopically expressed fluorescent 
chimeras was examined using confocal microscopy (Figure 30).  Surprisingly, over-
expression of Syn not only attenuates TRAF6 signaling, but also causes nuclear 
localization of ectopic WT TRAF6-YFP in 293 cells, as evidenced by colocalization with 
the co-expressed HcRed-Nuc nuclear marker.  Similarly, ectopic co-expression of 
unlabeled TRAF6 resulted in translocation of GFP-Syn into the nucleus (Figure 4.30).  
This nuclear localization correlates with the endogenous subcellular distribution in 
RANKL stimulated RAW264.7 cells (Figure 4.31).  This  result discounts the possibility 
that nuclear localization of TRAF6 by Syn is merely an artifact of over-expression.  
Immunoflourescent staining of endogenous Syn and TRAF6 reveals both proteins as 
largely cytoplasmic, but then simultaneously enter the nucleus (as seen by similar 
temporal kinetic) approximately 15min following stimulation of cell surface receptors 
that initiate TRAF6 mediated signal cascades. 
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Figure 4.30 Expression of ectopic Syntenin translocates TRAF6 into the nucleus.  
Expression plasmids (30 ng) coding for TRAF6ccMATH-YFP or YFP control vector   
(green) were co-transfected with pHcRed1-Nuc vector (30 ng) into one well of pre-
inoculated 293 cells in a 96-well tissue culture plate. Confocal images were taken 
after 24 hours of transfection. The fluorescent signal of HcRed1-nuc, a nuclear 
localization marker, is pseudo-colored red.  Confocal mages represent a subset of 
fields taken from three independent, qualitatively similar experiments. 
 
 
Traditionally, PDZ domain-bearing proteins are associated with membranes, 
suggesting that these domains are involved in either organizing transmembrane protein 
complexes at the plasma membranes or recruiting proteins to membranes from the 
cytosol.  Here, a Syn-TRAF6 complex promotes sequestration of TRAF6 into the nuclear 
compartment.  Sequestration may promote transcriptional activity or attenuate signaling 
to the nucleus by removing TRAF6 from its cytosolic signal transduction location.  
 
 












Figure 4.31 Subcellular localization of endogenous Traf6 and Syn in RANKL 
simulated RAW264.7 cells. RAW264.7 cells were seeded into 96 well plates, the next 
day they were stimulated with RANKL (50ng/mL) for 6-8 hours prior to fixing with 
4% PFA and subsequently processed for immunolabelling and confocal imaging.  
Syntenin and TRAF6 were immuno-labeled in separate wells and then 
counterstained with Alexa488 (green) conjugated antibody.  Confocal mages 
represent a subset of fields taken from three independent, qualitatively similar 
experiments. 
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4.3.6 Domains of Syntenin involved in relocalizing TRAF6 to Nucleus 
With both the Syn and TRAF6 deletion muteins available, the next set of 
experiments aimed to interrogate which domains were either necessary or sufficient for 
Syntenin mediated TRAF6 nuclear relocalization.  When expressed by itself, GFP-Syn 
was found throughout the cell.  However, when co-expressed with either RZcc (1-358) or 
wtTRAF6, ectopic GFP-Syntenin localizes primarily to the nucleus (visualized by ectopic 
expression of HcRED Nuc) and generates filipodia-like structures in 293 cells (Figure 
4.32).  Expression of inactive vectors coding for either the RZ or MATH domains co-
transfected with GFP-Syn did not display differences from control, with Syn expressed 
throughout the cell (Figure 4.32).   
 
Figure 4.32 Syntenin is enriched in the nucleus of 293 cells activated by ectopic 
TRAF6 or RZcc.  293 cells were seeded into 96 well plates and transfected with 25 
ng GFP-Syn, 25 ng of the nuclear marker HcRED Nuc and 25ng of control empty 
vector or TRAF6 muteins as indicated.    
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These results correlate with NF-κB activity data, demonstrating that the MATH domain 
of TRAF6 is not necessary for Syntenin nuclear enrichment or attenuation of TRAF6 
signaling.  These findings contradict reports that the nuclear localization of Syn is 
inversely correlated with podosome/plasma membrane formation in epithelial cells 
(Zimmermann, Tomatis et al. 2001) since an increase in podosome/filipodia is observed 
when Syn is enriched in the nucleus.  A possible mechanism here could be that activated 
TRAF6 must interact with other molecules such as Ubiquitin, before binding and co-
translocating with Syn.  Or, perhaps the effects on activity and subcellular localization 
have distinct mechanisms. To determine Syn domains critical for TRAF6 nuclear 
translocation, Syn deletion mutants were coexpressed with TRAF6-YFP in 293 cells 
(Results summarized in Table 8).   
 
Table 8 Summary of Syn Domains Effects upon TRAF6 Activity and Localization.  
 
The addition of wtSyn results in translocation of TRAF6 to the nucleus in nearly all 
transfected cells expressing the TRAF6-YFP mutein as demonstrated by colocalization 
with ectopically expressed HcRed-Nuc mutein (Figure 4.30, 4.33).  Coexpression of 
SynΔN with TRAF6-YFP in 293 cells produced a mixed population of TRAF6 in both 
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the cytoplasm and nucleus (Figure 4.33).  When co-expressed with SynΔPDZ1+2 or 
SynΔPDZ2 muteins, TRAF6-YFP remained largely cytoplasmic, which is similar to 
normal TRAF6 subcellular expression (Figure 4.33).  Collectively these results suggest 
that the NTD domain of Syn is necessary but insufficient for TRAF6 re-localization to 
the nucleus.  Mechanistically this may be due to the ability of the Syn NTD to bind 
Ubiquitin ergo “open” TRAF6.  On the other hand, coexpression of SynΔPDZ1 (retaining 
the PDZ2 and CTD of Syntenin) with TRAF6-YFP was able to relocalize TRAF6-YFP to 
the nucleus, suggesting that the dominant factor in Syn mediated relocalization of TRAF6 




Figure 4.33 Intranuclear translocation of TRAF6 depends on NTD and PDZ2 and 
CTD of Syn.  Removal of the C-terminus precludes TRAF6-YFP enter into the 
nucleus.  Images are merged signals from confocal subfields that represent three 
independently conducted experiments the nucleus is visualized by transient 
transfection of HcRED-Nuc reporter.  
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Unlike wtTRAF6, TRAF6C70A is inactive as an E3 ligase and deficient in poly-
ubiquitination (Walsh, Kim et al. 2008).  We confirmed this result and importantly 
detected monoubiquitinated.  TRAF6c70AYFP and TRAF6ΔRYFP, which in the case of 
C70AYFP revealed as a faint but distinct band when FLAG-C70AYFP was transfected 
into 293 cells, then immunoprecipitated by FLAG and resolved by SDS page and 
revealed by immunoblotted using anti-Ubiquitin antibody (Figure 4.34).   
 
 
Figure 4.34 TRAF6C70A is deficient in poly-ubiquitination.  293 cells were 
transfected with indicated plasmids and then prepared for immunoprecipitation 
using FLAG antibody and resolution by SDS page and detection by Immunoblot on 
PVDF membrane.  At left FLAG-C70AYFP and the ΔR muteins are  deficient in 
poly ubiquitination while smear above full length TRAF6 represents ply-Ub 
modification.  At right is control blot confirming FLAG IP occurred and ΔR mutein 
is unstable (smear beneath are degradation).   *Lowest two bands in each lane 
of both micrographs are antibody heavy (HC) and light (LC) chains 
respectively (Wang 2010, unpublished). 
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Ectopic expression of TRAF6C70AYFP in 293 cells reveals a subcellular localization, 
primarily in the cytoplasm, similar to that of wtTRAF6  (Figure 4.35).  When Syn was 
co-expressed with TRAF6C70A-YFP, TRAF6C70A-YFP failed to translocate to the 
nucleus.  Additionally, when TRAF6C70A-YFP was co-expressed with the Syn deletion 
muteins, none of them were able to translocate TRAF6C70A-YFP to the nucleus. 
Interestingly the large TRAF6C70A-YFP punctae decreased with coexpression of all Syn 
muteins except SynΔN and TRAF6C70A-YFP seemed more diffuse or in speckles in the 
cytosol (Figure 4.35).  This might indicate that Syn may not bind TRAF6 that is not poly-
Ub, but might use it’s others domains to block TRAF6 sequestosome formation, perhaps 
by association with another molecule that interacts with the Syn PDZ2 or CTD and in 





Figure 4.35 Intranuclear translocation of Syntenin and TRAF6 depends on an active 
ubiquitylated, TRAF6 and the NTD of Syntenin.  Images are merged signals from 
confocal subfields that represent three independently conducted experiments the 
nucleus is visualized by transient transfection of HcRED-Nuc reporter. 
TRAF6C70A displays subcellular localization opposite to that of wtTRAF6. Scale 
bar= 20μm.  
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Collectively, these results suggest that the PDZ2 and CTD of Syn requires TRAF6 + Ub 
to bind TRAF6 and bring it to the nucleus which interferes with TRAF6 signaling in the 
cytoplasm.  Further, TRAF6 - Ub blocks the Syn NTD from interacting and translocating 
TRAF6 to the nucleus.  These results are corroborated by reports that Syn binds ubiquitin 
directly through a novel Ub binding pocket, using a mechanism where  the recognition 
involves both N- and C-termini of Syn rather than its PDZ domains, which instead 
mediate prerequisite dimerization (Rajesh, Bago et al. 2011).  Furthermore, Syntenin 
interacts equally well with K48- or K63-linked polyubiquitin chains in a NTD- CTD Syn 
homo-dimer dependent manner (Rajesh, Bago et al. 2011).  Since the NTD of Syn is 
involved in binding to Ub and likely, ubiquitinated TRAF6, the inability of Syn to 
interact and relocalize the C70A muteins support this model of interaction.  The CTD 
(194-298) of Syn, comprised of the linker (T6IM), PDZ2 and CTD, alone are also critical 
components of Syn involved in TRAF6 nuclear localization.  
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4.4 Characterization of Sox4-TRAF6 Interaction 
4.4.1 Sox4 is a novel T6IM bearing protein that inhibits TRAF6 
Although TRAF6 and Syntenin co-localize in the nucleus, neither molecule bears 
a NLS.  Furthermore, Syntenin attenuates RZcc dominant positive signaling to NF-κB.   
These two results led to our hypothesis that Syn was acting as an adapter protein for 
another T6IM-bearing protein.  Presumably, this novel T6IM-bearing protein would 
associate with TRAF6 in a trimeric complex with Syn, mediating the attenuation of NF-
κB signaling and intranuclear localization of TRAF6.  Sox4 has been reported to 
accumulate with Syntenin in the nucleus (Beekman, Vervoort et al. 2012).  Sox4 has a 
bipartite nuclear localization signal (BP-NLS) at positions 60-77 and 129-136, as 
identified by the Nuclear Protein Database(NPD,  
http://npd.hgu.mrc.ac.uk/user/index.php).  Furthermore, analysis of the Sox4 primary 
amino acid sequence revealed a perfect TRAF6 TIM immediately adjacent to the HMG-
Box DNA binding domain at AA 147-154 (Figure 4.36). 
To investigate the possibility that Sox4 cooperates with Syn to modulate TRAF6 
signaling and subcellular localization, a similar strategy to that employed for 
interrogating the nature of Syn-TRAF6 interactions was utilized, with Sox4 substituting 
for Syntenin in the experiments.  Subsequent experiments were designed to  assess 
changes in activity, subcellular localization, physical interactions and 
morphological/developmental effects.  NF-κB-Luciferase reporter assays from bulk 
cellular extracts revealed that ectopic Sox4 attenuates NF-κB activity in a dose dependent  
 
 







Figure 4.36 Sox4 and Syntenin share many motifs for binding proteins that have 
been either previously implicated with TRAF6 signaling or direct TRAF6 binding.  
Putative TIMs were discovered in both Syn-1 & Sox4 primary sequences. The Sox4 
TIM is a consensus sequence also predicted by ELM Analysis. A) Schematic of Sox4 
domains and important binding motifs.  B) ELM Analysis confirms canonical 
TRAF6 TIM next to DNA binding domain of Sox4.    
 
 GRR: glycine rich region of Sox4 (151-155; 333 - 397) 
 SRR: serine-rich region 
 TAD/DD: Transactivation/degradation domain 
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manner when either 293R cells were stimulated with IL-1β or 293T cells transiently 
transfected with TLR4 (Figure 4.37).   
In the case of the ectopic TLR4 dominant positive, Sox4 is more effective than 
Syn at attenuating the NF-κB signal when equivalent amounts of plasmid was 
transfected.  This suggests that Sox4 is the dominant factor in Syn inhibition of TRAF6 
dependent receptor 
signaling to NF-κB (Figure 41B).  Similarly, Sox4 was also able to inhibit the upstream 
TIR adapter, MyD88, in a dose dependent manner (Figure 4.38). 
The next step was to use TRAF6 as a surrogate for upstream signaling events in 
TIR signaling and determine whether Sox4 inhibited the TRAF6 dominant positive in a 
manner that depends upon the MATH TIM groove.  In accordance with my hypothesis, 
ectopic Sox4 was able to attenuate wtTRAF6-induced NF-κB activity in 293R cells, but 
was unable to attenuate the RZcc dominant positive (Figure 4.39A). Similar to Syn, 
attenuation of TRAF6 signaling by Sox4 was affected by the Ub state of TRAF6.  Both 
Sx4 and Syn were reduced in their ability to inhibit NF-κB activity induced by 
TRAF6ΔK (Figure 4.39B).  This suggests that Syn and Sox4 cooperatively inhibit 
TRAF6 possibly through Syn interaction with Ubiquitinated TRAF6 and Sox4.  
Encouraged by these results, I sought to correlate the activity assays with information on 
the physical interaction of Sox4 with TRAF6.  First, confocal microscopy revealed that 
endogenous Sox4 and TRAF6 colocalize within cytoplasmic punctae pre-osteoclast 4B12 
cells upon RANKL stimulation (Figure 4.40). Co-immunoprecipitation of WCL from 293 
cells revealed that Sox4 precipitated with TRAF6-YFP but not RZcc-YFP (Figure 4.41).  
Thus, TRAF6- Sox4 interactions depend on the MATH domain.  
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Figure 4.37 Sox4 inhibits TIR receptor dependent NF-κB activation.  A) 293R cells 
were transfected with 25ng NF-κB luciferase reporter and indicated Sox4.  24 hours 
later the cells were stimulated with IL-1β (10ng/mL) for 6-8 h and assayed for NF-
κB activity.  B) 293 cells were transfected with 200ng TLR4 or EV and 50ng of LV-
Syn or LV-Sox4 as indicated along with 25ng NF-κB luciferase reporter to examine 
the effect of Sox4 on TLR4 signaling.  EV= pcDNA3.1 empty vector.   Values are 
quantified as average±s.d. for a representative experiment done in triplicate and 
qualitatively similar to at least three independent experimental replicates.  
 














Figure 4.38 Sox4 inhibits NF-κB activation induced by dominant positive ectopic 
expression of MyD88.  293T cells were transiently transfected with 50ng MyD88, 
indicated amounts of LV-Sox4 expression plasmid or EV (pcDNA 3.1 empty vector), 
and 25ng NF-κB luciferase reporter.  The next day cells were prepared for 
luciferase assay.  Values are quantified as average±s.d. for a representative 
experiment done in triplicate and qualitatively similar to at least three independent 
experimental replicates.   
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Figure 4.39 Sox4 inhibition of TRAF6 activated NF-κB depends on the MATH 
domain and Ubiquitinated TRAF6. A) 293 cells were transiently transfected with 
25ng NF-κB luciferase reporter along with 25ng (EV) pFLAG, TRAF6 or RZcc and 
indicated amounts of LV-Sox4 24 hours prior to lysis and harvesting for luciferase 
assay.  B) Normalized luciferase activity of 293T cells transfected with 25ng of 
indicated plasmids and 25ng NF-κB luciferase reporter 24 hours prior to 
preparation for luciferase assay. Values are quantified as average±s.d. for a 
representative experiment done in triplicate and qualitatively similar to at least 
three independent experimental replicates.   
 











Figure 4.40 Endogenous Sox4 and TRAF6 co-localize in cytoplasm of stimulated 
4B12 cells upon RANKL stimulation.  4B12 cells were fixed and immunostained 
following 5min stimulation with 50ng/mL RANKL or a control stimulation 
(optimum only).  Confocal mages are a subfield of at least three fields taken from 
three experimental and two biologically independent experiments that are 
qualitatively similar. 
  








Figure 4.41 Sox4 interaction with TRAF6 depends on the MATH domain.  Western 
blots containing 50 μg protein of whole cell lysates (WCL) of 293 cells plated into 6 
well tissue culture plates and harvested 24h after transfection of 1μg TRAF6-YFP, 
RZcc-YFP and LV-Sox4 plasmid as indicated.  Lysates were incubated with anti-
YFP antibody and subsequently blotted with anti-Sox4 (left) or anti-YFP (right) 
antibody following SDS-PAGE and transfer to PVDF membrane.  A representative 
blot of three independent experiments is shown.  Left panel indicates interaction 
with full length TRAF6-YFP but not RZcc-YFP, Left panel indicates that YFP IP 
occurred.   
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To expand on this data, the comparative subcellular localization of IRAK1, Sox4, 
Syntenin and TRAF6 was visualized by confocal microscopy.  Consistent with our 
observations thus far, in 4B12 cells, ectopic Syn disrupts IRAK1 and TRAF6 
colocalization and neither Syn nor Sox4 colocalizes with IRAK1 in 4B12 cells (Figure 
4.42).  To underscore the visual data, Sox4 was knocked-down by co-transfecting siRNA 
against Sox4 in 293 cells concurrently with transient transfection of TRAF6 
±Syntenin/Sox4 and an NF-κB Luciferase reporter.  Without Sox4, TRAF6 activity 
increased, arguing that Syntenin was unable to attenuate TRAF6 dependent NF-κB 
activity (Figure 4.43).  Taken together, these data suggest that TRAF6 and Sox4 bind in a 
MATH domain-dependent manner with Syntenin, serving cooperatively to stabilize the 
cargo carrying capacity of Sox4 for TRAF6 nuclear translocation and the attenuation of 
NF-κB activity.   
4.4.2 Quantification of relative Sox4, TRAF6 and Syn mRNA levels in various cell types 
 The differential ability of ectopic TRAF6 to act as a dominant positive for NF-κB 
activity in cell lines of different lineages is a novel finding that prompted further 
examination.  One possibility for the observed difference could be that the molecules 
regulating TRAF6 (Sox4 and Syn) are differently expressed in the pre-osteoclast 
RAW246.7 and 4B12 lines vs. the commonly used 293 epithelial cells.  To test this 
hypothesis, the appropriate primers were designed to quantify relative amounts of 
endogenous mRNA expression of TRAF6, Sox4 and Syn by qPCR was conducted in LPS 
stimulated THP-1 and RAW264.7 cells and compared against steady-state mRNA levels 
in 293 cells (Figure 4.44).  Interestingly, 293 cells were found to have relatively low 
amounts TRAF6 and virtually no Syn mRNA expression  as compared to Sox4.  At 
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steady state, THP-1 has equally low amounts of TRAF6, Sox4 and Syn, with Sox4 levels 
nearly 30 fold lower than that found in 293 cells.  Upon LPS stimulation Syn levels 
tripled before falling to tice that of steady state by 5 hours and persisting at two fold 
steady state for 24 hours.  Sox4 mRNA rose progressively to 20% the steady state levels 
found in 293, but 10 fold higher than base line levels in unstimulated THP-1 cells.  In 
RAW 264.7, TRAF6 mRNA expression was 3 fold higher than that found in 293 cells at 
steady state, increasing two fold by 3 hours post LPS stimulation and persisting for 24 
hours.  This represents a 6-fold increase over 293 steady state levels of TRAF6 mRNA 
expression.  Syn mRNA expression in RAW264.7 was the highest in RAW264.7 of the 
three cell lines compared, at least 5 fold higher than that of THP-1 or 293 expression 
levels.  Upon LPS stimulation, Syn mRNA expression increased to 10x then 15x at 3h 
and 6h respectively over 293 steady state levels, or 2x and 2.5x the baseline Syn levels in 
RAW264.7 itself.  Elevated Syn mRNA was sustained in response to LPS stimulation in 
RAW264.7 for upon to 24 hours, although by 24 hours the levels were reduced to 2x, 
similar to levels at 3hours.   Surprisingly, RAW264.7 seemed to be devoid of Sox4 
mRNA expression in both steady state and LPS stimulated conditions.  In summary, 293 
cells have low TRAF6 and Syn mRNA expression but high Sox4 expression that are 
consistent with the embryonic origin of the epithelial cell line.   On the other hand, 
RAW264,7 cells express higher levels of Syn and TRAF6 but virtually no Sox4.  Upon 
stimulation, TRAF6 mRNA levels increase in RAW264.7 but, Syn levels elevate 
dramatically in response to LPS stimulation.  THP-1 cells on the other hand, show similar 
starting points for TRAF6, Syn and Sox4 mRNA expression and LPS increases Syn and 
Sox4 expression but the increase in Sox4 is later and more robust.  Collectively, these 
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data suggest that mRNA expression of Syn critically regulates NF-κB activation in TIR 
signaling.  Further, ectopic TRAF6 may act as a dominant positive in 293 cells and not 
RAW264.7 cells because the inhibitory effect of Syn is more readily overcome in 293 vs 
RAW264.7.    




Figure 4.42 Syntenin disrupts IRAK1 and TRAF6 colocalization. 4B12 cells were 
transiently co-transfected with the indicated plasmids 24h prior to fixation with 4% 
PFA and DAPI staining to visualize the nuclei.  Confocal mages represent a subset 











Figure 4.43 Syntenin inhibition of TRAF6 is dependent on Sox4 interaction with 
TRAF6.  Sox4 was knocked down in 293 cells by transfection of siRNA to Sox4 and 
the 25ng indicated plasmids and 25ng NF-κB luciferase reporter.  24h later cell 
cultures were lysed and harvested for luciferase assay. Values are quantified as 
average±s.d. for a representative experiment done in triplicate and qualitatively 
similar to at least two independent experimental replicates.   
  






























Figure 4.44 Kinetic profile of mRNA expression of TRAF6, Syn and Sox4 in 293 vs. 
LPS (1μg/mL) stimulated THP-1 or RAW264.7 cells.  mRNA was extracted from 
cells at indicated timepoints following stimulation by LPS and processed for qPCR.  
Values represent relative expression levels were calculated using Ct method and are 
average±s.d. for an experiment done in duplicate and qualitatively similar to at least 
two independent experimental replicates.   
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4.5 Syntenin and TRAF6 involvement in Neurite Formation 
Amongst the inputs following injury to the nervous system, TRAF6 can transduce 
many of the signals intended for cell survival, death or proliferation.  For example, 
TRAF6 mediates p75 neurotrophic signaling, which is essential for activating either 
apoptosis or survival of the cell dependent cellular context and p75 stimulation 
(Khursigara, Orlinick et al. 1999, Wu and Arron 2003).  Syntenin has been shown to both 
couple transmembrane proteoglycans to cytoskeletal components and play a role in 
targeting receptors to the synaptic cleft (Zimmermann, Tomatis et al. 2001, Beekman and 
Coffer 2008, Chen, Du et al. 2008).  Previously, our group demonstrated that over-
expression of c-Src, MyD88 or TRAF6 in 293 cells, or addition of IL-1β to 293R cells, 
created long filipodia like cellular structures, reminiscent of axons or neurites (Wang, 
Wara-Aswapati et al. 2006).  These results, and our examination of TRAF6 and Syntenin 
interaction, prompted us to ask whether 293 cells could be differentiated into a neuronal-
like cell merely by ectopic expression of TRAF6.  Consequently, I sought to characterize 
the roles of Syntenin and TRAF6 in a neuronal PC12 cells.  PC12 cells are an established 
neuronal cell line derived from rat pheochromocytoma cells.  PC12 are widely used to 
study neurobiology and neurotoxicology as a model of neuronal differentiation.  
Importantly, PC12 cells respond to NGF with morphological changes phenotypically 
resembling sympathetic neurons.  In PC12 cells, NGF stimulation causes proliferation, 
extension of neurites and membrane excitability (Drubin, Feinstein et al. 1985, 
Schimmelpfeng, Weibezahn et al. 2004, Garcia, Castillo et al. 2013).  To test this, neurite 
growth was compared in PC12 cells either transfected with TRAF6 or stimulated with 
NGF  (Figure 4.45).   Transient  transfection  of  PC12 cells  with  TRAF6  was found  to 





Figure 4.45 Ectopic TRAF6 or NGF-induced neurite extension in PC12 cells.  24 
hours prior to transfection with 50ng of pF-TRAF6 or pFLAG empty vector 
(control), cells were plated on matrigel at a low density of (2x103 cells/cm2).  The 
next day, selected cells were treated with 50 ng/mL of human recombinant NGF 
(Millipore). Top: Phase contrast images of cells on Day 0 prior to treatment with 
NGF. Bottom:  Phase contrast image of cells after 96h of NGF treatment. 
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 induce neurite formation over 96 hours with qualitatively similar lengths.  Next, an 
expression vector for PKB/Akt Plekstrin-homology domain joined to GFP (PH-Akt-GFP) 
was used to detect phosphoinositol 3-kinase produced in response to either transfection of 
TRAF6 or NGF stimulation in both PC12 and 293 cells for comparison.  Phospho-Akt 
(and also its PH domain when expressed ectopically) is localized at the tips of growth 
cones, which supports a role for Akt in the regulation of neurite elongation (Higuchi, 
Onishi et al. 2003, Read and Gorman 2009).  293 cells have been previously 
characterized as pre-neuronal despite the widely held belief that they are kidney cells 
(Shaw G 2002).  Indeed, microarray data show that 293 are positive for the NGFR 
receptor and they might be responsive to NGF stimulation.  In both 293 and PC12 cells, 
TRAF6 was able to induce neurite/filipodia like structures of qualitatively similar 
morphologies (Figure 4.46, Figure 4.47).  This suggests that TRAF6 can drive the 
differentiation events by over-expression, expanding on demonstrations that it is critical 
by elimination (Geetha, Jiang et al. 2005, Wooten, Geetha et al. 2005).   
 Having confirmed and clarified the mechanisms by which Syntenin negatively 
regulates TRAF6 signaling, I sought to evaluate whether Syntenin can inhibit the ability 
of TRAF6 or NGF to differentiate 293 cells.   Using ectopically expressed PH-Akt-GFP 
reporter to monitor recruitment to growth cones and newly formed neurites, wtTRAF6 
and/or mSyn was co-transfected into cells that were either stimulated with 50ng/mL NGF 
(+NGF) for 96 hours or a control vehicle (-NGF) 24 hours after transfection.  Confocal 
images were then taken at 24h, 48h, and 96h post transfection for analysis (Figures 4.48-
4.50).  At 24hours, cells that were transfected with either mSyn or wtTRAF6 alone 
displayed filipodia/neurites.  However,  transfection of  both  mSyn  and TRAF6 seemed 
  138 
to have a cancelling effect, and neurite outgrowth was not observed.  Cells that were 
stimulated with NGF all displayed neuronal growth with the exception of the condition 
where mSyn and TRAF6 were transfected in addition to NGF stimulation.  Furthermore, 
stimulation of the cells with NGF produced a more robust overall length in neurite 
growth.  In particular, cells stimulated with NGF+mSyn or NGF+TRAF6 had 
dramatically longer neurite formation vs. NGF alone (Figure 49).   Neurite extension are 
marked with blue wedges, but only extensions that were at least 1x the diameter of the 
cell.  By 48 hours post-transfection, 293 cells co-transfected with wtTRAF6 and mSyn 
seemingly overcome the inhibitory effect of ectopic expression of both plasmids.  
However, the overall length lagged behind the other conditions where neurites began to 
appear at 24hours post transfection.  Notably, the PH-Akt-GFP displayed a neuronal 
buton like appearance, decorating the lengths of the membrane extensions, suggesting the 
development of a neuronal phenotype (Figure 4.49). The phenomena observed at 48hours 
post-transfection continued for up to 96 hours post-transfection (Figure 51).  By 96 hours, 
though the “buton -like” structures seems to have largely disappeared, but the presence of 
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Figure 4.46 Ectopic expression of TRAF6 can act as a surrogate for NGF induced 
neurite formation.   PC12 cells were seeded onto covered chamber slides (Nunc) pre-
treated with matrigel.  24 hours later, Cells were then transfected with 25ng of 
indicated plasmids or mock transfected with vehicle (optimum).  The following day, 
select cells were stimulated with 50ng/mL NGF. NGF stimulated cells were 
subsequently stimulated at 72hours with 50ng/mL NGF (Millipore). 
  







Figure 4.47 Ectopic expression of TRAF6 can act as a surrogate for NGF induced 
neurite formation.   293cells were seeded onto covered chamber slides pre-treated 
with matrigel.  24 hours later, Cells were then transfected with 25ng of indicated 
plasmids or mock transfected with vehicle (optimum).  The following day, select 
cells were stimulated with 50ng/mL NGF.  NGF stimulated cells were subsequently 
stimulated at 72hours with 50ng/mL NGF (Millipore).     
 
  











Figure 4.48 Ectopic expression of TRAF6 is sufficient to induce neurite formation, 
but inhibits neurite formation when coexpressed with Syn.  293 cells were seeded 
onto chambered cover slides pre treated with matrigel and transfect with 25ng of 
indicated plasmids and stimulated with NGF as previously described.  Total amount 
of DNA transfected was normalized across all conditions with pcDNA3.1.    
  









Figure 4.49 Ectopic expression of TRAF6 or Syntenin in 293 cells induces a 
neuronal differentiation state.  Inhibition of neurite extension by co-expression of 
ectopic Syntenin and TRAF6 is overcome 48 hours post transfection.    293 cells 
were seeded onto chambered cover slides pre treated with matrigel and transfect 
with 25ng of indicated plasmids and stimulated with NGF as previously described.   
Total amount of DNA transfected was normalized across all conditions with 
pcDNA3.1.   Wedges indicate extensions that are at least twice the diameter of the 
cell.    










Figure 4.50 PH-AKT-GFP localizes to membrane extensions induced by ectopic 
expression of TRAF6 or Syntenin or NGF stimulation in 293 cells and persists 96 
hours post transfection.  Inhibition of neurite extension by co-expression of ectopic 
Syntenin and TRAF6 is overcome 48 hours post transfection.    293 cells were seeded 
onto chambered cover slides pre treated with matrigel and transfect with 25ng of 
indicated plasmids and stimulated with NGF as previously described.   Total 
amount of DNA transfected was normalized across all conditions with pcDNA3.1.   
Wedges indicate extensions that are at least twice the diameter of the cell.    
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4.6 The Osteological Synapse 
4.6.1 Rationale 
It has been reported that RANK accumulates in membrane rafts, and these 
specialized domains may play an important role in the RANK signal transduction (Ha, 
Kwak et al. 2003, Ha, Kwak et al. 2003).  Further, DAP12, BTK, BLNK, and PLC, as 
well as RANK, were recruited to caveolin-rich membrane domains, which are the crucial 
signaling domains contained in lipid rafts, after RANKL stimulation (Shinohara, Koga et 
al. 2008).  Thus, I hypothesized that a synaptic complex between RANK bearing stromal 
cells and osteoclast precursors similar to the immunological synapse exists.  This 
“osteosynapse” (OS) would contain (on the osteoclast-side) both the RANK and ITAM 
signaling pathways is generated by RANKL stimulation and contribute to the facilitation 
of the osteoclastogenic signal transduction (Figure 4.5).  Synapses are stable adhesive 
junctions between two cells across which information is relayed by directed 
secretion.   The nervous system and immune system utilize these specialized cell surface 
contacts to directly convey and transduce highly controlled secretory signals between the 
constituent cell populations.  The phagocytic synapse has also been described to form 
when dectin 1-expressing phagocytes are exposed to particulate β-glucans, initiating 
phagocytosis (Goodridge, Reyes et al. 2011).  Such examples suggest a conserved 










Figure 4.51 Extracellular and Intracellular signaling molecules involved in 
osteoclastogenesis that might comprise the osteosynapse. 
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4.6.2 BTK but not Tec Kinase is recruited to the plasma membrane upon RANKL 
stimulation 
Based on the general structure of synapses, and the fact that osteoclast already 
form an adhesive junctions with bone, I looked at the subcellular localization of the Tec 
kinases BTK and Tec in the osteoclast precursor cell line RAW264.7.   Plasmids 
containing Tec- or BTK-GFP were transfected into RAW264.7 cells and then stimulated 
with RANKL.  Confocal microscopy revealed that BTK and Tec are normally expressed 
through the cytoplasm.  Upon RANKL stimulation, within 5 minutes, BTK was recruited 
to the plasma membrane as compared to control (GFP) or Tec Kinase-GFP.  The 
relocalization of BTK was sustained for nearly an hour (Figure 4.52).   
4.6.3 BTK is a component of Osteoclast Transcytotic Machinery and FSD 
 Osteoclasts are the primary cells responsible for bone resorption.  Waste products 
created by this process are transcytosed through the osteoclast and released through 
the functional secretory domain (FSD).  The mechanisms of this process are not fully 
understood.  To understand to the temporal stability of the OS, I stimulated RAW264.7 
cells transfected with PH-BTK-GFP with RANKL for up to 96 hours.  Interestingly, with 
extended differentiation by RANKL, visualization of PH-BTK-GFP reveals a structure 
that resembels the osteoclast FSD.  Further, the appearance of negatively stained tunnels 
from apical to basolateral membrane in RANKL differentiated RAW264.7 cells 
expressing PH-BTK-GFP, possibly representing a means for resorbed bone to be 
transcytosed through the cell and released by exocytosis at the FSD (Figure 4.52-4.54).  
Of note, finger like projections did not appear to be localized to a single FSD but rather in 
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multiplicity of FSDs.  This suggests a scenario where the FSD is built at the sRANKL-
signaling site.  Such a scenario would help to explain why pre-osteoclasts differentiated 
by membrane bound RANKL are more robust, functional osteoclasts (Galson, personal 
communication).  Here, in a co-culture cell-cell signaling system the RANKL signaling 




Figure 4.52 Subcellular Distribution of Full length BTK-GFP and Tec-GFP. BTK is 
recruited to Plasma Membrane but not Tec or GFP upon RANKL simulation. 50ng 
of A) GFP B) BTK-GFP C) Tec-GFP was transfected in RAW 264.7 and seeded 
onto a 96 well plate. 24h after transfection, cells were stimulated with RANKL 
[50ng/mL] and imaged by confocal microscopy. Images are representative confocal 
images extracted from z-stacks. Each pattern was observed consistently over the 
course of 1-3 experiments in dozens of cells imaged. D) 3D Perspective view E) Max 
projection of the same field of view. 
 











Figure 4.53 Left: 3D Max projection of PH-BTKGFP localization. Middle: z-stack 
demonstrates the localization of BTK to ‘finger like’ villi of FSD in basolateral 
membrane Right: 3D reconstruction from stack (Max projection) show FSD is not 
only localized to one spot of basolateral membrane. Media was changed and fresh 
RANKL was introduced every 48 hours during differentiation. 24h after 
transfection, cells were stimulated with RANKL [50ng/mL] and imaged by confocal 
microscopy. Images representative confocal images of consistently observed pattern 
for 2 experiments in dozens of cells imaged. 
 
  





Figure 4.54 Visualizations of BTK-GFP expression and localization in osteoclasts 
generated by 44-68h RANKL stimulation of RAW 246.7 cells. Images are 
representative 3D Max projection of z stacks. Red arrows point out FSD; Blue 
arrows denote transcytotic passageways. 
  






 Among the members of the TRAF protein family, TRAF6 has been uniquely 
demonstrated to transduce both TNFR family signaling and the unrelated Interleukin-1/18 
receptor/Toll-like receptor (IL-1R/TLR).  The goal of my research was to elucidate novel 
mechanistic details by which TRAF6 is activated under stimulating conditions and 
characterize how TIM (TRAF Interaction Motif) bearing molecules regulate TRAF6 
signaling across various cell types and receptor systems.  Due to the intramolecular 
association of its amino-terminus RING and carboxy-terminus MATH domains, TRAF6 
exists in either an active-open or inactive-closed (autoinhibited) conformation (Wang, 
Galson et al. 2010).  Interaction of TIM bearing molecules with the TRAF6 MATH 
domain modulates this state and downstream signaling.  The experimental data suggests 
that an open TRAF6 state facilitates both the activity and subcellular localization of the 
molecule.  Furthermore, besides auto-inhibition, the adapter protein Syntenin 
coordinately attenuates TRAF6 signaling to NF-κB in cooperation with the transcription 
factor Sox4.  While the interaction of TRAF6 and Syntenin has been previously reported, 
as well as that between Sox4 and Syntenin, there has been no previous report of the 
interaction between Sox4 and TRAF6.  Interestingly, the TRAF6 interactions with Sox4-
Syntenin appear to relocalize normally cytoplasmic TRAF6 to the nucleus, providing a 
novel mechanism for this largely unexplored, but previously reported, phenomenon 
(Nakamura, Kadono et al. 2002).  The results obtained by this study support the model of 
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TRAF6 activation from a closed autoinhibited state by IRAK1 and attenuation by 
association with a Syntenin/Sox4 complex, with possible sequestration of TRAF6 within 
the nucleus (Figure 4.57), concomitant with the termination of cytoplasmic signaling.  
Furthermore, in the nucleus TRAF6 can regulate transcription in a manner reported by 





Figure 5.1 Summary of TRAF6-Syntenin-Sox4 interactions.  Syntenin stabilizes 
Sox4, which binds to TRAF6 after it has been opened and activated.  TRAF6 auto-
ubiquitination supports Syntenin binding possibly stabilizing the Sox4 TRAF6 
interaction.  Attenuation of TRAF6 signaling is either via the relocalization of 
TRAF6 to the nucleus, away from cytoplasmic substrates for downstream signaling 
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5.2 Activity of keystone molecules like TRAF6 involves multiple regulatory mechanisms  
TRAF6 is associated with several distinct receptor signaling pathways, including: 
p75 NTR neurotropic receptor, IL1R/TLR (TIR) and nucleotide-binding oligomerization 
domain (NOD)-like receptor inflammatory responses, and RANK differentiation of 
osteoclasts.  Therefore, TRAF6 mediated signals are not only important for normal bone 
homeostasis, but also host defense and development.  Accordingly, TRAF6 has been 
implicated in several disorders and disease (Table 9).  Overexpression of immune-related 
genes chronically stimulates the immune system and increases the risk for development 
of disorders such as myelodysplastic syndrome (MDS) and rheumatoid arthritis.  Somatic 
mutations and copy number alterations (resulting from deletion or amplification of large 
portions of a chromosome) are implicit in human lung cancer development.  Detailed 
analysis of lung cancer-associated chromosomal amplifications could identify novel 
oncogenes.  Reportedly, TRAF6 was highly expressed in non-small cell lung cancer 
(NSCLC), small-cell lung cancer (SCLC) cell lines and tumors.  Inhibiting TRAF6 in 
these, two human lung cancer cell lines suppressed NF-κB activation, anchorage-
independent growth, and tumor formation and were found to be necessary for 
oncogenesis.  Furthermore, TRAF6 overexpression in NIH3T3 cells resulted in NF-κB 
activation, anchorage-independent growth, and tumor formation.  TRAF6 is an oncogene 
that is important for constitutive of NF-κB activation in RAS-driven lung cancers 
(Starczynowski, Lockwood et al. 2011).   Additionally, TRAF6 has been identified as a 
target for cancer therapeutics due to its ability to amplify the expression of hypoxia-
inducible factor-1α (HIF-1α) and tumor angiogenesis (Luong le, Fragiadaki et al. 2013, 
Sun, Li et al. 2013, Sun, Li et al. 2014). 
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ectodermal dysplasia 16527194(1) 
bone diseases 18778854(1) 
















Table 9 Diseases associated with TRAF6 Gene.  This table was generated from the 
literature and the Gene Cards database. 
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As such, it is necessary for cells to tightly regulate TRAF6 activity to preserve 
normal physiological function and prevent pathogenesis.  Understanding the mechanisms 
of TRAF6 inhibition and activation can assist in rational drug design, targeting either 
TRAF6 directly or its immediate interacting partners to avoid poor efficacy and off target 
effects of current therapeutics.  In particular, there is mounting evidence that warrants a 
concerted focus on IRAK1 and its interaction with TRAF6 as a therapeutic target (Jain, 
Kaczanowska et al. 2014, Rhyasen and Starczynowski 2015).  Clarification of the nature 
of these interactions is necessary because the details remain unclear and at times contrary 
to expectations.  For example, among the intracellular TLR signaling molecules MyD88, 
IRAK4, IRAK1 and IKKβ, only IRAK1 expression down-regulates TRAF6 in 293 cells 
(Hayden and Ghosh 2004, Muroi and Tanamoto 2008, Muroi and Tanamoto 2012).  
5.3 IRAK1 disrupts TRAF6 autoinhibition 
 Previously our group reported data (Wang, Wara-Aswapati et al. 2006) supporting 
a model for TRAF6 activation where, prior to stimulation, an intra-molecular interaction 
between the RING-Zinc and MATH domains of TRAF6 generated an inactive “closed” 
state reminiscent of protein kinase autoinhibitory mechanisms (Huse and Kuriyan 2002).  
Others have reported autoinhibition in E3-ligases; for example, with SCF (Skp1 x CUL1 
x F-box protein x ROC1) E3 ubiquitin ligase, where Nedd8 conjugation acts as a 
molecular switch to drive the E3 into an active state by diminishing the inhibitory ECTD 
x ROC1 interaction (Yamoah, Oashi et al. 2008).  This study demonstrates that ectopic 
expression of IRAK1 is able to disrupt the intramolecular RZ-MATH interaction, as seen 
by an intermolecular interaction between RZ-only mutein with wtTRAF6 when co-
precipitated in 293 cells co-expressing IRAK1 (Figure 4.10).  Overexpression of IRAK1 
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acts as a surrogate for receptor-dependent recruitment of TIM-bearing proteins and the 
activation of TRAF6.  Interactions with the TIM-recognition groove contained within the 
MATH domain (Ye, Arron et al. 2002) disrupts the “closed” autoinhibited TRAF6, 
opening the molecule, thereby enabling the RING-Zinc and coiled-coil domains to 
interact with E2 conjugating enzyme (Yin, Lin et al. 2009) resulting in trans-
ubiquitination events.  It is possible that the intramolecular RZ-MATH interaction is 
between an internal TIM within the RZ (Figure 4.12) and the MATH TIM groove.  
Mutation of the identified residues in a future study would easily resolve this question, 
possibly producing a constitutively open TRAF6.  Another possibility raised by this study 
is that the inhibitory pair: Syn-Sox4 bind to open TRAF6, with Syn associating with 
ubiquitinated TRAF6 via its NTD (as a dimer) while associated with the C-Terminus of 
Sox4.  In this model, Sox4 associates with TRAF6 in a T6IM dependent manner.  
Effectively then Sox4 and Syntenin bridge TRAF6 to associate the RZ and MATH 
domains and conferring a “closed” conformation to TRAF6 (Figure 5.2).  Importantly, 
  
Figure 5.2 Model of TRAF6 RZ-MATH interacting to form closed TRAF6 via a 
Syn-Sox4 bridge. 
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this model does not preclude direct RZ-MATH interaction; as with all molecular 
associations, there is an on-off rate and when the closed TRAF6 molecule breathes or is 
opened by activators such as IRAK1, the opportunity for Syn/Sox4 to associate with 
TRAF6 emerges.  It would be interesting to see how IRAK1 affects the ubiquitination 
state of TRAF6 or whether IRAK1 could rescue NF-κB activity in cells co-expressing 
wtTRAF6+RZ dominant negative.  One reason why ectopic expression of TRAF6 acts as 
a dominant positive in 293 cells is that overexpression increases the concentration of a 
low abundance equilibrium open TRAF6 state, permitting intermolecular RZ-RZ or RZ-
MATH interactions (Figure 4.9).   However, when poly-ubiquitination of TRAF6 exceeds 
the recycling capability of the sequestosome, recycling ceases and activity is lost due to 
the sequestration of inactive TRAF6 (Wang, Galson et al. 2010).  This can be visualized 
by the co-localization of p62 and TRAF6 (Figure 4.4) as well as the large cytoplasmic 
TRAF6 punctate aggregates (Figure 4.6). IRAK1 was found colocalizes with the MATH 
domain of TRAF6 (Figure 4.8) and that coexpression of IRAK1 with TRAF6-YFP 
reduced the number and size of sequestosomes.  One explanation might be that bound 
IRAK1 prevents excessive ubiquitination by sterically shielding Lysines on the TRAF6 
molecule or mono Ub from Ubiquitylating events.  Ubiquitination of TRAF6 may also 
have steric bulk effects, thus sustaining the active conformation, by preventing 
intramolecular re-association.  Another mechanism of TRAF6 dominant positive 
induction of NF-κB activity besides driving inter-molecular TRAF6 activation 
interactions could be the that an excess of TRAF6 saturates the antagonistic effect of an 
inhibitory molecule that associates with TRAF6 either constitutively (like a 
safety/modulator), or in response to stimulatory or activating conditions (like a brake).    
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5.4 IRAK1 and TRAF6 sequestosomes 
From the literature and findings in this study, it seems clear that IRAK1 associates 
with TRAF6 in a MATH and thus, T6IM dependent manner, However, the effect and role 
that IRAK1 has on TRAF6 subcellular localization is less clear.  The only published 
mutations done in this area seem to affect SQSTM1 binding to autophagy effector 
proteins LC3-A and -B.  Disrupting this event compromises the degradation of 
ubiquitinated protein aggregates by autophagy (Pankiv, Clausen et al. 2007).  Here, 
IRAK1 was found to induce TRAF6 localization from cytoplasmic speckles into to large 
sequestosomes (Figure 4.6), and activating TRAF6 by disrupting the RZ-MATH 
interaction, possibly by disrupting the Sox4-Syn pair.  This model comports with reports 
that IRAK disrupts Syn interaction with TRAF6 and increases TRAF6 poly-
ubiquitination (Chen, Du et al. 2008).  Further, since the T6DP is insufficient to inhibit 
TRAF6 signaling, a new peptide could be synthesized that more closely resembles either 
the Syn T6IM or Sox4 T6IM.  Such rational drug design of a peptide that resembles 
physiological, endogenous inhibitors of TRAF6 might assist in attenuating TRAF6 
signaling that is the basis for the various inflammatory and bone related diseases listed in 
Table 9. 
5.5 TRAF6 MATH domain recruits inhibitory molecules via its TIM groove  
 The TIM groove of the TRAF6 MATH domain (amino acid residues 346-522) is 
involved in receptor binding upon different signaling events.  Ectopic expression of the 
MATH domain itself acts as a dominant negative for downstream events such as NF-κB 
activity.  Others have suggested that the MATH domain competes with endogenous 
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TRAF in binding with upstream activators (Darnay and Aggarwal 1999, Yoshida, Kumar 
et al. 2004).  Our group has suggested that the MATH domain is necessary for 
autoinhibition of TRAF6 signaling (Wang, Galson et al. 2010).  Here, the results of this 
study suggest that the MATH domain is involved in recruiting inhibitory molecules to 
regulate TRAF6 conformation and activity.  Dominant positive signaling to NF-κB by 
ectopic TRAF6 is independent of upstream activators.  I hypothesized that ectopic 
expression of TRAF6 was providing a substrate for TRAF6 inhibitory binding.  
Therefore, I reasoned that induction of TRAF6 dominant positive activity by a minimal 
amount of ectopic TRAF6 should provide a reserve capacity for increased NF-κB activity 
by increasing the stimulatory input using either LPS or IL-1β, Surprisingly, the super-
stimulatory effects of IL-1β were modest in 293R cells transfected with wtTRAF6 
(Figure 4.14, 4.15), but much greater when the MATH domain was removed and the 
RZcc dominant positive was additionally stimulated by exogenous ligand (Figure 4.15).   
Unexpectedly, I was not able to induce a dominant positive effect using wtTRAF6 in 
monocytic cell lines RAW264.7 and 4B12, but those same cells could be stimulated by 
the RZcc dominant positive (Figure 4.16).  These phenomena could be due to the fact that 
different cell lines of various lineages express either different proteins or the same protein 
in differing amounts to enable differential cellular functions. Indeed, when mRNA levels 
were examined in monocytic-macrophage THP-1 or pre-osteoclast RAW264.7 vs pre-
neuronal 293 epithelial kidney cells, the expression profile of our two putative inhibitory 
molecules Syn and Sox4 showed marked difference between 293 and RAW264.7 cells 
(Figure 4.44).  Since TRAF6 acts as a dominant positive in 293 cells, and Sox4 levels are 
high, the data suggest that ectopic TRAF6 is overcoming the inhibition of Sox4.  
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However, RAW264.7 cells are deficient in Sox4 mRNA expression (Figure 4.4), 
suggesting that Sox4 is not the dominant factor in the inability for TRAF6 to act as a 
dominant positive for NF-κB activity.  Since the Sox4 protein is unstable without 
Syntenin it would make sense to increase Syntenin expression and subsequently Sox4 
protein levels in response to stimulatory events (LPS) to attenuate TRAF6 signaling.  
This is exactly what the THP-1 data suggest, that Syn mRNA increases first, followed by 
a delayed more robust Sox4 mRNA expression.  Of course, mRNA expression doesn’t 
always correlate to protein expression and so a logical follow up to this study would be to 
examine the steady state and stimulated protein levels for TRAF6 Syn and Sox4 in the 
various cell lines used in this study.  Taken together, the data that describes differential 
activation of NF-κB activity by TRAF6 in different cell lines point to the inhibitory 
proteins identified in this study, that interact with the MATH domain.  Additionally, these 
inhibitory proteins are expressed differentially in various cell lines or tissue types s seen 
at least at the RNA message level.  This expands the capacity of the MATH domain to 
inhibit beyond competition for upstream activators in experimental situations or 
autoinhibition.  It is estimated that 80% of proteins function within protein complexes 
(von Mering, Krause et al. 2002), rather than as isolated species.  For autoinhibited 
proteins, an inhibitory module regulates activity of a functional domain.  TRAF6 is 
autoinhibited by the association of its MATH and RZ domain (Wang, Galson et al. 2010).   
 Although previously unreported, the RING domain of TRAF6 possesses a perfect 
T6IM (Figure 4.12) that could be the basis for this interaction.  Validation of this would 
affirm the existence of a structurally “closed” inactive TRAF6 molecule.  Generally, 
autoinhibition can be either alleviated or reinforced by binding partners and post-
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translational modifications.  Since the TRAF6 MATH domain is necessary for both 
autoinhibition and extramolecular interactions with potential inhibitory molecules, our 
next goal was to identify novel proteins that might compete with upstream effectors 
possessing a T6IM peptide.  Such inhibitory proteins could explain why either a putative 
TRAF6 interaction peptide or a TRAF6 decoy peptide (T6DP) is insufficient for 
activation of TRAF6 while functioning as an inhibitor (Ye, Arron et al. 2002, Poblenz, 
Jacoby et al. 2007, Trudeau, Nassar et al. 2013).  However, an IRAK1 based T6DP can 
disrupt recruitment of TRAF6 to the cytoplasmic T6IM of RANK (Poblenz, Jacoby et al. 
2007).  A T6DP is available commercially for research purposes and inhibits RANKL 
mediated osteoclast differentiation.  Small molecule inhibitors targeting the TRAF6 
MATH domain have not been discovered and the T6DP is not currently in clinical use 
(Morrow, Du-Cuny et al. 2011).   
In general, the results of this study and those of others argue that a T6IM can 
inhibit TRAF6 recruitment to, and activation by, receptor-activated IRAK1, but requires 
full-length IRAK1 for downstream signaling.  This suggests that domains of the IRAK1 
molecule other than the T6IM are responsible for this activation.   Our group reported 
that a majority of the IRAK1 kinase domain could support TRAF6 interaction (Boch, 
Yoshida et al. 2003).  Similarly, multiple T6IM have been located within the kinase 
domains of IRAK-1 and -3 (Ye, Arron et al. 2002).  This suggests that the whole IRAK1 
molecule, either directly or indirectly, provides an activation function beyond the T6IM.  
Although our group has reported that LPS-activated TRAF6 can recruit c-Src kinase that, 
in turn, phosphorylates TRAF6 (Liu, Gong et al. 2012)this appears to occur downstream 
of IRAK-dependent activation. In addition, the above-described direct interaction of 
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TRAF6 with the IRAK kinase catalytic domain may suggest an inhibitory, rather than 
activating function.  A possible mechanism may simply be steric clashing with the RZ-
MATH domain kinetic interaction that our group previously reported (Wang, Galson et 
al. 2010).  Since the results obtained in this study describe that full-length IRAK1 can 
open/activate TRAF6, activation may simply be the result of the binding of a bulky 
molecule to the TRAF6 MATH domain.  In particular, the amino terminal Death domain 
of IRAK1 that our group reported to not be critical for TRAF6 interaction (Boch, 
Yoshida et al. 2003) but is associated with upstream receptor recruitment and may 
provide steric bulk for maintaining TRAF6 in an open and active state or disrupt a Sox4-
Syn bridge between the TRAF6 RZ- and -MATH domains.   
5.6 Molecular Dynamics of Syntenin TRAF6 Interaction  
De novo identification of protein-protein interactions can be accomplished by in 
vitro, in vivo, and in silico techniques.  Often, several techniques are concomitantly used 
by researches to find novel protein-protein interactions.  Initially, an in vitro approach 
was considered to identify T6IM bearing proteins that might regulate TRAF6 
autoinhibition.  In vitro methods for protein-protein interaction detection include tandem 
affinity purification, affinity chromatography, co-Immunopreciptation, protein arrays, 
protein fragment complementation, phage display, X-ray crystallography, and NMR 
spectroscopy (Rao, Srinivas et al. 2014).  However, the discovery that ectopically 
expressed Syntenin inhibits TIR signaling to NF-κB, but not TNFα induced NF-κB 
activity, spared us this initial effort (Chen, Du et al. 2008).  Therefore, I sought increased 
understanding of the molecular details of this Syn-TRAF6 interaction.  To obtain novel 
details of the interaction in other receptor systems that signal to NF-κB required careful 
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investigation.  Incorporating new findings would facilitate the refining of our model of 
TRAF6 inhibition and activation.   Syntenin seemed an attractive candidate for a TIM 
inactivation pathway due to its demonstrated ability to negatively regulate the TRAF6 
dominant positive effect for NF-κB activity (Chen, Du et al. 2008), in addition to a 
putative TIM sequence identified between its two PDZ domains (Figure 1.12).  Notably, 
the linker region of Syn is unstructured and disordered.  Such disordered regions have an 
increased ability to conform and bind to other proteins in a specific, yet transient, manner 
that enable their central roles in signaling pathways and act as hubs of protein interaction 
networks (Meszaros, Dosztanyi et al. 2012).  The results herein confirm that Syntenin can 
inhibit TIR signaling by ectopically expressing Syn in cells stimulated by TIR receptors 
(whose signals are transduced by TRAF6) such IL-1R (Figure 4.21 4.22) and, TLR4 
(Figure 4.22) and newly demonstrate inhibition of RANK signaling (4.22).  Arguably, 
suing of a cell line (RAW264.7) that endogenously expresses these receptors provides 
more relevant, physiological evidence of inhibitory effects of Syntenin, especially when 
considering that 293 expresses a low level of Syntenin (Figure 4.44).  Further, RANK 
signaling is unique to osteoclasts and so Syntenin can inhibit some TNFR family 
signaling but not other such as TNF-α (Chen, Du et al. 2008).  Since ectopic expression 
of TLR4 in 293 acts as a dominant positive for NF-κB and Syn can attenuate this activity 
(Figure 4.37), it would be interesting to see whether our 293R cells have mRNA 
expression of Syn, Sox4 and TRAF6 more similar to RAW 264.7 cells or stimulated 
THP-1 cells.  Notably, unmodified TLR4 has not previously been shown to act as a 
dominant positive for NF-κB activity, and others usually transient transfect 293 to 
express TLR4 prior to LPS stimulation.  Relatedly, 293R cells used in this study did not 
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have a high background level of NF-κB activity when transfected with empty vector 
(Figure 4.15).  Results from this study newly demonstrate that NF-κB activity, induced 
by ectopic IRAK1 and MyD88, is also attenuated by Syn (Figure 4.23).  I hypothesized 
that this was because Syn interacted with the TRAF6 MATH domain, although 
collectively the data seem to suggest that the Syn T6IM might be less important than the 
Sox4 T6IM.  When the putative TIM (194-198) spanning the PDZ tandem linker region 
was removed (ΔPDZ2) Syn was no longer able to attenuate ectopic TRAF6 induced NF-
κB activity (Figure 4.26, Table 8).  While this could be interpreted as the importance of 
the T6IM, PDZ2 and/or CTD, it also suggests that the NTD of Syn is insufficient to 
attenuate TRAF6 signaling.  Furthermore, I expected that Syn would not be able to 
inhibit RZcc if Syn associated with the MATH domain, using its putative TIM.  Contrary 
to my expectation, Syn was equally able to inhibit RZcc induced NF-κB  activity (Figure 
4.25A).  This finding contradicts other reports that that full length Syn is required to both 
interact with TRAF6 and inhibit TRAF6 signaling and (Chen, Du et al. 2008).  As such, a 
more complex mechanism for attenuation of TRAF6 signaling by Syntenin must exist.  
Furthermore, although the ΔPDZ1 or ΔN muteins could inhibit TRAF6 signaling the 
ΔPDZ1 and ΔN was insufficient for physical interaction with TRAF6 (Figure 4.27).  
Here, the underlying mechanism might be that the putative T6IM in Syn is not binding 
tightly to the MATH TI6M due to minor degeneracy in the sequence.  When the sequence 
was initially identified, I reasoned that while the last position, which calls for an (Ar/Ac) 
residue, was substituted in Syntenin for other hydrophobic residues, the final two 
positions for the T6IM were hydrophobic as seen in (Figure 5.3) and would be adequate 
to mitigate TRAF6-Syn interaction, perhaps as a minor TRAF6-binding motif.  Such 
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minor binding motifs have previously been reported (Schneider, Zimmermann et al. 
2012).  These data, coupled with the fact that the putative T6IM resides in an 
unstructured region, along with the robust activity data where the CTD was found to be 
inhibitory in wt. and RZ conditions (Figure 4.25) may yet allow this sequence to be 
confirmed as the binding motif for TRAF6 in Syn.  To be sure that the putative T6IM is 
dispensable, point mutations of the site or a small deletion of the site should be generated 
and used for assays similar to those performed in this study.  
  
Analysis of Syntenin TIM sequence 
 
P  X  E  X  X  ψ   (acidic residue)    Canonical TIM 
 
P  X  E  X  Φ       (aromatic residue) 
 
194  P  F  E  R  T  I    198  T     PDZ2 Human 
 
194 P  F  E  R  T  V   198  T  S  M    PDZ2 Mouse 
 
I is very hydrophobic aliphatic 
V is very hydrophobic 
T is hydrophobic as well  
 
Figure 5.3 Deviations of murine and human Syn T6IM from canonical T6IM.  
P-X-E-X-X-aromatic (F/W/Y)-acidic (D/E) is the TRAF6-binding motif (where 'X' 
indicates any amino acid and '/' indicates 'or'). 
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5.7 Syntenin associates with TRAF6 in an Ubiquitin-dependent manner 
Ubiquitination has been shown to be an important post-translational modification 
for protein function and cellular control.  Ubiquitin is covalently bound to proteins via an 
isopeptide bond between the carboxy-terminal glycine (G76) of ubiquitin (Ub) and the ε 
amino group of a lysine in target proteins. Ubiquitin contains seven lysine residues (K6, 
K11, K27, K29, K33, K48, and K63) which can attach to another Ub to form poly-Ub chains 
attached to a single lysine (Nath and Shadan 2009). Ubiquitinated TRAF6 recruits 
TAB1/2 and TAK1 kinase leading to the activation of TAK1, which phosphorylates both 
MAPK and IKK complexes to activate NF-κB (Figure 4.2).  Although auto-
ubiquitination is insufficient for NF-κB activity, our results and the literature suggest that 
TRAF6 auto-ubiquitination serves to sustain TRAF6 signaling by keeping it in the 
“open” state (Walsh, Kim et al. 2008, Wang, Galson et al. 2010).  Deletion of all lysines, 
which are potential ubiquitination sites, in TRAF6 reduces, but does not abolish, its 
signaling capacity (Walsh, Kim et al. 2008).   
Syn was found to inhibit the RZcc mutein in 293 cells (Figure 4.25), implying that 
it does not directly bind TRAF6 via a Syn-MATH interaction or that Syn binds to TRAF6 
through multiple interactions (Figure 5.1, 5.2).  When a lysine deficient TRAF6 
(TRAF6ΔK) was ectopically expressed in 293 cells, Syn inhibition was reduced (Figure 
4.28A).  Additionally, Syn ΔN was less effective at inhbiting TRAF6ΔK vs wtTRAF6.  
This suggests that the Syn NTD which has been shown to bind Ub in a novel manner 
(Rajesh, Bago et al. 2011) may bind to Ubiquinated, activated TRAF6 (Figure 4.28B).  
This conclusion is corroborated by differential colocalization of Syn and TRAF6 vs a 
poly-Ub deficient TRAF6c70A mutein (Figure 4.33, 4.34).  While Syn colocalizes with 
  166 
TRAF6 in the cytoplasm and translocates TRAF6 into the nucleus under stimulating 
conditions (dominant positive or ligand stimulation; Figures 4.30, 4.31) TRAF6C70A 
r3mained in the cytoplasm (Figure 4.32),  Collectively, these results suggest that the 
PDZ2 and CTD of Syn requires TRAF6 + Ub to bind TRAF6 and bring it to the nucleus 
which interferes with TRAF6 signaling in the cytoplasm.  Further, TRAF6 (-) Ub blocks 
the Syn NTD from interacting and translocating TRAF6 to the nucleus.  These results are 
corroborated by reports that Syn binds ubiquitin directly through a novel Ub binding 
pocket, using a mechanism where  the recognition involves both N- and C-termini of Syn 
rather than its PDZ domains, which instead mediate prerequisite dimerization (Rajesh, 
Bago et al. 2011).  Furthermore, Syntenin interacts equally well with K48- or K63-linked 
polyubiquitin chains in a NTD- CTD Syn homo-dimer dependent manner (Rajesh, Bago 
et al. 2011).  Since the NTD of Syn is involved in binding to Ub and likely, ubiquitinated 
TRAF6, the inability of Syn to interact and relocalize the C70A muteins supports this 
model of interaction.  The CTD (194-298) of Syn, comprised of the linker (T6IM), PDZ2 
and CTD, alone are also critical components of Syn involved in TRAF6 nuclear 
localization.  
A future study should include a co-IP of C70Aand Syn, which should not bind if 
Ub-TRAF6 is critical for Syn interaction.  Additionally, the study should test whether 
Syn can inhibit RZcc dominant positive in RAW264.7 and 4B12 cells.  The mechanism 
by which Syn binds to TRAF6 might be that ubiquitinated TRAF6 is necessary, but 
insufficient, for the Syn-TRAF6 interaction.  Taken together, the results that both the 
CTD and NTD of Syntenin are required for interaction with TRAF6, along with the 
demonstration that IRAK1 binds to the MATH domain of TRAF6 and disrupts RZ-
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MATH interaction, lead to consider the temporal dynamics of a Syn-TRAF6 association 
and regulation.  Specifically, IRAK1 opens the TRAF6 conformation allowing TRAF6 to 
be auto-ubiquitinated, optimizing the Syn interaction and attenuation of TRAF6 
signaling.  This model conflicts with reports that Syn and TRAF6 are pre-associated and 
that IRAK1 disrupts this interaction in concert with an increase in TRAF6 
polyubiquitination (Chen, Du et al. 2008).  Since Syn dimerization is required for Ub 
binding (Rajesh, Bago et al. 2011), this may reconcile the fact that TRAF6 was not 
crystallized as a trimer (McWhirter, Pullen et al. 1999, Park, Burkitt et al. 1999, Ely, 
Kodandapani et al. 2007) like other TRAFs, but rather as a MATH domain monomer 
devoid of a coiled-coil (cc) multimerization domain (Ye, Arron et al. 2002, Ye, Cirilli et 
al. 2002).   
5.8 Syntenin and Sox4 interact with TRAF6 cooperatively Protein interactions with 
TRAF6  
Examination of Syn and Sox4’s primary amino acid sequences yielded two novel 
TIM-bearing TRAF6regulatory proteins: the adapter protein Syntenin-1 and the 
transcription factor Sox4 (Figures 9, 10, 21, 40). Syn is a dual PDZ domain-containing 
adaptor protein consisting of asymmetric N- and C-terminal domains joined by a linker 
peptide (Beekman and Coffer 2008, Pham, Zhou et al. 2008).  Often PDZ containing 
proteins bind to the carboxy-terminal residues of other proteins, which is in keeping with 
the C terminus position of The MATH domain or the reported stabilization of Sox4’s last 
33 C-terminus residues by Syntenin (Beekman, Vervoort et al. 2012).  PDZ proteins can 
act as multi-functional adaptor proteins, playing a role in assembling multi-protein 
complexes in appropriate regions of the cell (Harris and Lim 2001).  Proteins of the PSD-
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95/Discs large/ZO-1 (PDZ) class can interact with Sox factors.  All Sox-family proteins 
share a conserved High Mobility Group (HMG)-like DNA binding domain.  Sox 
transcription factors can activate or repress many target genes associated with 
development using the conserved HMG domain.  However, it is the non-HMG domains 
that have been proposed to influence partner protein selection and binding stability 
(Wilson and Koopman 2002).  There are three different classes of Sox protein–protein 
interaction: 1) DNA-binding proteins that partner with Sox proteins to regulate 
transcription 2) adaptor-proteins, that link Sox factors to other proteins; and 3) Importins, 
required for the nuclear import of all Sox proteins, all of which have relevance to this 
study.  Poulat et al. demonstrated that the PDZ protein, SIP-1 interacts with the carboxy-
terminal seven amino acids of SRY and proposed SIP1 connected SRY to other, 
unidentified proteins (Poulat, de Santa Barbara et al. 1997).  By interacting with both 
Sox4 and the interleukin 5-receptor α subunit (IL-5α), Syntenin acts adapter facilitating 
IL-5R stimulated Sox4-dependent transcriptional activity.  The results of my research 
support a new model where Syn works as an adapter protein possibly by both protecting 
Sox4 from proteosomal degradation and TRAF6-Sox4 interaction to attenuate TRAF6 
signaling and TRAF6 nuclear import.   Ectopic Sox4 was found to inhibit TIR signaling 
at multiple levels in the TIR signaling pathway to NF-κB (Figure 4.37, 4.38) but perhaps 
most telling of its specificity for TRAF6 was the ability to inhibit the TRAF6 dominant 
positive for NF-κB, which is independent of upstream events (Figure 4.39).  Sox4 
associated with TRAF6 in a MATH dependent manner (Figure 4.39-4.41) since the RZcc 
was not able to co-precipitate with Sox4 and ectopic Sox4 was unable to attenuate the 
RZcc dominant positive for NF-κB activity.   Tellingly, Syntenin was unable to inhibit 
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TRAF6 when Sox4 was knocked down in cells treated with si-RNA directed against 
Sox4 expression.  One possible experiment for a future study would be to see if si-Sox4 
could induce dominant positive NF-κB activity in RAW264.7 or $b12 cells, either alone 
or in conjunction with ectopic wtTRAF6.  These results found in this study suggest that 
the inhibition of TRAF6 by Syntenin is dependent on Sox4 and that Syn acts as an 
adapter to facilitate Sox4 binding to TRAF6, possibly stabilizing the Sox4-TRAF6 
interaction by associating with open Ubiquitinated TRAF6 or a transient association of its 
degenerate TRAF6 interaction motif.  Sox4 was initially identified as a transcription 
factor required for B- and T-lymphocyte differentiation (Beekman, Vervoort et al. 2012, 
Vervoort, van Boxtel et al. 2013).  Among the genes targeted by Sox4, are the cmyb and 
FHL2, which have been previously implicated as regulated by nuclear TRAF6 (Bai, 
Kitaura et al. 2005, Bai, Zha et al. 2008).  These studies do not provide a clear 
mechanism for the nuclear import of TRAF6 from the cytoplasm.   I found that over-
expression of Syn translocates TRAF6 to the nucleus. Importantly, neither TRAF6 nor 
Syn possess a nuclear import signal (NLS). Therefore, my results provide the first 
description of a mechanism by which TRAF6 enters the nucleus using Syntenin-
stabilized Sox4 as the cargo carrying protein for nuclear import and attenuation of 
TRAF6 signaling. 
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5.9 TRAF6 Interaction Motif Directs Subcellular Localization 
Many TRAF family members translocate from their normal cytoplasmic residence 
to various subcellular compartments including: the plasma membrane, sequestosome, and 
nucleus upon stimulating conditions in various receptor systems.  TRAF2 and TRAF3 
move from the cytoplasm to plasma membrane raft microdomains of anti-CD40 antibody 
treated B cells upon CD40 engagement (Hostager, Catlett et al. 2000).  Moreover, CD40 
engagement initiates formation of the immunological synapse has which contain TRAF2 
and TRAF3 (Dustin, Chakraborty et al. 2010).  RANKL induced recruitment of TRAF6 
to detergent resistant lipid microdomains was demonstrated biochemically in RANKL 
stimulated RAW264.7 cells and osteoclasts (Ha, Kwak et al. 2003, Ha, Kwak et al. 
2003).  In cells that were pre-treated with a lipid raft disruption reagent, methyl-β-
cyclodextrin (MBCD), there was a decrease in the presence of TRAF6 in the detergent 
insoluble fraction.  Coupling the results with the observation that TRAF2/3 are recruited 
to the IS, points to the possibility that lipid rafts were as an osteoclastogenic signaling 
platform to support a RANK/TRAF6 complex resembling the immunological synapse.  
While TRAF6 is normally associated with signal transduction in the cytoplasm, others 
have noted that TRAF6 is dual target to both the nucleus on the cytoplasm.  This study 
demonstrates that ectopic TRAF6 resides in punctae (Figure 4.3) whose size has been 
shown to correlate with TRAF6 activity as measured by a NF-κB Luciferase reporter 
(Wang, Galson et al. 2010).  Cytoplasmic granules enriched in Sequestosome-1 
(p62/SQSTM1), an ubiquitin-binding scaffold protein (Geetha and Wooten 2002, 
Donaldson, Li et al. 2003) that activates p38 MAPK (Diradourian, Le May et al. 2008) 
and IKK (Sanz, Diaz-Meco et al. 2000).  SQSTM/p62 is dual targeted to proteasomes 
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and autophagosomes (Wojcik 2013) and inhibition of  the TRAF6-p62 interaction has 
been shown to blocks TRAF6 activity, reducing K63 linked ubiquitination of its target 
substrate, the tyrosine receptor kinase A (TrkA) (Geetha, Jiang et al. 2005) and 
neurotrophin receptor interacting factor (NRIF).  Intranuclear TRAF6 has been reported 
in lymphoma B cells where it interacts with c-Myb and represses c-Myb-mediated 
transactivation (Pham, Zhou et al. 2008). 
This study demonstrates that ectopic Syn can translocate normally cytosolic 
TRAF6 to the nucleus (Figure 4.32, 4.33). Similarly, ectopic co-expression of unlabeled 
TRAF6 resulted in translocation of GFP-Syn into the nucleus (Figure 38).  To determine 
the important domains of Syn for TRAF6 translocation to the nucleus, deletion mutants 
of Syn were coexpressed with TRAF6-YFP in 293 cells.   The results suggests that the C-
terminus (194-298) of Syn comprised of the linker (TIM) PDZ2 & C-terminal Domain, 
along with the unstructured N-Terminus, are the critical components of Syn involved in 
TRAF6 nuclear localization (Figure 4.33).  TRAF6C70A is inactive and deficient in 
poly-ubiquitination (Figure 4.34) (Walsh, Kim et al. 2008).  Ectopic expression of 
TRAF6C70AYFP in 293 cells reveals a subcellular localization, primarily in the 
cytoplasm, similar to that of wtTRAF6  (Fig 17 Bottom).  When Syn was co-expressed 
with TRAF6C70A-YFP, TRAF6C70A-YFP failed to translocate to the nucleus.  
Additionally, when TRAF6C70A-YFP was co-expressed with the Syn deletion muteins, 
the opposite effect to that of co-expression with wtTRAF6-YFP was seen.  SynΔPDZ2 
was unable to translocate wtTRAF6 to the nucleus, but was able to support translocation 
when co-expressed with TRAF6C70A-YFP.  I have already determined that the N-
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terminus of Syn are involved in binding to Ubiquitinated TRAF6; thus, the effects 
observed here support this interaction.  
Traditionally, PDZ domain-bearing proteins are associated with 
membranes, suggesting that these domains are involved in either organizing 
transmembrane protein complexes at plasma membranes or recruiting proteins to 
membranes from the cytosol.  However, Syn was observed to have nuclear 
enrichment in an inverse correlation with plasma membrane localization.  The 
authors imagine that syndecans sequester Syntenin to the plasma membrane and 
depleting it from a nuclear pool.  This suggests that when syndecans are down 
regulated, Syn moves to the nucleus, where it could have transcriptional activities 
(Zimmermann, Tomatis et al. 2001).  By extension, I proposed a model where Syntenin 
interacts with activated TRAF6 at the membrane, and that this association then sequesters 
TRAF6 into the nucleus in order to attenuate receptor signaling and propagate TRAF6 
transcriptional activity, such as that reported by others (Bai, Kitaura et al. 2005, Bai, Zha 
et al. 2008, Pham, Zhou et al. 2008).  In these reports, TRAF6 was previously found in 
the nuclei of both normal and malignant CD40 stimulated B-lymphocytes. TRAF6 does 
not possess a nuclear localization signal but enters the nucleus through the nuclear pore 
complex containing RanGap1 a Ran GTPase-activating enzyme. Nuclear TRAF6 is 
modified by SUMO-1 at lysines 124, 142 and 453, interacts with HDAC-1, repressing c-
Myb-mediated transactivation.  Of the SUMO proteins, only SUMO-1 contains a nuclear 
localization signal that functions by transporting the cargo protein into the nucleus.   
 Interestingly, Syn also contains two Small Ubiquitin-related Modifier-1 (SUMO-
1) binding motifs (Vijayakumaran, Wong et al. 2015).  Nuclear TRAF6 is reportedly 
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modified by (SUMO-1), interacts with histone deacetylase 1, and represses c-Myb-
mediated transactivation (Pham, Zhou et al. 2008).  This could indicate the potential for 
Syn to recruit SUMO-1 for targeting TRAF6 within the nucleus.   
To ensure that nuclear localization of TRAF6 by Syn was not an artifact of over-
expression, I confirmed that endogenous Syn and TRAF6 enter the nucleus with similar 
kinetics upon RANKL stimulation of RAW246.7 cells (Figure 39). Immunoflourescent 
staining of endogenous Syn and TRAF6 revealed both proteins as largely cytoplasmic, 
but then simultaneously enter the nucleus upon stimulation of cell surface receptors that 
initiate TRAF6 mediated signaling cascades.  This was also observed for LPS stimulation 
(data not shown), which comports with data presented by others, although misrepresented 
or incorrectly interpreted as cell surface membrane aggregations (see Fig 6b of Yin et al. 
(Yin, Lamothe et al. 2009)).  Altogether, it can be concluded that attenuation of TRAF6 
signaling may also result from sequestration of cytoplasmic TRAF6, providing a 
mechanism for previous reports of nuclear translocation of cytoplasmic TRAF6.    
While ectopic Syn can translocate normally cytosolicTRAF6 to the nucleus, 
neither Syn nor TRAF6 has a Nuclear Localization Signal (NLS).  Sox4 has been 
reported to accumulate with Syntenin in the nucleus (Beekman, Vervoort et al. 2012).  
Sox4 has a bipartite nuclear localization signal (BP-NLS) at positions 60 -77 and 129-
136, as identified by the Nuclear Protein Database (NPD,  
http://npd.hgu.mrc.ac.uk/user/index.php) (Figure 1.11).  Endogenous TRAF6 and Sox4 
were found to colocalize in 4B12 cells (Figure 4.40) and that LPS stimulation resulted in 
intranuclear TRAF6 accumulation in a manner similar to that of Syntenin.   Ectopic 
IRAK1 and TRAF6 colocalize in cytoplasmic punctae but ectopic Syntenin disrupted this 
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and neither Sox4 nor Syn seemed to affect IRAK1 localization.  These results underscore 
a model where the T6IM bearing molecules IRAK1, Sox4 or Syn can either activate or 
attenuate TRAF6 by affecting its subcellular distribution or conformation and presumably 
Ubiquitination state.   We have recently undertaken some pilot studies where, it seems 
that there may be a constitutively high amount of Syn mRNA that is followed by an 
increase in Sox4 mRNA in response to LPS stimulation in THP-1 and 293 cells.  We are 
further examining whether there is any message difference in the monocytic cell line 
RAW264.7 that would account for the inability for wt. TRAF6 to act as a dominant 
positive in those cells.   Upon first examination, the data supports model where Syn is 
available to interact with activated TRAF6, perhaps stabilizes Sox4 and then the two 
cooperatively translocate TRAF6 into to the nucleus to attenuate signaling to NF-κB by 
sequestration and possibly allowing for TRAF6-Sox4 transcriptional events, including the 
repression of FHL2 and cMyb expression. 
5.10 Syntenin and TRAF6 involvement in Neurite Formation 
Nervous system disruption often results in irreversible loss of sensation and 
paralysis.  This is in part because neurons in the central nervous system (CNS) are unable 
to overcome an unfavorable extracellular environment to regrow long cellular processes 
(axons) after they have been damaged.  Neurotrophic factors, proinflammatory cytokines, 
and transcription factors are often reported to have conflicting trophic and inhibitory roles 
in neurite extension.  As such, the success of regeneration depends largely on the severity 
of the initial injury and resultant degenerative changes (Harrington, Kim et al. 2002).  
The processes of injury-induced neuronal cell death and subsequent regeneration remain 
poorly understood. However, conditions within the local microenvironment of the injury 
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site, and the intercellular signaling cascades they trigger, are undoubtedly important.  The 
regenerative capacity of the peripheral nerve microenvironment has been studied since 
the early 1900s when Cajal proposed that it was the peripheral nerve milieu, rather than 
intrinsic neuronal differences between peripheral and central nervous system neurons, 
that explained the failure of regeneration in the latter (Yiu and He 2006, Lobato 2008).  
Since then, it has been demonstrated that CNS neurons can regenerate in a peripheral 
nervous system (PNS) environment and that peripheral neurons lose this ability when 
placed in a central environment (Harrington, Kim et al. 2002).  The presence of growth-
supportive Schwann cells in the PNS, and inhibition by oligodendrocytes and glial scar in 
the CNS, contribute to this difference in regenerative capability.  Upon injury, CNS 
axonal growth cones undergo Wallerian degeneration, while the PNS axons assemble 
new actin-rich growth cones after injury (Knoll and Nordheim 2009).  Clearly, the PNS 
environment facilitates a program of cytoskeletal rearrangement in response to neuronal 
injury in order to initiate the actin polymerization necessary for axonal growth and 
synapse formation (Revenu, Athman et al. 2004, Chia, Patel et al. 2012, Montani and 
Petrinovic 2014).  Yang et al reported that TRAF6 is a direct E3 ubiquitin ligase for Akt 
kinase K63 linked poly-ubiquitination. Such modification is critical for Akt recruitment to 
the plasma membrane and activation (Yang, Zhang et al. 2009).  In this study, they found 
that two lysine residues (K8 and K14) located inside the PH (Plekstrin Homology) domain 
of Akt were targeted for:  TRAF6 directed ubiquitination; ubiquitination of Akt, required 
for its phosphorylation and membrane recruitment; and contribution to both survival and 
oncogenic signaling pathways (Restuccia and Hemmings 2009).  A construct containing 
the PH-domain of AKT fused to GFP was used P to see whether TRAF6 could induce 
  176 
neurite extensions or neuronal like filipodia in either PC12 cells or 293 cells.  
Interestingly, 293 cells were found to be responsive to NGF (Nerve Growth Factor) and 
produced extensions in response to the NGF stimulation (Figure 4.47), in a manner 
similar to a previous study published by our group where 293 cells produced extensions 
in response to either TRAF6 overexpression or IL-1β stimulation (Wang, Wara-Aswapati 
et al. 2006).  Interestingly, when Syntenin was co-expressed with TRAF6, the two 
ectopic molecules seemed to have antagonistic morphological effects (Figure 4.48-4.50), 
analogous to Syn attenuation of TRAF6 signaling to NF-κB).   Of note, either TRAF6 or 
Syn alone seemed to induce either neurite formation or enhance neurite formation in cells 
additionally stimulated with NGF (Figures 4.48-4.50).  It was not unexpected that Syn 
would generate extensions, since the overexpression of wild-type MDA-9/Syn has been 
shown to increase migration in non-metastatic cancer cells, and correlates with a more 
polarized distribution of F-actin and increased pseudopodia formation (Grootjans, 
Zimmermann et al. 1997).  Further, deleting the PDZ tandem inhibits the formation of 
filipodia, suggesting that Syn plays an important role via interaction with ubiquitin in the 
regulation of cancer metastasis and invasion (Okumura, Yoshida et al. 2011).  These 
results underscore that different tissues may utilize the same adapter protein to 
accomplish different cellular outputs, dependent on the biophysiological system.  
However, some of the molecular componentry and mechanisms remain constant across 
these systems.   
5.11 Tec Kinases Osteosynapse and Transcytotic Machinery 
 Osteoclasts are multinucleated giant cells (MNC) responsible for bone resorption. 
These syncytial cells are differentiated from hematopoietic myeloid precursors of the 
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monocyte/macrophage lineage.   Mature osteoclasts are polarized cells with a ruffled 
border and a sealing zone at the apical membrane towards bone surface.  To differentiate 
osteoclast precursors into mature osteoclasts, a cell-cell interaction between osteoclast 
precursors and osteoblasts/stromal cells is required (Udagawa, Takahashi et al. 1990).   In 
the late 1980’s an in vitro culture system for osteoclast formation was established.  This 
system revealed the importance of the cell-to-cell contact of osteoblast/stromal cells and 
hematopoietic cells for osteoclast differentiation (Takahashi, Yamana et al. 1988).  
Specifically, the system enabled production of the TNF-related cytokine RANKL and the 
polypeptide growth factor colony-stimulating factor-1 (CSF-1) that were subsequently 
shown to induce, together, the expression of genes necessary for osteoclastogenesis 
(Nakagawa, Kinosaki et al. 1998, Boyle, Simonet et al. 2003).   The sealing zone between 
an osteoclast and the resorbed bone is a large F-actin rich structure that is important for 
the bone-resorbing activity of osteoclasts, anchoring it to the mineralized extracellular 
matrix.  Additionally, in order to generate a bone resorption pit, osteoclasts may form 
other F-actin rich structures known as podosomes, which are used for migration in a 
manner similar to focal adhesions plaques, but independent of actin stress fibers (Jurdic, 
Saltel et al. 2006).  These two structures share molecular components and architecture 
with other integrin-mediated adhesive structures, and parallels exist between the 
regulatory mechanisms that contribute to the formation of these adhesive structures 
(Wernimont, Cortesio et al. 2008).   An osteopetrotic phenotype in Tec-/- BTK-/- mice 
revealed these two kinases to play a crucial role in the regulation of osteoclast 
differentiation.  This study establishes their crucial role in the integration of the two 
essential osteoclastogenic signals, RANK and ITAM (Figure 4.51).  Thus, although 
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immune and bone cells share components of signaling cascades, they play distinct roles 
in each cell type. Furthermore, our studies identified an osteoclastogenic signaling 
complex composed of Tec kinases and adaptor proteins that may provide a new paradigm 
for the signal transduction mechanism of osteoclast differentiation: ITAM 
phosphorylation results in the recruitment of Syk, which phosphorylates adaptor proteins 
such as BLNK and SLP-76, which in turn function as scaffolds to recruit the Tec kinases 
activated by RANK and PLCγ to the osteoclast signaling complex so as to induce 
maximal calcium influx. Such complexes are similar to those formed in the 
immunological synapse in T cells, which are associated with membrane rafts (Cherukuri, 
Dykstra et al. 2001).  Each of these synaptic types is built around a microdomains 
structure comprised of central active zones of exocytosis and endocytosis encircled by 
adhesion domain surface molecules that may be incorporated into and around the active 
zones, contributing to modulation of the function state of the synapse.   Similarly, T cell 
activation and function requires a structured engagement of antigen-presenting cells.  The 
cell contacts are characterized by two distinct dynamics in vivo: transient contacts 
resulting for promigratory junctions called immunological kinipsases or prolonged 
contacts from stable junctions called immunological synapses. Synapses are induced by T 
cell receptor  (TCR) interactions with agonist self-peptides (MHC) under specific 
conditions and correlate with robust immune response that generate effector and memory 
T-cells.  Additionally, parallels exist between the regulatory mechanisms that contribute 
to the formation of these adhesive structures (Wernimont, Cortesio et al. 2008).  This 
study demonstrated the rapid recruitment of BTK and Tec kinases to the plasma 
membrane of RAW264.7 cells stimulated with RANKL (Figure 4.52).  This patterning 
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could indicate that the signaling complex activated by RANK includes these two bridge 
molecules (Figure 4.51).  Attempts to visualize TRAF6 as part of this complex were 
unsuccessful and TRAF6 was not observed to be recruited to the membrane (data not 
shown).  Instead, TRAF6 was observed to relocalize to the nucleus in a concomitant 
manner with Syntenin in stimulating conditions (Figure 4.31).  However, when 
RAW264.7 were stimulated with RANKL rapid recruitment of fluorescently labeled PH 
domains or full-length Tec kinases BTK and Tec kinases to the membrane was seen, in a 
manner similar to reports of CD40 induced recruitment of TRAF2/3 to the plasma 
membrane (Hostager, Catlett et al. 2000).  Confocal microscopy revealed that BTK and 
Tec are normally expressed through the cytoplasm.  Upon RANKL stimulation, within 5 
minutes, BTK was recruited to the plasma membrane as compared to control (GFP) or 
Tec Kinase-GFP.  The relocalization of BTK was sustained for nearly an hour (Figure 
4.52).   
Another important question is how the dissolved mineral within the sealed 
resorption pit is transported away from the bone surface.  It has long been suggested that 
a transcytotic process accomplishes this. Using transfected fluorescent BTK, I observed a 
continuous collection of vesicles suggestive of the proposed transcytotic mechanism.  
Osteoclasts are the primary cells responsible for bone resorption.  Waste products created 
by this process are transcytosed through the osteoclast and released through 
the functional secretory domain (FSD).  The mechanisms of this process are not fully 
understood.  Serendipitously, in an effort to understand to the temporal stability of the 
OS, I stimulated RAW264.7 cells transfected with PH-BTK-GFP with RANKL for up to 
90 hours.  Interestingly, what appeared to be a structure resembling the osteoclast FSD 
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was formed and the appearance of negatively stained tunnels from apical to basolateral 
membrane, possibly representing a means for resorbed bone to be transcytosed through 
the cell and released by exocytosis at the FSD (Figure 4.53, 4.54).  Of note, finger like 
projections did not appear to be localized to a single FSD but rather in multiples, perhaps 
suggesting that the FSD is built at the sRANKL signaling site, whereas in a co-culture 
cell-cell signaling system the RANKL signaling complex might be concentrated into a 
single structure analogous to the Immunological Synapse.    
5.12 Conclusions 
TRAF6 is an E3 ubiquitin ligase that is unique among TRAF family proteins in 
both its structure and protein-protein interaction specificity. It is further distinguished by 
its ability to transduce a multiplicity of receptors in varied biological systems.  Although 
TRAF6 is recruited by these receptors, the mechanisms by which TRAF6 is activated 
under these stimulating conditions remain largely unclear.  To address this, I used 
standard molecular biological techniques to gain insight into the interplay of three 
proteins with TRAF6: 1) Syntenin-1 (Syn); 2) SRY (sex determining region Y)-box 4 
(Sox4); and 3) IL-1 receptor associated kinase 1 (IRAK1). These three proteins 
physically interact with TRAF6 and affect its signaling activity by modulating subcellular 
localization and activation of the NF-κB/Rel family of transcription factors under 
stimulating conditions in cell lines of various tissue types. While many studies have 
focused on cytoplasmic TRAF6 and its activation, there are a several reports on the 
localization of TRAF6 (Geetha and Wooten 2002, Nakamura, Kadono et al. 2002, Bai, 
Zha et al. 2008, Pham, Zhou et al. 2008) as well as TRAF3 (Gamper, van Eyndhoven et 
al. 2000) and TRAF4 (Regnier, Tomasetto et al. 1995) to the nucleus in response to either 
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extracellular stimulation or disease.  Overexpression of either Syn or Sox4 was found to 
not only attenuates TRAF6 signaling, but results in its nuclear localization in 
hematopoietic and monocytic cells.  This study demonstrates that IRAK1 can activate 
TRAF6 by disrupting a constitutively closed, autoinhibited conformation.  Syn attenuates 
TRAF6 activity in an ubiquitin and Sox4 dependent manner.  This study demonstrates 
that either mutagenesis or deletion of a newly identified TRAF Interaction motif (TIM) in 
Syn and conjunction with the PDZ2 and CTD can affect TRAF6 signaling and 
localization.  Moreover, in agreement with previous reports, Syn appears to interact with 
TRAF6 directly when TRAF6 is in an ubiquitinated, open-active state. This, and our 
observation that Syn is impaired in its ability to attenuate a non-ubiquitinated TRAF6 
mutein (TRAF6ΔK), led to a hypothesis that Syn associates with TRAF6 in the 
cytoplasm following activation by IRAK1.  Furthermore, knockdown of Sox4 potentiates 
TRAF6 activation and abrogates Syn inhibition of TRAF6.  Contrary to prior reports, 
protein domain deletions in both TRAF6 and Syn show that the full-length molecules are 
not necessary for their interaction. Interestingly, Syn also localizes to the nucleus when 
overexpressed with either wild type (WT) or a constitutively active TRAF6 (RZcc).  
Lastly, Syn binds to the transcription factor Sox4, resulting in Sox4-Syn relocalization to 
the nucleus.  This study demonstrates that Sox4 also induces TRAF6 nuclear 
translocation that depends on a unique Sox4 TIM, providing a novel mechanism for 
TRAF6 entry into the nucleus.  Thus, intranuclear TRAF6 suppresses either 
morphogenesis or differentiation and that inactivation of TRAF6 dependent NF-κB 
activity involves a novel interaction with the Sox4 transcription factor that controls 
TRAF6 nucleocytoplasmic partitioning, conformation and modification state.  
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